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Abstract 
 
Reliable biomarkers of axonal damage are urgently needed in neurological diseases. 
Neurofilaments (Nf) are specific structural elements of neurons composed of at least 
three subunits:  Nf light chain (NfL), Nf medium and Nf heavy chain (NfH). 
This PhD aimed to characterise NfL levels and their correlation with clinical features in 
patients with neurological diseases with a different rate of progression and following 
and under different treatment regimes. An important aim was also to develop a 
bioassay for NfL measurements in blood. 
Cerebrospinal fluid (CSF) NfL levels discriminated patients with a clinically isolated 
syndrome (CIS) (p=0.001) or multiple sclerosis (MS) (p=0.035) from healthy controls 
more efficiently, and was more sensitive to change after natalizumab therapy 
(p<0.0001) than CSF NfH (p=0.002). Further, CSF NfL levels decreased in fingolimod-
treated MS patients (p=0.001), but not in those receiving placebo (p=0.433). Based on 
these findings, a sensitive method for the detection of NfL in serum was developed and 
validated. Patients with neurological diseases had higher serum NfL values than 
controls. In acute spinal cord injury (SCI), serum NfL levels correlated with injury 
severity and long-term motor outcome, and Minocycline treatment was associated with 
decreased NfL levels in complete SCI patients compared to placebo. Finally, I found 
that serum NfL levels were higher in CIS patients than in healthy controls but did not 
predict conversion to clinically definite MS (CDMS). Independent predictors of CDMS 
were instead oligoclonal bands, number of T2 lesions and age at CIS. Lower 25-OH-
vitamin D levels were associated with CDMS in univariate analysis, but this was 
attenuated in the multivariate model. 
In conclusion, NfL proved to be an analytically stable protein which is an important 
prerequisite for biomarkers. The role of NfL quantification as a surrogate measure of 
neuroaxonal damage is corroborated by my findings and further supports the 
usefulness of NfL as a putative biomarker of axonal damage in various neurological 
diseases. 
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1. Introduction 
 
 
1.1. Intermediate filaments 
The neuronal cytoskeleton is composed of three interconnected structures: 
microfilaments, microtubules, and intermediate filaments (IF). The diameter of IF (10 
nm) is “intermediate” between the microfilaments (6-8 nm, mostly actin) and 
microtubules (24 nm, mostly tubulin). Based on molecular structural homology, five 
types of IF have been identified, and neurofilaments (Nf) belong to type IV (type I: acid 
keratins, type II: basic keratins, type III: desmin, GFAP, peripherin/vimentin, type V: 
nuclear lamins) (1). Neurons differentially express several IF proteins depending on 
their developing stage and their localisation in the nervous system: for example nestin 
(200 kDa), three Nf subunits (Nf light chain, NfL, 68 kDa; Nf medium chain, NfM, 160 
kDa and Nf heavy chain, NfH, 205 kDa), α-internexin (66 kDa), peripherin (57 kDa) and 
synemin (41 kDa) (2).  
 
1.2. Neurofilament function and structure 
Nf are highly specific to the neuro-axonal compartment. Their main role is to increase 
axon calibre of myelinated axons and consequently their conduction velocity. 
Numerous rodent studies have shown that both number of Nf and a precise 
stoichiometry of their subunits are essential in the expansion of the axonal diameter 
(2). Nf account for approximately 13% of total and 54% of Triton-insoluble proteins in 
some neurons, representing the most abundant structures in large myelinated axons 
(3, 4). Their number relative to axonal cross-sectional area does not change during 
development or after axonal injury, leading to the proposal that Nf density is essential 
in determining axonal diameter (5). This has also been demonstrated in genetically 
engineered animals that either contain enhanced levels or lack axonal Nf (6). Despite 
being present also in perikarya and dendrites, Nf are particularly abundant in the 
axons. They have exceptionally long half-lives and their elastic fibrous properties 
enable them to maintain the shape of neurons (7). 
 
All Nf subunits share a common structure, with non-helical amino and carboxy-terminal 
regions (the head and tail domains) flanking a central α-helical rod domain of about 
310 amino acids (figure 1.1) (2, 8). The central rod domains, including regions 1a, 1b, 
and 2, contain highly conserved motifs and every seventh residue is hydrophobic 
facilitating the formation of coiled-coil parallel dimers. The tail domain is the distinctive 
feature of the Nf and contains numerous repeats of the phosphorylation sites Lys-Ser-
Pro (KSP) in both NfM and NfH. These sites are called KSP repeats: 51 are present in 
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mice NfH, 7 in mice NfM and 43-44 in human NfH. Most of the serines in the KSP 
repeats are phosphorylated and it is suspected that phosphorylation contributes to Nf 
spacing by inducing charge repulsion and prevention of protease degradation during 
the long lifespan of these proteins (9, 10).  
 
 
Figure 1.1. Mouse, rat and human Nf subunits and predicted molecular weights from 
the DNA sequences. The three subunits share a highly conserved central α-helical 
domain of approximately 310 amino acids that is flanked by the amino and carboxy-
terminal head and tail regions. The tail domains are of variable size and in case of NfM 
and NfH contain multiple KSP repeats (orange) which can be heavily phosphorylated 
(arrow-heads) (2). 
 
1.3. Nf assembly, transportation and degradation 
It was originally thought that Nf were composed only by NfL, NfM and NfH, but later 
studies indicated that other proteins such as α-internexin and peripherin are also co-
assembled with Nf (2, 11, 12). Nf are obligate heteropolymers requiring NfL with either 
NfM or NfH (13, 14); the exact mechanisms leading to Nf assembly are not known yet. 
The first step of Nf formation is the dimerisation of NfL with either NfM or NfH to form 
parallel head-to-tail coiled coil dimers (13-15). Two dimers line up forming half-
staggered anti-parallel tetramers. These tetramers form protofilaments, which finally 
assemble to constitute the 10 nm filament (16) (Figure 1.2.). The C-termini of NfM and 
NfH are not in the coils, but they form the side arms of Nf (1). NfL is known to be able 
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to self-assemble, while NfM and NfH cannot perform self-assembly, but only co-
polymerize with assembled NfL (14, 17) with a stoichiometry of 4 (NfL):2 (NfM):1 (NfH) 
(14, 18, 19). In vivo, these partly understood processes are strongly influenced by 
phosphorylation of several Ser residues in the KSP repeats. 
In numerous animal studies only mice overexpressing >3-fold NfL and NfM/NfH double 
knockout mice showed severe phenotypes. From these experiments it was concluded 
that NfL is responsible for Nf assembly, and NfM/NfH subunits are also required, 
whereas NfM is more critical for axonal growth than NfH (1). 
 
Nf are the most extensively phosphorylated proteins in neurons, and the 
phosphorylation state in different neuronal compartments depends on a dynamic 
balance between the activities of a complex network of kinases and phosphatases (2). 
It is assumed that phosphorylation also plays an important role in regulating Nf 
transport, formation and function. Most phosphorylation sites are in KSP motifs of the 
tail domains of NfM and NfH and myelination promotes Nf phosphorylation and radial 
growth of axons, while demyelination of motor neurons causes loss of phosphorylation 
of NfM and NfH (20, 21). Interestingly, phosphorylation also plays a critical role in 
inhibiting Nf assembly in the perikaryon, which explains why Nf only form filaments in 
axons, and in protecting the neuron from abnormal accumulation of phosphorylated Nf 
aggregates in cell bodies (1, 4, 22-24). Abnormally phosphorylated Nf in the cell bodies 
represent a characteristic pathological finding in several neurodegenerative diseases 
such as amyotrophic lateral sclerosis (ALS), Alzheimer’s disease (AD), Lewy bodies in 
Parkinson’s disease (PD), progressive supranuclear palsy (PSP), Charcot-Marie-Tooth 
disease (CMT), diabetic neuropathy and giant axonal neuropathy (25-29). 
Whereas phosphorylation has been intensely studied, the role of another common 
modification, the attachment of O-linked N-acetylglucosamine (GlcNAc) to individual 
serine and threonine residues, is hardly understood. O-linked glycosilation regulates 
signaling events related to nutrient sensing and stress responses, among other 
functions (30). It has been shown that the amount of glycosilated NfM, which is highest 
in axons of human neurons, is decreased in brains from patients with Alzheimer’s 
disease (AD) (31), similarly in a rat model of ALS (32). The functional significance of Nf 
glycosilation awaits further investigation; this also needs to take into account potential 
technical artefacts like altered glycosylation in post-mortem tissue (32). 
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Figure 1.2. Model of Nf assembly. Two Nf subunits (NfL, and either NfH or NfM) form 
head-to-tail coiled-coil dimers, anti-parallel half-staggered tetramers, protofilaments, 
and 10-nm Nf. Side arms formed by the C-termini of NfH and NFM stick out of the stem 
of NF (1). 
 
 
After their assembly in the perikaryon, NFs are transported by the slow axonal 
transport (0.2-1 mm/day) towards the nerve terminal where they are degraded by non-
specific proteases such as lysosomal cathepsin D, trypsin and α-chymotrypsin (33). 
The mechanism by which Nf are transported has been under debate for many years. It 
is also not clear whether assembled Nf or subunits are transported (34). 
Many neurons in humans extend their axons up to one meter. During the passage 
through the axon, the cytoskeletal proteins are metabolically stable and do not undergo 
degradation. Therefore, it is believed that Nf degradation takes place mainly at the level 
of synapses (35). This process is preceded by Nf dephosphorylation by phosphatases, 
further suggesting that phosphorylation has a protective function (10). 
 
 
1.4. Neurological diseases studied in this thesis 
In this thesis I studied CSF and serum samples from patients with neurological 
diseases with a different rate of progression and following and under different 
treatments. The main focus of the work is multiple sclerosis (MS) (chapters 2., 3., and 
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6.), but I also investigated samples from patients with AD, Guillain-Barré-syndrome 
(GBS), ALS (chapter 4) and acute spinal cord injury (SCI, chapter 5). 
 
1.4.1. Multiple Sclerosis (MS) 
MS is a disseminated, chronic, inflammatory demyelinating disease of the CNS with 
progressive neuroaxonal degeneration. The phenotype is very heterogeneous and the 
course unpredictable. MS is the most frequent cause of nontraumatic neurological 
disability in young adults (36).  
Approximately 85% of MS patients show a relapsing-remitting course, in which acute 
exacerbations are followed by periods of remission of symptoms (relapsing-remitting 
MS (RRMS)). The first clinical episode of RRMS patients is often referred to as 
clinically isolated syndrome (CIS). Most of RRMS cases will enter in the long term the 
secondary progressive phase of MS (SPMS), which is characterized by progressive 
deterioration of neurological function, independent of relapses (37). In approximately 
15% of MS patients, disability progression occurs from onset of first symptoms. This is 
called primary progressive MS (PPMS) and up to approximately 10% can also have 
relapses (also termed progressive relapsing MS) (38). Importantly, these categories 
are based on subjective views of MS experts, lack objective biological support and 
have recently been revised (39-41). Interestingly, while the length of the relapsing 
remitting phase is very variable, the rate of neurological decline at some stage of the 
disease course appears less heterogeneous, regardless of the preceding disease 
course and severity (42, 43). These findings suggested that the underlying 
neurodegenerative process in MS depends more on the patient’s age and not on 
number of relapses which have previously occurred (44). This led to the hypothesis 
that MS could be a two-stage disease, starting with an inflammatory phase and later 
entering a distinct neurodegenerative phase. However, more recent imaging and 
neuropathology studies in early MS have shown that axonal injury and 
neurodegeneration start since the very early phases of the disease, and that the 
transition from RRMS to SPMS is likely to be a point at which compensatory 
mechanisms of neuronal injury fail (45).  
Highly efficacious immunomodulatory treatments for RRMS have been developed; 
however, no effective treatment has been identified for the progressive forms of MS 
(PPMS; SPMS). This is a significant unmet need as the accrual of disability, loss of 
quality of life and socioeconomic costs predominate in the progressive stage of the 
disease. 
MS is unsurpassed for patient variability in terms of disease progression. However, no 
robust prognostic markers regarding the individual disease course have been 
established. Optic neuritis (ON), isolated sensory symptoms, long interval to second 
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relapse, no disability after 5 years (46, 47) and a normal initial brain MRI (48-51) 
predict a good prognosis in CIS. Whereas a multifocal CIS (52), involvement of efferent 
systems (47), a high relapse rate in the first 2 - 5 years (53), disability after 5 years (47) 
and an abnormal MRI with large lesion load (49-51, 54-56) all have been associated 
with a poor prognosis (57). Early motor, cognitive, cerebellar and sphincter dysfunction 
and cigarette smoking have been described as additional factors predicting an 
unfavorable course (58, 59). Progressive disease (SPMS and PPMS) has a worse 
prognosis than RRMS, and in RRMS, incomplete recovery from relapses is associated 
with a worse outcome (60). 
 
1.4.2. Alzheimer’s dementia (AD) 
AD is the most common form of dementia, accounting for 50 - 60% of all cases. The 
prevalence of AD among people aged 85 years or older ranges between 24 and 33% in 
the Western world (61). Slowly progressive impairment of episodic memory is the key 
feature, accompanied by aphasia, apraxia and agnosia, together with more general 
symptoms such as impaired judgment, decision-making and orientation. 
The differential diagnosis of dementia is broad and the diagnostic criteria keep evolving 
in order to improve sensitivity and specificity (62-66). Mild cognitive impairment (MCI) 
describes an intermediate stage between normal ageing and dementia. The conversion 
rate of MCI to dementia is 10 - 15% per year and approximately 80% at 6 years of 
follow-up (67). 
 
1.4.3. Guillain-Barré Syndrome (GBS) 
The diagnosis of GBS is mainly clinical, based on a combination of progressive 
symmetrical weakness and areflexia. Acute inflammatory demyelinating 
polyradiculoneuropathy (AIDP) is the most common subtype in western countries, 
whereas forms primarily affecting the axons are less frequent (acute 
motor axonal neuropathy [AMAN] and acute motor and sensory 
axonal neuropathy [AMSAN]) (68, 69). Cerebrospinal fluid (CSF) findings are 
characterized by a normal cell count and 
increased protein concentration (i.e. ‘albuminocytological dissociation’). Most patients 
reach their maximum weakness within 2 weeks; by definition this should be reached 
within 4 weeks followed by a variable plateau phase from days to several months (70, 
71). Up to 20% of the most severe GBS cases remain wheelchair-bound after 6 months 
despite treatment with intravenous immunoglobulin (IVIg) or plasma exchange (72). 
Older 
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age at onset, longer time to nadir, necessity for ventilator support, preceding diarrhea 
or axonal degeneration in electrophysiological examinations are related with poor 
outcome (73-75). 
 
1.4.4. Amyotrophic Lateral Sclerosis (ALS) 
ALS, the most common (> 80%) and most severe form of motor neuron disease, is a 
fatal neurodegenerative disorder of large motor neurons of unknown etiology. 
Approximately 10% of ALS cases are familial with mutations in the gene encoding 
cytosolic copper-zinc superoxide dismutase 1 (SOD1) in about 15 - 25% of these 
cases (approximately 1.5 - 2% of all ALS patients) (76). ALS has a considerable 
variability in outcome. The median age of onset is 55 years, and the median survival 
from onset to death in ALS is reported to vary from 20 to 48 months (77-79). 
Importantly, 5 - 10% of the patients are consistently reported to survive more than 10 
years; nevertheless, 50% die within 3 years and approximately 90% within 5 years 
(80). 
 
1.4.5. Acute spinal cord injury 
See chapter 5.1. 
 
 
1.5. Pathophysiological mechanisms of axonal degeneration in MS 
The exact mechanisms driving MS pathogenesis are currently unknown. However, 
current knowledge indicates that environmental exposures in genetically susceptible 
individuals lead to an immune mediated demyelination process within the central 
nervous system. It is thought that the immune cell invasion across the blood-brain 
barrier leads to continuous activation of CNS-homing and CNS-resident innate immune 
cells (macrophages and microglia) in the brain and spinal cord with resulting 
demyelination and neurodegeneration (45, 81). Axonal loss is thought to be the 
pathological substrate that results in the acquisition of irreversible disability in MS and 
appears to occur by at least two principle mechanisms. Firstly, as a result of axonal 
transection in acutely inflamed focal lesions (82). For example, the inflammatory 
process in acute optic neuritis leads to axonal transection in the optic nerve and to 
retinal nerve fiber layer thinning, that can be detected using optical coherence 
tomography (83). Secondly, axonal loss can occur as a delayed consequence of earlier 
and chronic damage that renders axons vulnerable to degeneration when 
compensatory mechanisms fail (84). In comparison to axonal loss in acute focal 
lesions, this process is less understood. Focal inflammation occurring early in the 
course of the disease could prime the damaged, but surviving, axons for degeneration 
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in the future (85). Several additional mechanisms have been proposed to cause this 
delayed axonal loss and include persistent demyelination (despite axonal injury also 
occurs without demyelination) (86-89), oxidative stress, free radical damage, 
mitochondrial dysfunction, microglial activation, hypoxia, ageing and energy deficits 
secondary to excessive sodium loading of axons (90). 
 
 
1.6. Overview of NfL findings in different neurological diseases 
Nf subunits are among the most abundant proteins of the nervous system and are 
concentrated in neurons and axons. 
NfL is the most abundant and also most soluble Nf subunit. Therefore, it is expected 
that NfL would be released in relatively large amounts from damaged neurons and 
particularly their dying axons. I thought that this could eventually provide a unique 
opportunity to reliably measure axonal degeneration in the peripheral blood 
compartment of neurological patients. In this chapter I summarize findings from 
previous studies on NfL levels in neurological diseases. Noteworthy, these have so far 
been performed exclusively in CSF.
  
 
Table 1.1. Studies describing NfL assays. 
Ref. no. Healthy 
control 
groups 
studied (n): 
NfL: [median 
(IQR), pg/ml] 
Investigated 
compartment 
(CSF/serum/ 
plasma) 
Type of disease 
studied (n): 
NfL [median (IQR), 
pg/ml] 
[NfL] in disease 
different to 
controls 
Correlations of [NfL] 
with clinical or 
laboratory measures 
Assay 
characteristics 
NfL: [median 
(IQR), pg/ml] 
Special features: 
e.g. longitudinal 
design 
1.) 
Rosengren et 
al., 1996 (91) 
Neurologically 
healthy 
individuals 
(34): 138 
CSF (mean levels) 
AD (11): 346 
RRMS (5): 463 
NPH (6): 582 
VD (6): 597 
OPCA (2): 892 
CI (5): 958 
ALS (12): 1743 
- all patient 
groups higher 
than controls 
- higher levels in ALS 
with upper motor 
neuron involvement 
than lower (<0.05) 
- age in controls (0.41, 
<0.05) 
“Gothenburg 
assay” 
- sensitivity 85 
 
2.) 
Norgren et al., 
2003 (92) 
(mean levels) 
Neurologically 
healthy 
individuals 
(11): 2 above 
detection 
limit: 31 
CSF (mean levels) 
PD (5): 200 
AD (5): 300 
VD (5): 1400 
PSP (3): 1900 
RRMS (5): 2500 
ALS (5): 3600 
CI (6): 19800 
MSA (2): - 
- all patient 
groups higher 
than controls 
- “Umea assay” 
(mAb 47:3 and 
mAb 2:1) 
- sensitivity 60 
pg/ml 
 
3.) 
van Geel et al., 
2005 (93) 
No 
neurological 
disease (110): 
<15 y (39): 8 
(5-17) 
15-50y (40): 5 
(0-6) 
>50y (31): 9 
(0-25) 
(no signif. 
correlation 
CSF Mild TBI (3): 5 
TIA (2): 30 
SAH (13): 67 (32-
136) 
CVA (13): 142 (7-
276) 
Severe TBI (3): 470 
(n.a.)  
 
 
Higher levels in 
SAH, severe TBI 
and CVA (no 
statistical 
analysis) 
- 
 
“Nijmegen 
assay” 
- detection limit: 
5 
- two overnight 
incubation 
steps 
- 76/110 
controls 
measurable 
- Commercially 
available 
antibodies 
- compared with 
(91) levels by 
factor 34.4 higher 
  
 
with age) 
4.) 
Gaiottino et al., 
2013 (94) 
(see chapter 4) 
(geometric 
means) 
Serum/CSF: 
HC (67): 3/- 
CP (68): 4/324 
(median age 
35y) 
CSF and 
serum 
(geometric means) 
Serum/CSF: 
ALS: 95/5513 
GBS: 79/1361 
AD: 31/1396 
 
- serum levels 
higher in ALS 
(<0.0001) and 
GBS (<0.0001) 
versus HC and 
CP 
- CSF levels 
higher in ALS 
(<0.0001) and 
GBS (<0.0001) 
versus CP 
- higher CSF 
levels in ALS 
(<0.0001) than 
AD and GBS 
- CSF levels in CP and 
age (0.68, <0.0001) 
 
 - CSF levels 97-
fold higher than 
serum levels 
- CSF/serum 
correlations: 
AD (0.48, 0.033), 
GBS (0.79, 
<0.0001), ALS 
(0.7, <0.0001) 
For correlations the coefficient r and p-values are given (r, p-value). 
AD: Alzheimer’s disease; ALS: amyotrophic lateral sclerosis; CI: cerebral infarction; CP: control patients; CVA: cerebrovascular accident; HC: healthy 
controls; NPH: normal pressure hydrocephalus; OPCA: olivopontocerebellar atrophy; SAH: subarachnoid hemorrhage; TBI: traumatic brain injury; 
TIA: transient ischemic attack; VD: Vascular dementia; y: year; -: not done. 
 
Three different ELISAs for NfL in CSF have been developed previously. The “Umea assay” has been used most widely. Chapter 4 describes the 
development and validation of an ECL-based NfL assay for measurements in human serum samples employing the identical monoclonal antibodies 
(mAb) used in Norgren et al., 2003 (“Umea assay”: mAb 47:3 and mAb 2:1) (92, 94, 95). 
 
  
 
Table 1.2. Overview of studies on NfL in multiple sclerosis (MS) or neuromyelitis optica.  
Ref. no. Healthy 
control 
groups 
studied (n): 
NfL: [median 
(IQR), pg/ml] 
Type of disease 
studied (n): 
NfL [median (IQR), 
pg/ml] 
[NfL] in disease 
different to 
controls 
Correlations of [NfL] 
with clinical or 
laboratory measures 
Assay Special features: 
e.g. longitudinal 
design 
1.) 
Lycke et al., 
1998 (96) 
Healthy 
subjects (11): 
below 
detection 
limit in all 
RRMS (60): 265 - higher in RRMS 
than controls 
- EDSS (0.27, <0.05) 
- exacerbation rate 
during the 2-year trial 
(0.38, <0.01) 
- time of lumbar 
puncture (-0.48, 
<0.001) 
(91) - 2-year acyclovir 
trial with two CSF 
samplings, no 
influence of 
acyclovir on NfL 
levels 
2.) 
Malmeström et 
al., 2003 (97) 
Healthy blood 
donors (50): 
measurable 
in n=4; (mean 
age: 35y) 
RRMS relapse (23): 
91% detectable 
RRMS remission 
(18): 44% 
detectable 
SPMS (25): 48% 
detectable 
- higher in all 
stages (<0.001) 
- RRMS relapse 
higher than 
RRMS remission 
and SPMS 
(<0.001) 
- no relationship with 
age or gender, EDSS, 
disease duration 
(91)  
3.) 
Norgren et al., 
2004 (98) 
Thunderclap 
headache 
(25): 
detectable in 
one 
(means) 
PRMS (5): 0 
PPMS (15): 240 
RRMS (58): 248 
SPMS (21): 367 
(partially 
extrapolated from 
figure 2a) 
- (stable) RRMS 
(<0.01), SPMS 
(<0.001) and 
PPMS (0.04) 
higher than 
controls 
- trend for SPMS 
higher than 
(stable RRMS) 
- higher in relapse (3 
months, n=39) than 
stable (n=60): mean 
754 versus 266, 0.004 
- after 14 years: 
correlation with MSSS 
(0.3, 0.005), higher 
levels predictive of 
SPMS (=0.01) and 
higher MSSS score 
(OR=3.2) (99) 
(92) - NfL (relapse 
patients excluded) 
correlated with 
EDSS at clinical 
FU examination 
(r=0.28, p=0.03) 
and progression 
index: stable 
patients: r=0.29, 
p=0.023; relapse 
patients: r=0.49, 
p=0.002 
- CSF cell count 
(patients in 
  
 
relapse): r=0.52, 
p=0.001 
4.) 
Teunissen et 
al., 2009 (100) 
NIND 
(18):1000 
(mean age: 
47y) 
IND (40): 1300 
(mean age: 
53y) 
ND (28): 800 
(mean age: 
40) 
(extrapolated 
from figure 3) 
CIS (38): 1000 
PPMS (6): 1200 
SPMS (28): 1400 
RRMS (42): 1800 
(extrapolated from 
figure 3) 
- NIND (<0.006) 
and IND 
(<0.0001) higher 
than ND 
- ND vs CIS: 
<0.001 
- ND vs RRMS: 
<0.0001 
- CIS vs RRMS: 
<0.04 
- ND vs SPMS: 
<0.0001 
- ND vs PPMS: 
<0.004  
- number of T2 lesions 
(0.35, 0.024) 
- number of Gd+ 
lesions (0.50, <0.001) 
- EDSS (0.19, <0.05) 
- higher in CIS and MS 
with OCB (<0.01) or in 
relapse (<0.05) 
- higher in CIS with 
conversion to RRMS 
(<0.05) 
- NfL with NfH (0.49, 
<0.0001) 
Uman 
Diagnostics NF-
light (only 
reagents 
provided) 
 
5.) 
Gunnarsson et 
al., 2010 (101) 
(mean) 
Controls (28, 
blood donors, 
university 
students): 350 
(mean age 
43y) 
(means) 
RRMS (92): 1300 
(after NTZ: 400) 
RRMS relapse (30): 
2300 (after NTZ: 
350) 
RRMS stable (62): 
860 (after NTZ: 430) 
SPMS with relapses 
(9): 1600 (after NTZ: 
630) 
(partly extrapolated 
from figures 1 and 
2) 
 - higher levels in 
MS (<0.001) than 
in controls 
- reduced levels 
after NTZ 
(<0.001), no 
difference to 
controls after 
NTZ 
- Uman 
Diagnostics NF-
light 
- longitudinal 
sampling before 
and after NTZ 
6.) 
Khalil et al., 
2013 (102) 
NIND (15): 
500 (mean 
age 35y) 
(extrapolated 
from figure 1) 
CIS (47): 1200 
(extrapolated from 
figure 1) 
- higher in CIS 
(<0.001) than 
controls 
- no difference between 
relapse and remission 
- age (0.93, <0.001) 
- no difference between 
converters to CDMS 
and non-converters 
Uman 
Diagnostics NF-
light 
- clinical follow-up 
in 46, follow-up 
MRI in 28 patients 
available 
  
 
- NfL with NfH (0.55, 
<0.001) 
- CSF cell count (0.65, 
<0.001), IgG index 
(0.46, <0.001) and qAlb 
(0.35, <0.01) 
7.) 
Romme et al., 
2013 (103) 
NIND (7, lower 
back pain, 
headache, 
psychosomatic 
complaints): 
250 (mean 
age 53) 
(extrapolated 
from figure 1) 
SPMS (40): 500 
PPMS (21): 500 
RRMS in relapse 
(36): 1100 
(extrapolated from 
figure 1) 
- RRMS (0.002), 
SPMS (0.04), 
PPMS (0.001) 
higher than 
controls 
- osteopontin (0.49, 
<0.0001) 
- CXCL 13 (0.35, 
0.007) 
- MMP9 (0.15, 0.25) 
Uman 
Diagnostics NF-
light 
- repeat sampling 
in 22 SPMS after 
1 year: no change 
in NfL (p=0.08) 
8.) 
Kuhle et al., 
2013 (104) (see 
chapter 2) 
(geometric 
mean) 
No objective 
clinical or 
paraclinical 
finding (72): 
272; (median 
age: 38y) 
(geometric means) 
CIS (62): 766 
SPMS (25): 785 
PPMS (23): 1007 
RRMS (38): 1201 
- CIS (<0.0001), 
RRMS (<0.0001), 
SPMS (0.001), 
PPMS (<0.0001) 
higher than 
controls 
- RRMS (0.025) 
higher than 
SPMS 
- age in controls (0.61, 
<0.0001) 
- CSF cell count in CIS 
(0.27,0.016) and 
RRMS (0.43, 0.01) 
- qAlb in CIS (0.28, 
0.025), RRMS (0.49, 
0.002) and SPMS 
(0.67, <0.0001) 
- EDSS in CIS and 
RRMS (0.31, 0.002) 
- relapse higher than 
remission (1070 versus 
734, p=0.054) 
Uman 
Diagnostics NF-
light 
- differences larger 
than for NfH 
- correlation with 
NfH (after age 
correction): 
controls (0.058, 
0.627), CIS (0.46, 
<0.0001), RRMS 
(0.56, <0.0001), 
SPMS (0.31, 
0.128), PPMS 
(0.41, 0.054) 
9.) 
Modvig et al., 
2013 (105) 
Healthy 
controls (27): 
414 (262-630) 
(median age 
33y) 
CIS (optic neuritis, 
56): 1476 (1024-
3036) 
- higher in CIS 
(<0.0001) than 
controls 
- age in controls (-, 
<0.0001) 
- dissemination in 
space in MRI (-, 
0.0512) 
- time from onset to 
CSF sampling (0.46, 
Uman 
Diagnostics NF-
light 
- no correlation 
with severity of 
visual function, or 
Gd+ lesions on 
MRI 
  
 
0.0024) 
- CHI3L1 (0.39, 0.073) 
- osteopontin (0.5, 
0.0023) 
10.) 
Wang et al., 
2013 (106) 
(mean) 
OND (18, 
schizophrenia, 
sciatica, 
cervical 
spondylosis): 
703 (mean 
age 38y) 
(means) 
RRMS (25): 991 
NMO (32): 1570 
 
- higher in NMO 
than RRMS 
(0.001) and OND 
(<0.0001) 
- higher in RRMS 
(0.0003) than 
OND 
- EDSS in NMO (0.48, 
0.006) and RRMS 
(0.47, 0.017) 
Uman 
Diagnostics NF-
light 
- sampling during 
relapse 
11.) 
Axelsson et 
al., 2014 (107) 
(mean) 
Healthy 
controls (14, 
blood donors): 
577 (mean 
age 42y) 
(mean) 
PPMS (5) and 
SPMS (30): 1780 
(after treatment: 
870) 
- higher levels in 
MS than controls 
(<0.001)   
- reduced levels (0.007) 
after treatment 
- higher levels after 
treatment than controls 
(0.045) 
- higher levels in 
previously untreated 
(2462) than treated 
patients (874, 0.019) 
- higher baseline levels 
in Gd+ patients (2925, 
n=12) versus non Gd+ 
patients 1184 (0.013) 
- CXCL 13 (0.53, 
<0.01) 
- GFAP (0.47, <0.01)  
- no correlation with 
EDSS or MSSS 
Uman 
Diagnostics NF-
light 
- patients treated 
with mitoxantrone 
(29) or rituximab 
(5) 
- repeat sampling 
after 12-24 
months 
- clinical measures 
unchanged over 
follow-up 
12.) 
Burman et al., 
2014 (108) 
Controls (15, 
other non-
inflammatory 
neurological 
diseases: e.g. 
thunderclap 
RRMS Gd+ (25): 
1700 
RRMS Gd- (19): 400 
SPMS Gd+ (3): 
1950 
SPMS Gd- (17): 900 
- Gd+ RRMS 
higher than 
controls (<0.001) 
- Gd+ RRMS 
higher than Gd- 
RRMS (<0.01) 
- increased in patients 
with Gd+ lesions 
- 2 controls with iih 
above reference: after 
exclusion: Gd- SPMS 
versus controls: <0.01 
Uman 
Diagnostics NF-
light (normal 
values 
established by 
this group: 
  
  
 
headache, 
idiopathic 
intracranial 
hypertension 
(iih) or no 
objective signs 
of MS): 300 
(mean age: 
40y) 
(extrapolated from 
figure 2) 
- number Gd+ lesions 
(0.51, <0.0001) 
- number T1 lesions 
(0.31, 0.013) 
- number T2 lesions 
(0.27, 0.033) 
- age in controls (0.83, 
0.0004) 
<30y: <380; 30-
39y: <560; 40-
59y: <890; > 
59y: <1850)  
13.) 
Trentini et al., 
2014 (109) 
NIND (15, 
headache, 
vertigo, 
hydrocephalus 
secondary to 
tumor, 
trigeminal 
neuropathy, 
polyradiculopa
thy, epilepsy): 
532 (273-812) 
SPMS (10): 697 
(495-1380) 
PPMS (21): 839 
(723-1514)  
- higher in PPMS 
than NIND 
(0.003) 
- NfL predictor of EDSS 
annual increase (0.44, 
<0.05) 
- NfH in patients (0.71, 
<0.01), in controls 
(0.54, <0.01) 
Uman 
Diagnostics NF-
light 
- 23 patients 
followed-up for a 
median of 9 years 
14.) 
Romme et al., 
2014 (110) 
- (mean) 
SPMS (12) : - 
PPMS (12) : - 
SPMS and PPMS : 
657 
- - MTR in NAWM (-0.73, 
0.003) 
- MTR in grey matter (-
0.66, 0.01) 
Uman 
Diagnostics NF-
light 
- mean decrease 
by 243 pg/ml after 
1 year of 
natalizumab 
treatment (p=0.03) 
15.) 
Villar et al., 
2014 (111) 
NIND (37, 
headache, 
benign 
intracranial 
hypertension, 
cranial nerve 
palsy, 
epilepsy, 
vitamin B1 
deficiency): 
335 
RRMS (127): - - (55 patients 
with <900 and 72 
>900) 
- higher levels in 
relapse/Gd+ lesions 
(0.03) 
- not age in patients or 
controls 
- T2 lesions (0.44, 
<0.0001) 
- Gd+ lesions (0.50, 
<0.0001) 
- MSSS (0.54, 
<0.0001) 
Uman 
Diagnostics NF-
light 
- more lipid 
specific IgM bands 
in patients with 
high NfL (<0.0001) 
  
 
- T1 black holes (0.47, 
<0.0001)  
- CD4+ cells (0.33, 
0.002), CD8+ (0.42, 
0.0007), CD19+ (0.48, 
<0.0001) 
Summary 457 (292-672) (only studies using 
Uman Diagnostics 
NF-light assay): 
CIS: 1100 (825-
1407) 
RRMS: 1200 (461-
1675) 
SPMS: 950 (400-
1550) 
PPMS: 754 (305-
1152) 
    
For correlations the coefficient r and p-values are given (r, p-value). 
CIS: Clinically isolated syndrome; CHI3L1: chitinase-3-like-1; EDSS: Expanded disability status scale; GBS: Guillain-Barré syndrome; Gd+: 
gadolinium enhancing MRI lesions; IND: Inflammatory neurological disease; MSSS: Multiple Sclerosis severity score; NAWM: normal appearing white 
matter; ND: normal donors; NIND: non-inflammatory neurologic diseases; NMO: neuromyelitis optica; NTZ: natalizumab; OCB: oligoclonal bands in 
CSF; PPMS: primary progressive MS; RRMS: relapsing remitting MS; SPMS: secondary progressive MS; T2 lesions: T2 hyperintense lesions; -: not 
done. 
 
Most of the studies in CIS/MS were done using the Uman Diagnostics NF-light ELISA (12/15 studies and all published after 2004). I also used the 
Uman Diagnostics NF-light ELISA (chapters 2 and 3) and the mAB it is based upon (chapters 4-6). 
  
 
NfL levels in controls showed considerable variation (250 pg/ml to 800 pg/ml) between the different studies and this clearly complicates their 
comparison. Different criteria have been used to define control groups (healthy controls versus patients without objective clinical or paraclinical 
findings versus patients with “other” neurological diseases) (112) and variability in assay performance between different sites (113) probably adds to 
this complexity. In summary all stages of MS showed increased CSF NfL levels, with CIS and RRMS patients having slightly higher concentrations 
than SPMS and PPMS. Also, levels correlated with clinical and paraclinical measures of disease activity to a variable extent. Three studies showed 
CSF NfL responds to immunomodulatory treatment in RRMS (101) and in progressive MS (107, 110), (chapter 3) and no studies on blood NfL levels 
in CIS or MS have been published so far. 
  
 
 
 
 
 
 
 
 
  
 
Table 1.3. Overview of NfL studies in different forms of dementia. 
Ref. no. Healthy 
control 
groups 
studied (n): 
NfL: [median 
(IQR), pg/ml] 
Type of disease 
studied (n): 
NfL [median (IQR), 
pg/ml] 
[NfL] in disease 
different to 
controls 
Correlations of [NfL] 
with clinical or 
laboratory measures 
Assay 
characteristics 
NfL: [median 
(IQR), pg/ml] 
Special features: 
e.g. longitudinal 
design 
1.) 
Rosengren et 
al., 1999 (114) 
(mean) 
Control 
subjects 
(minor 
surgery, spinal 
anesthesia, 
39): 156 
(mean age: 
72y) 
(means) 
AD (37): 348 
VAD (20): 674 
FTD (5): 997 
- higher in all 
patient groups 
than controls 
(<0.001) 
- age in controls (0.41, 
<0.05), but not patients 
(0.18, ns) 
- no difference between 
mild and moderate 
dementia (455 vs. 559) 
(91)  
2.) 
Sjögren et al., 
2000 (115) 
Control 
subjects (18): 
241 (mean 
age 71y) 
FTD (18): 1442 
EAD (21): 498 
LAD (21): 1006 
- higher in FTD 
(<0.05) and LAD 
(<0.001) than 
controls 
- higher in LAD 
(<0.05) than EAD 
- tau in EAD (0.58, 
<0.01) and in controls 
(0.71, <0.01) 
- degree of cognitive 
impairment in FTD 
(0.59, <0.05) and LAD 
(0.61, <0.01) 
(91)  
3.) 
Wallin et al., 
2001 (116) 
Healthy 
controls (18): 
241 (median 
age 71y) 
SWD (25): 1316 - higher in SWD 
(<0.001) than 
controls 
- no difference for CSF 
tau 
(91)  
4.) 
Andreasen et 
al., 2001 (117) 
(mean) 
Subjects 
without 
symptoms or 
signs of brain 
disorders (19): 
295 (mean 
age 71) 
(mean) 
AD (35): 615 
- higher in AD 
than controls 
(0.002) 
- little additional value 
as diagnostic 
biochemical marker for 
AD 
(91)  
  
 
5.) 
Sjögren et al., 
2001 (118) 
Healthy 
volunteers 
(20): 156 
(mean age: 
66y) 
(means) 
AD (22): 569 
SVD (9): 1977 
Insignificant WMC 
(37): 394 
Extensive WMC 
(14): 1347 
- higher in AD 
(<0.001) and 
SVD (<0.001) 
than controls 
- higher in extensive 
WMC than insignificant 
WMC (<0.001) 
- higher in SVD than 
AD (<0.05) 
(91) Study on “white 
matter changes” 
6.) 
Pijnenburg et 
al., 2006 (119) 
(mean) 
Nondemented 
controls (19 
nonprogressiv
e subjective 
memory 
complaints, 3 
cognitively 
healthy 
spouses, 3 
other, 25): 390 
(mean age: 
59y) 
(means) 
BvFTD (17): 510 
EAD (20): 950 
- higher in EAD 
than controls 
(<0.001) (not 
seen for NfH) 
- age in controls (0.68, 
<0.001) 
- NfH (FTD: 0.71, 
0.001; controls: 0.83, 
0.001) 
- Tau (AD: 0.73, 
<0.001) 
Uman 
Diagnostics NF-
light 
- large variation in 
patients with FTD 
7.) 
Petzold et al., 
2007 (120) 
  - higher levels in 
AD than controls 
(OR 1.27, 95% 
CI 1.03-1.51) 
- higher in FTD 
than controls 
- higher in SVD 
than controls 
- higher in FTD 
than AD 
  Meta-analysis 
8.) 
De Jong et al., 
2007 (121) 
Controls 
(underwent 
CSF 
examination 
for various 
reasons, no 
EAD (37): 6.1 
LAD (33): 15.2 
DLB (18): 10.4 
FTD (28): 16.9 
- higher in FTD 
than EAD (<0.01) 
and controls 
(<0.001) 
- no correlation with 
MMS, duration, age 
(93)  
  
 
neurological 
disorder, 26): 
5.0; (median 
age 60y) 
9.) 
Mattson et al., 
2008 (122) 
- Rapidly progressing 
FTD (13): 410 
Slowly progressing 
FTD (11): 125 
- no difference 
between rapid 
and slow 
progressors 
(p=0.186) 
- no correlation with 
CDR or MMS 
(91)  
10.) 
Bjerke et al., 
2009 (123) 
Healthy 
controls 
(senior 
citizen’s 
organizations, 
spouses, 51): 
250 (250-250) 
(median age: 
66y) 
MCI - SVD (8): 424 
(255-1414) 
MCI - MCI (113): 
250 (250-250) 
MCI – AD (18): 250 
(250-406) 
MCI – MD (15): 250 
(250-406) 
- MCI – SVD 
higher than 
controls (<0.001) 
and MCI-MCI 
(<0.001) 
- MCI – MD 
higher than 
controls (<0.01) 
and MCI – MCI 
(<0.001) 
- MCI – AD 
higher than 
controls (<0.05) 
and MCI – MCI 
(<0.001) 
- for separation 
between MCI – SVD 
and stable MCI, NfL 
was the most influential 
marker, while Aß42, T-
tau and P-tau provided 
more discriminating 
power for the other 
comparisons 
(91) (detection 
limit: 250) 
- 4-year 
longitudinal study 
-large number of 
samples below 
detection limit 
 
11.) 
Van Eijk et al., 
2010 (124) 
Non-demented 
controls (no 
neurological 
disease, 23): 5 
(0-20); 
(mean age 
58y) 
sCJD (21): 78 (33-
123) 
AD (55): 7 (6-18) 
- sCJD higher 
than AD 
(<0.0001) 
- sCJD higher 
than controls 
(<0.0001) 
- higher in AD 
than controls 
(0.044) 
(- 14-3-3 present in 20 
sCJD and 5 AD) 
- Age (AD: 0.30, 0.022) 
- NfH (0.47, <0.001) 
- GFAP (0.45, <0.0001) 
(93)  
12.) 
Bjerke et al., 
2011 (125) 
Healthy 
controls (30): 
600 (median 
AD (30): 1000 
SVD (9) + MD (17): 
1700 
- higher in SVD 
than controls 
(<0.0001) and 
- Age in controls (0.60, 
0.001) 
- contributing most to 
Uman 
Diagnostics NF-
light 
 
  
 
age 68y) 
(extrapolated 
from figure 1) 
(extrapolated from 
figure 1) 
AD (<0.05) 
- higher in AD 
than controls 
(<0.0005) 
SVD versus controls 
- contributed third most 
for AD versus controls 
(1. Aß1-42, 2. T-tau) 
13.) 
Skillbäck et al., 
2013 (126) 
- Overall study 
population (clinical 
routine samples, 
5542): 1530 
 - T-tau (0.42, <0.001) 
- P-tau (0.23, <0.001) 
- Aß42 (-0.13, <0.001) 
- age (<0.001), sex 
(<0.001) and AD 
biomarker profile 
(0.001) predict NfL 
- only 29% with positive 
AD biomarker profile 
had normal NfL levels 
Uman 
Diagnostics NF-
light 
- defined threshold 
value for 
subcortical axonal 
degeneration: 108 
healthy volunteers 
(median age 38y): 
95th percentile: 
1400 
14.) 
Landqvist et 
al., 2013 (127) 
Healthy 
controls (26): 
250 
(median age 
70y) 
FTD (34): 
BvFTD (23): 770 
SD (7): 1340 
PNFA (7): 455 
Post mortem verified 
FTD (10): higher in 
tau neg. cases than 
tau-positive cases 
(1620 vs. 665, 
0.017)  
AD (20): 415 
- higher in FTD 
than AD (<0.001) 
and controls 
(<0.001) 
- SD higher than 
AD (<0.001) 
- bvFTD higher 
than AD (<0.001) 
- no correlation with 
neuropathological 
severity of 
degeneration or brain 
weight 
(91) (17 healthy 
controls below 
detection limit) 
 
15.) 
Scherling et 
al., 2013 (128) 
(mean) 
NC (29/17): 
1197/1107 
 
(mean age 
66y/65y) 
(means) 
BvFTD (22/22): 
6227/4267 
PNFA (8/10): 
4304/6347 
SD (10/6): 
6726/6405 
AD (31/17): 
2828/2972 
probable or possible 
PSP (11/10): 
- all FTD higher 
than NC (<0.001; 
validation: 
<0.001) and AD 
(<0.03; 
validation: SD 
and PNFA: 
<0.001, not 
bvFTD: 0.795) 
- SD higher than 
PSP (<0.003; 
- CDRsb (all FTD: 0.41, 
0.008 and 0.36 and 
0.002) 
- MMS (-0.33, 0.039 
and -0.55, 0.002) 
- CDRsb (bvFTD: 0.41, 
0.008; SD:0.64, 0.019; 
PNFA: 0.63, 0.011) not 
in AD and PSP 
- backward digit span (-
0.47, 0.005) 
Uman 
Diagnostics NF-
light 
- included 
validation cohort 
- CSF NfL levels 
correlated with 
disease severity in 
FTD 
- tendency for 
higher levels in SD 
versus other FTD 
phenotypes 
  
 
1899/2843 
CBS (9/7): 
5524/3950 
<0.007) 
- higher in AD, 
PSP, and CBS 
than NC (<0.001; 
<0.001) 
- phonemic fluency (-
0.54, 0.002/-0.44, 
0.019) 
- category fluency (-
0.56, 0.001/-0.65, 
0.001) 
- stroop color naming (-
0.41, 0.038/-0.53, 
0.012) 
- interference (-0.49, 
0.016/-0.55, 0.01) 
- gray matter density (-
0.35, <0.05) 
16.) 
Skillbäck et al., 
2014  (129) 
Clinically 
ascertained 
healthy (107): 
275 
 
(mean age 69) 
EAD (223): 360 
LAD (1194): 510 
FTD (146): 855 
DLB (114): 436 
AD+VAD (517): 660 
PDD (45): 360 
CVD (465): 701 
- all groups 
except DLB and 
PDD had 
significantly 
higher values 
than controls 
- FTD 
significantly 
higher than all 
other groups 
- age (LAD 0.28, 
<0.001; DLB 0.26, 
0.05; PDD 0.45, 0.002; 
VAD 0.19, <0.001; 
controls 0.6, <0.001 
- MMS (all <0.001; LAD 
<0.001; VAD 0.018; not 
FTD) 
- survival (<0.001) 
3 methods for 
CSF NfL 
measurements: 
(91), adapted 
version from 
(91), Uman 
Diagnostics NF-
light 
 
For correlations the coefficient r and p-values are given (r, p-value). 
AD: Alzheimer’s disease; BvFTD: behavioural variant frontotemporal dementia; CBS/D: Corticobasal syndrome/degeneration; CDRsb: Clinical 
dementia rating; DLB: dementia with Lewy bodies; EAD: early onset AD; FTD: frontotemporal dementia; LAD: late onset AD; MCI:  Mild cognitive 
impairement; MD: mixed type dementia; MMS: Mini mental status; NC: normal controls; PD: Parkinson’s disease; PDD: Parkinson’s disease with 
dementia; PNFA: Progressive nonfluent aphasia; PSP: Progressive supranuclear palsy; sCJD: sporadic Creutzfeld-Jakob disease; SD: Semantic 
dementia; SVD: Subcortical vascular dementia; SWD: subcortical white matter dementia; VAD: vascular dementia; WMC: white matter changes.  
  
 
 
There is variability in the assays used to quantify NfL in patients with different forms of dementia. Noteworthy, there are no studies published on 
measurements in the blood compartment so far in this condition. Nf show particularly high expression in large myelinated axons. In line with this 
observation, high CSF NfL levels were primarily found in disorders with subcortical pathology such as vascular dementia, while less increased levels 
were typically found in more cortical pathologies such as AD. Nevertheless, CSF NfL levels in AD were in general higher than in the various control 
groups and correlated with MMS in LAD and VAD. Also, NfL levels correlated with white matter lesion load and were particularly high in FTD. 
It is generally thought that tau protein (reflecting neuronal degeneration) and Aß42 (reflecting disturbances in Aß metabolism and possibly Aß 
deposition in the senile plaque) are more sensitive and specific biomarkers for differentiating AD from controls than Nf. However, the specificity of 
these molecules in dementias other than AD is not optimal. It is still unclear whether blood NfL measurements can add to the diagnosis and the 
assessment of treatment effects in patients with dementia. 
 
 
 
 
 
 
  
 
Table 1.4. Overview of NfL studies in amyotrophic lateral sclerosis. 
Ref. no. Healthy 
control 
groups 
studied (n): 
NfL: [median 
(IQR), pg/ml] 
Type of disease 
studied (n): 
NfL [median (IQR), 
pg/ml] 
[NfL] in disease 
different to 
controls 
Correlations of [NfL] 
with clinical or 
laboratory measures 
Assay 
characteristics 
NfL: [median 
(IQR), pg/ml] 
Special features: 
e.g. longitudinal 
design 
1.) 
Zetterberg et 
al., 2007  (130) 
Healthy control 
individuals 
(40): 175 
(mean age: 
63) 
Unrelated 
patients with 
other 
neurological 
disorders 
(206): 277 
(mean age 63) 
ALS (79): 2110 - higher in ALS 
than healthy 
controls (<0.001) 
and reference 
patients (<0.001) 
- age in reference 
(0.022) and control 
(<0.001) group 
- sensitivity 93%, 
specificity 91% for 
diagnosis ALS versus 
healthy controls 
- survival time (-0.52, 
0.001) 
- shorter survival with 
levels above median 
(0.002) 
(91) - lower in patients 
with SOD1 
mutation (0.001) 
2.) 
Reijn et al., 
2009 (131) 
- (means) 
ALS (32): 62 
ALS-mimic 
disorders (26): 24 
- ALS higher than 
ALS-mimics 
(0.005) 
- disease duration 
(0.74, -) 
(93)  
3.) 
Tortelli et al., 
2012 (132) 
Other 
neurological 
disorders: 
CIDP (25): 
1000; (mean 
age: 61) 
OND (21, eg 
AD, MCI): 
1800; (mean 
age: 62) 
(extrapolated 
ALS (37): 5500 
(extrapolated from 
figure 1) 
- higher in ALS 
than in CIDP 
(<0.0001) or 
OND (<0.0001) 
- no difference 
between CIDP 
and OND 
- no correlation with 
age 
- higher in rapidly 
progressive patients 
(<0.006) 
- diagnostic delay (-
0.55, <0.0001) 
- ALSFRS-r score (-
0.41, 0.014) 
- progression rate 
(0.65, <0.0001) 
Uman 
Diagnostics NF-
light 
 
  
 
from figure 1) 
For correlations the coefficient r and p-value is given (r, p-value). 
OND: other neurological disease; AD: Alzheimer’s disease; MCI: Mild cognitive impairment; ALSFRS-r: Amyotrophic Lateral Sclerosis Functional 
Rating Scale 
 
CSF NfL levels were found consistently higher in ALS than in controls in three studies (all using different assays). CSF NfL levels also correlated with 
measures of disease activity and disease progression. The high CSF NfL levels in ALS may be related to the higher content of axonal proteins in 
large myelinated motor neurons compared to other neuronal populations. In conclusion, NfL appears a sensitive biomarker of disease severity, 
progression and potentially treatment response in ALS that clearly deserves further investigation. 
 
 
 
 
 
 
 
  
 
 Table 1.5. Overview of NfL studies in vascular diseases. 
Ref. no. Healthy 
control 
groups 
studied (n): 
NfL: [median 
(IQR), pg/ml] 
Type of disease 
studied (n): 
NfL [median (IQR), 
pg/ml] 
[NfL] in disease 
different to 
controls 
Correlations of [NfL] 
with clinical or 
laboratory measures 
Assay 
characteristics 
NfL: [median 
(IQR), pg/ml] 
Special features: 
e.g. longitudinal 
design 
1.) 
Nylen et al., 
2002 (133) 
CNS vasculitis 
unlikely (40): 
855 
(means) 
CNS vasculitis (32): 
1639 
- - higher levels in 
patients with CNS 
injury than without 
(<0.001) 
- higher in patients with 
>5/ul CSF cells (<0.01) 
and increased IgG 
index (<0.01) 
(91)  
2.) 
Nylen et al., 
2006 (134) 
- SAH (44): 9035 
pg/ml 
- - no difference between 
neurosurgical clipping 
and endovascular 
coiling 
- higher in surgical 
versus no intervention 
group (<0.01), 
unfavorable versus 
favorable outcome 
(<0.01), 
parenchymatous 
versus no parench. 
lesion (<0.001) 
- long-term outcome (-
0.56, <0.001), MMS (-
0.52, 0.001), and 
NIHSS (0.50, <0.001) 
(91) - CSF sampling 
10-14 days after 
SAH 
3.) 
Jonsson et al., 
2010 (135) 
- Mild WML (15): 250 
Moderate WML (23): 
300 
- - volume of WML (0.48, 
<0.001) 
(91)  
  
 
Severe WML (15): 
630  
4.) 
Zanier et al., 
2011 (136) 
Non-
neurological 
patients (13): 
undetectable 
SAH (35): 643 - - higher in patients with 
cerebral ischemia than 
without (<0.01) 
- no significant 
difference regarding 
outcome 
adapted from 
(93) 
 
For correlations the coefficient r and p-value is given (r, p-value). 
SAH: Subarachnoid hemorrhage, MMS: Mini mental status; NIHSS: NIH stroke scale; WML: white matter lesions 
 
Few studies have investigated CSF NfL levels in patients with cerebrovascular ischemia. An obvious reason for this is the fact that lumbar punctures 
are not indicated in patients with stroke or transient ischemic attacks (TIA). No studies in blood samples have been performed. Interestingly, none of 
the mentioned investigations used the Uman Diagnostics NF-light assay. Two studies demonstrated increased CSF NfL levels in patients with SAH, 
partly also associated with clinical outcome. 
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1.7. Types of biomarkers and surrogate endpoints 
An expert working group convened by the National Instutute of Health defined a  
biological marker (biomarker) as a characteristic that is objectively measured and 
evaluated as an indicator of normal biological processes, pathogenic processes, or 
pharmacologic response to a therapeutic intervention (137). 
Biomarker applications include the following: 
1. Use as a diagnostic tool for the identification of those patients with a disease or 
abnormal condition (eg, blood glucose levels in diabetes mellitus). 
2. Use as a tool for staging of disease or classification of the extent of disease (eg, 
prostate-specific antigen concentration in prostate cancer). 
3. Use as an indicator of disease prognosis. 
4. Use for prediction and monitoring of clinical response to an intervention (137). 
The expert working group also proposed important definitions for “clinical endpoint”: a 
characteristic or variable that reflects how a patient feels, functions, or survives; and 
“surrogate endpoint”: a biomarker that is intended to substitute for a clinical endpoint. A 
surrogate endpoint is expected to predict clinical benefit (or harm or lack of benefit or 
harm) based on epidemiologic, therapeutic, pathophysiologic, or other scientific 
evidence (137). Although all surrogate endpoints can be considered biomarkers, it is 
likely that only a few biomarkers will achieve surrogate endpoint status  (137). For a 
surrogate endpoint to be used in a clinical trial, it needs to be shown that the effect of 
the intervention on the surrogate end point predicts the effect on the clinical outcome 
(138). Prentice developed criteria to validate surrogate endpoints in phase 3 clinical 
trials: 
1. The treatment must have an effect on the surrogate 
2. Treatment must have an effect on the clinical outcome 
3. The surrogate and the clinical outcome must be correlated 
4. Intervention effect on the true clinical outcome must disappear when adjusting for 
the surrogate (139). 
Several factors may explain the potential failure of surrogate endpoints: 
a) the surrogate may not be in the causal pathway of the disease process. 
b) of several causal pathways of disease, the intervention affects only the pathway 
mediated through the surrogate. 
c) the surrogate is not in the pathway of the intervention’s effect or is insensitive to its 
effect. 
d) the intervention has mechanisms of action independent of the disease process 
(138). 
These factors explain why effects on surrogate endpoints often do not predict the true 
clinical effects of an intervention (140-142). Nevertheless, the successful use of a 
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surrogate endpoint in a clinical trial could allow reduction in sample size or trial duration 
(139).  
 
 
1.8. Preliminary work of the student leading to the experiments detailed in the 
thesis 
Electrochemiluminescence (ECL) based assays are known to be highly sensitive, 
exhibit a broad dynamic range and require small sample volume; the technology has 
demonstrated the ability to quantify levels of nucleic acids, recombinant proteins and 
bacterial and viral components in the sub-picogram range with increased precision 
compared to conventional enzyme-linked immunosorbent assay (ELISA) (143-148). 
 
Highly sensitive methods for detecting soluble biomarkers for neuro-axonal damage 
are needed in neurodegenerative diseases. I have previously developed an ECL solid-
phase sandwich immunoassay on the Meso Scale Discovery (MSD, Gaithersburg, MD, 
USA) to measure the soluble fraction of neurofilament heavy chain (NfHSMI35) in 
cerebrospinal fluid (CSF) employing the same commercially available antibodies used 
in a conventional ELISA (cELISA) (149-151). Adhering to a previously proposed 
nomenclature, the soluble fraction of NfH measured is indicated with the capture 
antibody in the superscript (149). 
The NfHSMI35 assay protocol was optimised and validated for reproducibility, precision, 
accuracy and parallelism. The analytical sensitivity (background plus three standard 
deviation (SD)) of this assay was 2.4 pg/ml. The mean intra-assay coefficient of 
variation (CV) was 4.8% and the inter-assay CV 8.4% (151). Patients with ALS (160.1 
pg/ml, n=50), mild cognitive impairment (MCI)/AD (65.6 pg/ml, n=20), GBS (91.0 pg/ml, 
n=20) or subarachnoid haemorrhage (SAH) (345.0 pg/ml, n=20) had higher CSF 
NfHSMI35 values than the reference cohort (27.1 pg/ml, n=73, p<0.0001 for each 
comparison). The reference cohort included patients who, based on extensive 
diagnostic evaluation, had no objective clinical or paraclinical signs of a neurological 
disease: tension type headache (n=17), lower back pain (n=5), psychiatric disorders 
(n=30) or miscellaneous diseases for which no neurological explanation could be found 
(n=21) (151). 
 
In a next step, employing this ECL-based immunoassay, we measured levels of the 
NfHSMI35 protein in the CSF of healthy controls (HC) and in patients with a clinically 
isolated syndrome (CIS) or Multiple Sclerosis (MS) (151, 152). In particular, we 
examined whether NfHSMI35 levels differ between MS patients and controls and between 
specific stages (relapsing-remitting versus progressive forms) or states (relapsing 
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versus stable) of disease. The main findings of this study were that CSF levels of 
NfHSMI35 increase in the course of disease evolution from CIS to definite MS and 
correlate with the Expanded Disability Status Scale score (EDSS) as clinical measure 
of disability in CIS and relapsing remitting MS (RRMS), but not in progressive stages 
(secondary progressive MS (SPMS) and primary progressive MS (PPMS)). In contrast, 
none of the CSF measures related to the immune response (CSF cell count, intrathecal 
IgG, IgM or IgA production, CSF total protein or albumin quotient as measures of the 
blood CSF barrier integrity) correlated with EDSS at any time point of MS evolution. 
In summary our results supported the utility of NfHSMI35 as a specific biomarker for on-
going neuroaxonal damage that can be quantified with high sensitivity and a broad 
dynamic measuring range, a pre-requisite for use in clinical practice (153).  
 
These findings were important, because we anticipated that further development of the 
assay in serum/plasma samples could have provided tools to measure longitudinally 
NfHSMI35 levels during disease progression as well as in clinical trials of potential 
neuroprotective drugs in diseases like MS and ALS. 
 
To date there are only very few studies on NfH in the blood compartment (154-156). 
These results await validation and I and others have previously experienced analytical 
difficulties with reliable and reproducible quantification of NfH levels in blood samples 
(characterised by the so called “hook effect” or other matrix interferences and thus lack 
of parallelism between plasma samples and standards in serial dilutions). This effect is 
most likely based on either the formation of aggregates or endogenous binding of Nf by 
antibodies and poses an important pre-analytical problem for a quantitative 
immunoassay of Nf levels (157, 158). A method for solubilising Nf aggregates by urea 
preincubation of samples has been recently proposed (159).  
 
Unfortunately, during the following months in 2011 we were not able to adapt the 
NfHSMI35 ECL immunoassay to measurements in serum or plasma samples due to 
insufficient recovery and lack of dilutional linearity. Despite several attempts to reach 
acceptable analytical performance, I finally decided not to follow this development for 
NfHSMI35 further. 
 
Nevertheless, an assay including the benefits of the ECL technology seemed a 
promising approach forNf measurements in the blood compartment. Such an assay 
could potentially provide a sufficiently sensitive tool for blood measurements in several 
chronic neurodegenerative diseases. 
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1.9. Specific aims 
Chapter 2 aims to compare CSF levels of NfL (UmanDiagnostics NF-light® assay) with 
those of (previously determined) NfHSMI35 in a well characterised group of 148 CIS/MS 
patients and 72 controls (152). Second, I evaluated the analytical and clinical 
performance of the UmanDiagnostics NF-light® assay and stability of its analyte (160). 
 
In chapter 3A, I aimed to determine CSF NfHSMI35 levels using the  NfHSMI35 assay I 
have developed in a subset of MS patients who had previously shown reduced NfL 
(UmanDiagnostics NF-light®) levels after natalizumab treatment (101). 
 
In chapter 3B, I aimed to assess the ability of CSF NfL (by UmanDiagnostics NF-light®) 
as a therapeutic biomarker in RRMS, by comparing levels in fingolimod-treated patients 
versus placebo, and correlating NfL levels with clinical and MRI outcomes. 
 
In chapter 4 I aimed to develop and validate a sensitive ECL-based NfL assay suitable 
for the quantification of NfL in serum at concentrations relevant to clinical settings. 
 
In chapter 5, I aimed to analyse NfL levels in longitudinally collected serum samples 
from subjects enrolled in a phase II clinical trial investigating the utility of minocycline to 
attenuate neurological deficits after spinal cord injury (SCI)  (161). I report the 
correlation of serum NfL with acute and long-term clinical outcome in these patients. 
Further, I investigated the potential of serum NfL as drug response marker of the 
therapeutic effect of minocycline in SCI. 
 
Finally, in chapter 6, my objective was to assess the ability of serum NfL to predict the 
risk of conversion from adult CIS to CDMS (defined by occurrence of a second clinical 
attack) using the largest cohort of adult CIS cases ever studied to date (n=1,047). I 
decided to use a two steps strategy by initially measuring serum NfL in the 100 patients 
with the shortest time to conversion to CDMS (fast converters (FC)), the 100 patients 
with the longest follow-up time in the absence of conversion to CDMS (non converters 
(NC)) and 100 healthy controls. I decided that only if I saw a difference in serum NfL 
levels between FC and NC serum NfL, I would have measured serum NfL in the rest of 
the cohort. 
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2. A comparative study of CSF NfL and NfH protein in MS (104) 
 
 
2.1. Introduction 
In this chapter, I first evaluated the analytical and clinical performance of the 
UmanDiagnostics NF-light® assay and the stability of its analyte (160). Second, I 
compared the ability to discriminate between MS patients and controls of CSF levels of 
NfL (as measured with the UmanDiagnostics NF-light® assay) with previously 
determined CSF NfHSMI35 levels in a well characterized group of 148 CIS/MS patients 
and 72 controls (152). 
 
2.2. Patients and Methods 
2.2.1. Patients and CSF samples 
Samples were collected in the Department of Neurology, University Hospital Basel in 
the course of routine diagnostic measures as indicated by the treating physicians and 
after patient informed consent. The sample collection procedure, clinical measurement 
methodology and immunomodulatory treatment have been described in reference: 
(152). Eighty six patients with MS and 62 patients with a CIS were included. Patients 
were classified as having clinically definite RRMS (n=38), SPMS (n=25), or PPMS 
(n=23) by a trained neurologist (152, 162). 
The control group consisted of 72 patients who, based on extensive diagnostic 
evaluation, had no objective clinical or paraclinical signs of a neurological disease. Due 
to lack of CSF, samples from one CIS, one RRMS and one control used in NFHSMI35 
could not be assayed for NfL (table 2.1) (152).
  
 
Table 2.1. Demographic and clinical characteristics of patients and controls. 
 
Controls CIS RRMS SPMS PPMS All 
N 72 62 38 25 23 220 
Females 
(n [%])a 44 (61.6) 50 (80.6) 25 (65.8) 13 (52.0) 10 (43.5) 142 (64.5) 
Age [years, 
median (IQR)]b  
38.2 
(26.6-46.4) 
34.2 
(26.3-43.0) 
34.3 
(28.8-46.2) 
52.8 
(46.0-58.4) 
57.8 
(40.5-64.6) 
39.8 
(29.5-49.0) 
Disease 
duration [years, 
median (IQR)]b  
- 
0.1 
(0.0-0.2) 
2.3 
(1.0-7.0) 
14.9 
(10.0-22.8) 
3.0 
(1.0-6.0) 
1.0 
(0.1-7.0) 
EDSS 
[median, IQR]c - 2 (1.5-2.5) 2 (1.5-3) 4 (3.5-5.75) 3 (2.5-4.5) 2.5 (2-3.5) 
Relapse at LP (n 
[%])d - 33 (53.2) 20 (52.6) 8 (32.0) - 61 (48.8) 
 
a There were more female CIS patients compared to controls (p=0.015), SPMS (p=0.015) and PPMS patients (p=0.002). 
b Controls, CIS and RRMS were younger and had a shorter disease duration compared to SPMS (p<0.0001 for each) and PPMS (p<0.0001 for each 
comparison). PPMS had a shorter disease duration compared to SPMS (p<0.0001). 
c Lower EDSS in CIS versus SPMS (p<0.0001) and PPMS (p<0.0001). Lower EDSS in RRMS compared with SPMS (p<0.0001) and 
PPMS (p<0.0001) and in PPMS compared with SPMS (p=0.022). 
d chi-square test: ns 
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2.2.2. UmanDiagnostics NF-light® ELISA and ECL-NfHSMI35 assay 
The UmanDiagnostics NF-light® ELISA was performed at room temperature. CSF 
samples were diluted 1:1 with sample dilution buffer to a total volume of 100µl and 
incubated with agitation (800rpm) for 1 hour in precoated anti-NFL ELISA plates. 
Thereafter, a 100 µl solution of tracer antibody (biotin anti-NfL) was added to each well 
and incubated for 45 minutes. Washing cycles were performed after all incubations. 
Detection was performed using 100µl of streptavidin-HRP incubated for 30 minutes, 
followed by another incubation with 100µl 3,3’,5,5’-tetramethylbenzidine for 15 minutes. 
A volume of 50µl stop solution (8% v/v sulphuric acid) was added to each well, and 
absorbance was read at λ490nm. The sensitivity of the NfL assay was 31pg/ml. 
The ECL-NfHSMI35 assay and basic CSF analysis has been described in my published 
work on developing a sensitive ECL based immunoassay for NfHSMI35 (151). Baseline 
demographics, disease and CSF characteristics were not significantly influenced by 
omission of one control, one CIS and one RRMS samples due to lack of material (table 
2.1., and table 2.2.). 
 
 
  
 
Table 2.2. Distribution of CSF parameters in patients and healthy controls. 
 Controls CIS RRMS SPMS PPMS 
N 72 62 38 25 23 
cell count a 
(n/mm3) ¶  
ref: ≤5 
1.0 
(0.6-1.7) 
 
4.0 
(2.3-8.9) 
* 
6.2 
(3.0-12.5) 
* 
2.0 
(0.9-5.4) 
p=0.015 
1.6 
(0.7-3.3) 
ns 
Qalb b 
ref: age 
adjusted¶# 
4.5 
(3.5-5.6) 
4.8 
(3.8-6.0) 
ns 
5.7 
(4.3-8.5)  
p=0.002 
5.9 
(4.6-7.5) 
p=0.01 
6.0 
(4.1-7.9) 
p=0.012 
IgG-Index¶ 
ref: <0.7 
0.48 
(0.45-0.5) 
0.87 
(0.6-1.3) 
* 
0.92 
(0.6-1.4) 
* 
0.86 
(0.6-1.2) 
* 
0.87 
(0.7-1.1) 
* 
IgGIF 
(%)¶ <10% 
19.0 
(0.0-46.9) 
* 
22.2 
(0.0-49.6) 
* 
22.0 
(0.0-39.3) 
* 
20.5 
(0.0-33.0) 
* 
IgAIF 
(%)¶ <10% 
0.0 
(0.0-0.0) 
p=0.008 
0.0 
(0.0-0.0) 
* 
0.0 
(0.0-0.0) 
p=0.001 
0.0 
(0.0-0.0) 
p=0.012 
IgMIF 
(%)¶ <10% 
0.0 
(0.0-0.0) 
ns 
0.0 
(0.0-0.0) 
* 
0.0 
(0.0-0.0) 
p=0.001 
0.0 
(0.0-0.0) 
p=0.015 
  
 
OCB+ c 
(n (%)) 0 (0) 
48 (77.4) 
* 
35 (92.1) 
* 
18 (72.0) 
* 
18 (78.3) 
* 
 
¶ Values represent median (IQR), p values versus controls are displayed, * denotes p<0.0001; ns: not significant 
Cell count: white cell count in CSF, Ref: upper reference value. OCB+: oligoclonal bands in CSF, evidence for intrathecal IgG synthesis. 
#
 age-dependent upper limit of Qalb calculated by the formula: Qalb ref: (age/15+4) x10-3. 
a
 Higher CSF cell count in CIS versus SPMS and PPMS (p=0.003 and <0.0001). Higher cell count in RRMS versus SPMS and PPMS (p<0.0001 for 
both). 
b
 Lower Qalb in CIS versus RRMS and SPMS (p=0.025 and 0.021). Lower Qalb in stable RRMS (5.7 (3.2) versus RRMS in relapse (7.8 (3.7), p=0.009). 
c OCB were less frequently detected in SPMS compared to RRMS (p=0.042).
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2.2.3. Precision of the NF-light® ELISA and stability of NfL 
I evaluated reproducibility (intra-assay variability) and repeatability (inter-assay 
variability) of the NF-light® ELISA using 4 native CSF samples in 5 consecutive assays 
on independent days. I tested the stability of NfL at room temperature (RT), 4°C and 
compared this to samples stored at -80°C. Three aliquoted CSF samples were frozen 
at -80°C. The aliquots were thawed on day 0, 3 hours, 1, 4 and 8 days in advance of 
measurement and stored at RT or 4°C until analysis. I normalized the measured 
signals to the signal of the day 0. I analyzed three CSF samples for stability during 
freeze-thawing cycles (151). The samples underwent 1, 2, 3, or 4 freeze-thawing 
cycles and I normalized the signal to the sample freeze-thawed once. Samples were 
refrozen for 24 hours after each thawing step. Due to limited volume, samples for these 
experiments were chosen based on their CSF NfL levels (high, medium and low NfL 
levels) from patients with other diagnoses than CIS, MS or control patients. 
 
2.2.4. Statistical evaluation 
Continuous variables were described by their median and interquartile range (IQR), 
and categorical variables by numbers and percentages. Comparison of basic 
quantitative CSF parameters across groups was performed using the Kruskal-Wallis 
test, and pair wise post-hoc comparisons using the Mann-Whitney U test. Comparisons 
of categorical variables were done using the chi-square test. CSF levels of NfL, Qalb 
and other basic CSF parameters were log-transformed to achieve a normal distribution 
for subsequent analyses. Yet, for simplicity of notation, I used the original terms of CSF 
parameters when reporting and discussing results. To control for age as a potential 
confounding factor an analysis of covariance with age as a covariate and disease stage 
group as a fixed factor was performed. Group-specific levels of NfL and other 
biomarkers were expressed as geometric means with 95%-confidence intervals. For 
log-normal variables, the geometric mean equals the median. Partial correlations 
adjusted for age were computed by first regressing the two variables on age and then 
determining the Spearman rank correlation coefficient (rs) of the respective residuals. 
Receiver operating characteristic (ROC) curves were derived from logistic regression 
(with age as a covariate) to compare the discriminatory power of NfL and NfHSMI35 
between CIS/different stages of MS and healthy controls. The area under the curve 
(AUC) was calculated for NfL and NfHSMI35 and compared using the method of DeLong 
et al (163). A two-sided p-value < 0.05 was considered as significant. P-values of post 
hoc comparisons were adjusted using a Bonferroni correction. All statistical analyses 
and graphs were prepared using SPSS (Version 15.0 SPSS, Chicago, IL) and Graph 
Pad Prism 5.02 for Windows (GraphPad Software, San Diego, CA). 
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2.3. Results 
2.3.1. Analytical performance of the NfL assay and stability of the analyte 
The mean coefficients of variation (CV) of duplicates within given assays were 5.6% 
(5680 pg/ml), 3.1% (564 pg/ml), 5.5% (242 pg/ml) and 3.0% (156 pg/ml). In-between-
assay variation was 8.9% (5680 pg/ml), 7.3% (564 pg/ml), 11.3% (242 pg/ml) and 
13.5% (156 pg/ml). 
Then, I tested the stability of the NfL protein at room temperature (RT) and 4°C as 
compared to reference aliquots stored at -80°C. There was no significant change in 
measured concentration in samples stored at RT and at 4°C for up to 8 days (RT: day 
8: 1.04±0.053 (mean normalized ratio between day 0 and day 8±SD), p=1.0 and 4°C: 
day 8: 1.05±0.051, p=0.5) (figure 2.1.) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1. Stability of the NfL protein at RT (left) and 4°C (right). 
Three CSF samples (S. 1-3) were thawed on day 0 (0 hours, reference), 3 hours in 
advance of measurement (3 hours), and 1 (1 Day), 4 (4 Days) and 8 days (8 Days) 
before the experiment and stored at RT and 4°C. There was no significant change in 
measured concentration in samples stored at RT and at 4°C up to 8 days (RT: day 8: 
1.04±0.053 (mean normalized ratio between day 0 and day 8±SD), p=1.0 and 4°C: day 
8: 1.05±0.051, p=0.5). Mean calculated pg/ml of duplicates (SD) are displayed 
 
 
Next, I analyzed three CSF samples for stability during freeze-thawing cycles. There 
was again no significant effect of freeze-thawing up to 4 times on the measured 
concentrations in three CSF samples (4 freeze-thawing cycles: 1.03±0.026, p=0.25) 
(figure 2.2.). 
S. 1
S. 2
S. 3
0
1000
2000
3000
4000
5000
6000
7000
0 hours 3 hours 1 Day 4 Days 8 Days
N
fL
 
(p
g/
m
l)
0
200
400
600
800
0 hours 3 hours 1 Day 4 Days 8 Days
N
fL
 
(p
g/
m
l)
0
50
100
150
200
250
300
350
400
0 hours 3 hours 1 Day 4 Days 8 Days
N
fL
 
(p
g/
m
l)
0
1000
2000
3000
4000
5000
6000
7000
0 hours 3 hours 1 Day 4 Days 8 Days
N
fL
 
(p
g/
m
l)
0
200
400
600
800
0 hours 3 hours 1 Day 4 Days 8 Days
N
fL
 
(p
g/
m
l)
0
50
100
150
200
250
300
350
400
0 hours 3 hours 1 Day 4 Days 8 Days
N
fL
 
(p
g/
m
l)
 53 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2. Stability of CSF NfL during freeze-thawing cycles. 
Three CSF samples (S. 1-3) underwent 1, 2, 3 or 4 thawing cycles and the measured 
concentrations were normalized to the sample freeze-thawed once, without any 
relevant effect of freeze-thawing (4 freeze-thawing cycles: 1.03±0.026, p=0.25). Mean 
calculated pg/ml of duplicates (SD) are displayed. 
 
 
2.3.2. NfL levels in CSF as a  function of clinical features and age 
CSF NfL levels were increased (F4, 215=26.89, p<0.0001) in all forms and stages of MS 
compared to controls (p<0.0001 for all comparisons). Levels of CSF NfL were 2.8, 4.4, 
2.9 and 3.7 fold higher in CIS, RRMS, SPMS and PPMS, respectively, compared with 
controls. A strong correlation with age was seen for NfL in controls (r=0.61, p<0.0001), 
while this association was absent in CIS (r=0.06, p=0.778), RRMS (r=0.11, p=0.417), 
SPMS (r=0.13, p=0.444) and PPMS (r=-0.08, p=0.694). 
Subsequent analysis of covariance with age confirmed the previous highly significant 
group differences between CIS and all stages of MS in comparison to controls (F4, 
214=26.05, p<0.0001; p=0.001 for SPMS, p<0.0001 for CIS, RRMS and PPMS). 
Moreover, this analysis also revealed a difference between RRMS and SPMS 
(p=0.025) (figure 2.3.). 
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Figure 2.3. NfL levels in the controls, patients with CIS, and patients with MS. 
Geometric mean and 95% confidence interval are displayed (and box and whiskers: 
median and 10-90% percentile). CIS (765.8 pg/ml), RRMS (1200.8 pg/ml), SPMS 
(784.6 pg/ml), and PPMS (1007.0 pg/ml) showed higher CSF NfL levels than controls 
(271.9 pg/ml) and RRMS higher values than SPMS (p=0.025). Dots represent 
individual samples. P Values are adjusted for age and corrected by Bonferroni method. 
 
 
2.3.3. Correlations of NfL with CSF markers of inflammation 
In CIS and RRMS levels of NfL correlated with CSF cell count (rs=0.27, p=0.016 and 
rs=0.43, p=0.01) and albumin quotient (qAlb) in CIS, RRMS and SPMS (rs=0.28, 
p=0.025, rs=0.49, p=0.002 and rs=0.67, p<0.0001). CIS and RRMS patients with a CSF 
cell count >5 cells/mm3 showed almost twice higher NfL concentrations as compared to 
those with normal CSF cytosis (>5 cells/mm3, n=47: 1252 pg/ml [899-1744] versus ≤5 
cells/mm3, n=53: 684 pg/ml [544-859]; p=0.0078). In contrast, no such correlation could 
be observed in progressive MS.  
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IgG index, and intrathecal fractions of the immunoglobulin subclasses were not related 
to CSF NfL levels. Similarly, levels of NfL were not influenced by presence or absence 
of OCB in CIS/MS (OCB+, n=119: 908.3 pg/ml [770.1-1097.9]; OCB- , n=29: 869.5 
pg/ml [604.7-1250.6], p=0.983).  
 
2.3.4. Correlations of NfL with disability and disease activity 
Age-corrected NfL levels correlated with EDSS score in patients with relapsing disease 
(CIS and RRMS: rs=0.31, p=0.002), but not in progressive stages of MS (SPMS and 
PPMS: rs=-0.18, p=0.218). There was no significant correlation between any of the 
inflammation-related CSF markers (Qalb, CSF cell count, OCB positivity, IgG index, 
IgGIF, IgAIF, IgMIF) and EDSS (data not shown). 
Patients with a relapse at the time of lumbar puncture tended to have higher NfL values 
(n=61: 1070 pg/ml [818-1401]) than those in remission (n=64: 734 pg/ml, [598-900]) 
(p=0.054). Similarly, the levels of NfL in patients with relapses due to spinal cord 
pathology was nearly double the levels seen in patients with relapses due to cerebral 
lesions (n=16: 1728 pg/ml [924-3229] vs. n=45: 906 pg/ml [674-1217], p=0.037). As 
previously reported, Qalb levels were higher during relapses (7.0) than in stable disease 
(5.2) (p=0.012) only in RRMS, while  all other inflammation-related CSF markers were 
not influenced by the presence of relapses at the time of spinal tap (152).  
 
2.3.5. Discriminatory power of NfL and NfHSMI35 between CIS/MS and controls and 
relationship of NfL and NfHSMI35 
Figure 2.4 shows ROC plots of NfL and NfHSMI35 in CIS and MS (RRMS, SPMS and 
PPMS) patients. The discriminatory power of NfL was greater than that of NfHSMI35 in 
CIS patients (figure 2.4., left)  and RRMS, SPMS and PPMS together (figure 2.4., 
right) (CIS: AUC 0.83 versus 0.67, p=0.001; all MS patients (RRMS, SPMS, PPMS): 
AUC 0.91 versus 0.85, p=0.035). In separate analyses for RRMS, SPMS and PPMS, 
the differences between NfL and NfHSMI35 did not reach significance (RRMS: p=0.273, 
SPMS: p=0.480 and PPMS: p=0.308). 
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Figure 2.4. ROC plots of NfL and NfHSMI35 in CIS and MS patients versus controls. The 
discriminatory power of NfL was greater than that of NfHSMI35 in CIS patients (AUC 0.83 
versus 0.67, p=0.001) and in all MS patients (RRMS, SPMS, PPMS) grouped together 
(AUC 0.91 versus 0.85, p=0.035). 
 
There was a highly significant correlation of NfHSMI35 and NfL in controls (r=0.40, 
p<0.0001), CIS (r=0.44, p<0.0001), RRMS (r=0.57, p<0.0001) but not SPMS (r=0.23, 
p=0.163) or PPMS (r=0.40, p=0.061). After age correction, this relationship was no 
longer observed in controls (rs=0.058, p=0.627), persisted in CIS (rs=0.46, p<0.0001) 
and RRMS (rs=0.56, p<0.0001)  and was still absent in SPMS (rs=0.31, p=0.128) and 
PPMS (rs=0.41, p=0.054). 
 
2.4. Discussion 
The primary findings of this comparative study were that NfL proved to be a stable 
analyte, and its assay system used here is more sensitive than that for NfHSMI35. NfL is 
considered to represent the most abundant and also most soluble subunit, but there 
have been concerns about its susceptibility to proteases, especially in the protease-rich 
CSF or blood (160). Several groups, have therefore previously concentrated on NfH, as 
a biomarker for axonal damage, as its phosphorylated state is assumed to be more 
stable (149, 164-166). In the present study, CSF NfL levels were demonstrated to be 
stable up to eight days at room temperature and for up to four freeze-thawing steps 
(93, 132). These results are well in line with my previous findings of NfHSMI35 levels in 
CSF being stable over prolonged storage times and repeated freeze-thawing steps 
(151). We conclude that there is no basis to prefer NfH over NfL as biomarker of axonal 
damage due to concerns of sample stability. 
 
Persisting neurological deficits in MS likely emerge as a consequence of accumulating 
nerve injury starting in the very early phase of the disease. Confirming my previous 
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NfHSMI35 results, levels of NfL were increased already in CIS and in all other stages of 
the disease as compared with controls. Interestingly, differences between CIS and MS 
patients and controls were more pronounced for NfL than for NfHSMI35 (figure 2.3.) 
(152). The increased discriminatory power of the commercial NfL ELISA as compared 
with the ECL-NfHSMI35 assay, especially in CIS stages, was also reflected by the results 
of the ROC curve analyses. The higher abundance of NfL and/or better performance of 
the two monoclonal antibodies (versus the polyclonal detection antibody in the ECL-
NfHSMI35 assay) included in the UmanDiagnostics NF-light® assay seem to outweigh the 
known high sensitivity and higher dynamic range of the ECL technology used in the 
NfHSMI35 assay (95) (see also chapter 1). 
In my previous study, NfHSMI35 showed a strong correlation with age in controls (rs=0.5, 
p<0.0001) and in patients with a CIS (rs=0.5, p<0.0001); the correlation was weaker in 
RRMS (rs=0.35, p=0.027) and absent in SPMS and PPMS (152). In this study, the 
correlation between age and NfL was even more pronounced in controls (rs=0.61, 
p<0.0001), but absent in all other stages of disease. Both NfHSMI35 and NfL findings are 
well in line with a recent report on CSF NfH and NfL levels showing that  NfH (r=0.71, 
p<0.005) and NfL (r=0.93, p<0.001) were strongly correlated with age in controls. In 
patients with CIS, this correlation was less strong for NfH (r=0.33, p<0.01) and absent 
for NfL levels (r=0.15, p>0.05) (102) (see chapter 1). I therefore hypothesize that 
disease related neurodegenerative processes outweigh physiologic, age-related 
changes of NfL clearance even in the earliest stages of MS and that this effect is more 
evident in NfL given the higher sensitivity of this assay compared to the NfHSMI35. 
In the above mentioned recent work by Khalil et al., NfH and NfL levels in CSF of CIS 
patients significantly correlated with CSF cell count, IgG index and Qalb. Therefore, my 
results suggest that CSF NfL levels not only reflect chronic neurodegenerative 
processes but also are linked to more acute inflammatory processes (102). NfL levels 
correlated with the extent of blood-CSF barrier damage in CIS, RRMS and SPMS, and 
with CSF inflammatory cell counts in CIS and RRMS. Further, NfL levels determined at 
the time of a relapse, especially during spinal cord related relapses were highly 
increased. This further supports the concept that  Nf release in MS reflects two parallel 
neurodegenerative processes: 1) a chronic brain-diffuse neuroinflammation; 2) an 
acute focal inflammatory activity in the course of plaque formation.  
 
Similarly to  my findings on NfHSMI35, NfL levels correlated with disability in earlier (CIS 
and RRMS) but not in progressive (SPMS and PPMS) stages (152). Conversely, none 
of the other inflammatory CSF markers correlated with the EDSS. Likewise NfL and 
NfHSMI35 concentrations in CIS and RRMS (but not controls) showed a robust 
correlation, whereas this was not seen in progressive disease. It remains speculative, if 
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the relatively small sample number of patients in progressive MS, the difficulty in 
quantifying neurological deficits by the EDSS, or a dissociation of liberation of different 
Nf subunits in progressive MS have contributed to these findings. In addition, a number 
of biological mechanisms may act over time to change Nf bioavailability and 
disproportionally distort correlations between different Nf isoforms or clinical measures. 
These include: 1) the formation of aggregates which may reduce Nf detection and 2) 
the raising levels of autoantibodies against NfL which may have a clearing effect of 
circulating proteins (157-159).     
 
NfL levels in CSF have been reported to be higher in different stages of MS compared 
to healthy controls and in relapse versus remission (92, 97) (see chapter 1). Previous 
studies also reported relatively weak correlations of NfL levels with the EDSS (96, 98, 
167) and, in fewer studies, with age in controls (91). Teunissen and colleagues 
performed the only study so far investigating NfL and NfH levels in all stages of MS and 
control groups. NfL was determined by the Uman-Diagnostics NF-light® ELISA 
(reagents) and NfH by a modified conventional ELISA assay (100, 149). Similarly to my 
findings, NfL was increased in CIS and all stages of MS and, after age correction, 
correlated weakly with the EDSS in CIS and MS (r=0.192, p<0.05). Patients in relapse 
also displayed higher levels than those in remission (p=0.04). Differences for NfH were 
less pronounced than previously reported by our group. Information regarding 
correlation of NfL and NfH and/or age in controls and separate stages of MS were not 
given and performance of the NfL versus the NfH assay was not described (100, 152). 
 
Limitations of this study include the relatively small number of patients (especially 
SPMS and PPMS) and lack of follow-up data and samples. Furthermore, I did not have 
access to CSF samples from healthy controls, but only to samples from individuals who 
did not have any objective clinical or paraclinical findings, but anyway needed to 
perform a lumbar puncture. Also I was not able to choose age matched controls and 
had to apply statistical correction for age. Finally, conventional and advanced MRI data 
were not available. 
Taken together my results confirm and expand on previous findings of Nf as 
quantitative markers of neurodegeneration in CSF. NfL and NfHSMI35 are both stable 
proteins, an important prerequisite for biomarkers. It is important to note, that based on 
my findings, we cannot conclude that NfL is a superior analyte over NfH in general. 
Some of my results are likely to reflect the properties of the assays used and not wholly 
the properties of the proteins. Rather, in comparison to the very sensitive ECL-NfHSMI35 
assay, the NF-light® ELISA differentiates better between health and disease, especially 
in the CIS stage. All my analyses were performed in CSF, conversely, serum Nf 
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measurements would be the most relevant for clinical practice, an aim so far reached 
more frequently for analyses of NfH (154, 159, 168, 169) as compared to serum NfL 
(170). Based on this, further development of an NfL assay including the benefits of the 
ECL technology seemed a promising approach towards NfL measurements also in 
serum/plasma samples. These findings support the role of Nf as a useful measure of 
neurodegeneration and their potential usefulness as surrogate measure for treatment 
studies in MS.  
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3. CSF NfL and NfH as therapy response biomarkers in multiple sclerosis 
 
 
3A. NfL and NfH as therapy response markers to natalizumab (171) 
3.1. Introduction 
Increased NfL and NfH levels have been found in all stages of MS with the highest 
levels observed during relapses and in the presence of Gd+ lesions on MRI (96, 97, 
100, 152). Natalizumab binds to α4β1-integrin, preventing lymphocyte transmigration 
into the CNS and is approved as monotherapy for RRMS (172). 
The UmanDiagnostics NF-light® assay uses two highly specific non-competing 
monoclonal antibodies to quantify NfL in human body fluids (95). A recent study 
employed this assay in patients with RRMS showed that natalizumab treatment 
normalized CSF NfL levels (101). As pointed out in the introduction, we had developed 
a sensitive ECL-based solid-phase sandwich immunoassay for NfHSMI35 in CSF (151).  
The aim of this study was to measure CSF NfHSMI35 levels using our ECL based assay 
and compare these with CSF NfL levels in a subset of the patients who had previously 
shown significantly reduced NfL levels after natalizumab treatment (101).   
 
3.2. Patients and Methods 
3.2.1. Patients, CSF samples and Nf assays 
CSF was consecutively collected from 30 patients by lumbar spinal taps before 
(preNat) and after (postNat) 12 months of natalizumab treatment (all samples from the 
Sahlgrenska Academy, University of Gothenburg that were included in (101)). All 
patients (median age 35.0 (IQR 28.8-40.5) years; disease duration 6.5 (4.0-9.3) years, 
EDSS 3.5 (2.0-6.0)) were in the RRMS stage of the disease. CSF NfHSMI35 levels were 
determined by ECL-based solid-phase sandwich immunoassay (151). CSF NfL levels 
were measured with the UmanDiagnostics NF-light® ELISA as described in (101). The 
investigator who conducted the NfHSMI35 measurements had no access to the clinical 
data.  
 
3.2.2. Standard Protocol Approvals, Registrations, and Patient Consents  
Samples were collected after written patient informed consent and the study was 
approved by the regional ethical board of Uppsala University, Sweden. 
 
3.2.3. Statistical evaluation 
Nf levels are described by median and IQR and compared by Wilcoxon matched pairs 
test or Mann-Whitney U test. Correlation analysis was done by Spearman rank 
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correlation coefficient (r). Partial correlations adjusted for age were computed by first 
regressing the two variables on age and then determining the Spearman rank 
correlation coefficient (rs) of the respective residuals. A two-sided p-value < 0.05 was 
considered as significant. All statistical analyses and graphs were prepared using 
SPSS (Version 15.0 SPSS, Chicago, IL) and Graph Pad Prism 5.02 for Windows 
(GraphPad Software, San Diego, CA). 
 
3.3. Results 
3.3.1. Effect of natalizumab treatment 
22/30 patients (73.3%) had lower NfHSMI35 levels in postNat compared with preNat 
(median 32.4 (IQR 22.5-44.8) pg/ml vs. 27.4 (21.0-34.7) pg/ml, p=0.002, figure 3.1.). 
In comparison 27/30 (90%) patients had lower NfL levels in postNat compared with 
preNat (820 (405-2130) pg/ml vs. 375 (293-575) pg/ml, p<0.0001, figure 3.1.).  
 
 
Figure 3.1. CSF NfHSMI35 (left) and NfL (right) levels before (PreNat) and after 
natalizumab treatment (PostNat). 
22/30 patients (73.3%) had lower NfHSMI35 levels in postNat compared with preNat 
(median 32.4 (IQR 22.5-44.8) pg/ml vs. 27.4 (21.0-34.7) pg/ml, p=0.002) (left). In 
comparison 27/30 (90%) patients had lower NfL levels in postNat compared with 
preNat (820 (405-2130) pg/ml vs. 375 (293-575) pg/ml, p<0.0001) (right).  
 
3.3.2. Age association 
NfHSMI35 showed a moderate correlation with age at both time points (preNat: r=0.38, 
p=0.038; postNat: r=0.399, p=0.029). Conversely, this was not seen for NfL (preNat: 
r=-0.07, p=0.73; postNat: r=0.20, p=0.299). 
 
3.3.3. Disability and disease activity 
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NfHSMI35 and NfL did not correlate with EDSS score after age correction at either of the 
two time points (NfHSMI35: preNat: rs=0.29, p=0.123; postNat: rs=0.05, p=0.794; NfL: 
preNat: rs=0.001, p=0.997; postNat: rs=0.058, p=0.761). 
Eight of the 30 patients experienced a relapse within 3 months prior to preNat and 3 
patients had a relapse whilst receiving natalizumab prior to sampling (postNat) (one 
patient experienced a relapse prior to both samplings). NfHSMI35 levels were significantly 
higher in preNat patients experiencing a relapse (47.7 pg/ml, n=8) versus those in 
remission (27.6 pg/ml, n=22, p=0.001), whereas this difference was not significant for 
NfL (relapse: 1055 pg/ml, remission: 725 pg/ml, p=0.256). The duration since onset of 
relapse and NfHSMI35 correlated (R=0.73, p=0.04); this was less clear for NfL (R=0.64, 
p=0.091). 
After exclusion of the 10 patients experiencing a relapse in the 3 months prior to or 
after starting natalizumab, median NfL levels dropped from 830 pg/ml to 365 pg/ml 
(p=0.0002) after natalizumab treatment. This was less clear for NfHSMI35 levels (preNat: 
28.3 pg/ml; postNat: 26.9 pg/ml, p=0.086), i.e. 90% of the patients experienced a 
reduction of NfL, whereas this was only seen in 65% of the patients for NfHSMI35. Both 
NfL and NfHSMI35 levels in the 10 patients experiencing a relapse were clearly lower in 
postNat compared with preNat (775 pg/ml versus 550 pg/ml, p=0.013 and 45.6 pg/ml 
versus 32.2 pg/ml, p=0.013). 
 
3.3.4. Relationship of NfL and NfH SMI35 in preNat and postNat 
NfL levels in preNat correlated with NfL levels in postNat (r=0.59, p=0.001). This 
relationship was more pronounced for NfHSMI35 (r=0.73, p<0.0001). After age 
correction, NfL and NfHSMI35 levels in preNat correlated (rs=0.38, p=0.037) while this 
was not seen in postNat (rs=0.25, p=0.179). 
 
3.4. Discussion 
Persisting neurological deficits in MS likely emerge as a consequence of accumulating 
axonal injury starting in the very early phase of the disease. Due to the lack of reliable, 
quantitative biomarkers, the effect of immunomodulatory treatments on neuro-axonal 
damage and degeneration has been difficult to assess. Increased CSF levels of Nf 
reflect on-going axonal deterioration, the culprit of disability development in MS. 
Several other body fluid biomarkers mirror different parts of the actual immune activity 
in MS. In comparison with these inflammatory biomarkers, the therapeutic impact of 
immunomodulatory drugs on Nf levels adds essential information about the effects on 
neuro-axonal damage. 
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A recent study in 92 patients with RRMS showed that natalizumab treatment for 6-12 
months reduced NfL levels from a mean of 1300 pg/ml to 400 pg/ml (p<0.0001). Post 
natalizumab treatment values were similar to levels from healthy subjects (350 pg/ml) 
(101). In this study the mean NfL concentration in patients with a recent relapse was 
2300pg/ml (n=30), as compared to 860pg/ml in patients in remission (n=62, p<0.038). 
Importantly, when analyzing exclusively the patients in remission, NfL levels were still 
significantly reduced following natalizumab treatment (p<0.001). I confirmed the 
reduction in CSF Nf levels after natalizumab treatment by independently measuring 
CSF NfHSMI35 in a subset of 30 patients from this cohort (p=0.002). Despite losing 
significance for the reduction of NfHSMI35 after excluding 10 of the 30 patients that 
experienced a relapse within 3 months of sampling, these results support and confirm 
mitigation of neuro-axonal damage or degeneration by natalizumab treatment. 
Of note, the NfL measurements seemed to be more treatment responsive than 
NfHSMI35: the mean post-treatment reduction of NfL was 45% as opposed to 11% for 
NfHSMI35. This suggests that measurements of NfL could be superior over NfHSMI35 to 
detect treatment effects in the CSF of MS patients. 
Previous studies have reported relatively weak correlations of NfL with the EDSS (98) 
and with age in controls (91). Similar findings have been reported for NfH in CSF of MS 
patients (152). Sample access in this study was limited to 30 CSF pairs and the follow-
up was limited to 12 months. Furthermore, we need to remember that measured Nf 
values likely reflect the rate of on-going axonal destruction rather than established 
cumulative damage, and this may well represent a possible explanation for the lack of 
correlation between the investigated Nf proteins and EDSS scores. 
Limitations of this work include availability of only a relatively small subfraction of 
samples from the original study (101) and the lack of imaging data. Because high 
disease activity is the main indication for treating patients with natalizumab and a 
parallel placebo group was missing, regression to the mean cannot be excluded as an 
additional effect. 
Taken together, I confirmed CSF Nf as promising candidates to measure neuro-axonal 
damage or degeneration in MS treatment trials. In comparison to the ECL-NfHSMI35  
assay, the responsiveness of the NF-light ELISA to natalizumab treatment was more 
pronounced, suggesting that the UmanDiagnostics NF-light® assay should be 
considered the preferred assay for future investigations. 
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3B. Fingolimod reduces CSF NfL levels in relapsing multiple   
 sclerosis (173) 
 
3.5. Introduction 
The effect of immunomodulatory treatments on neuroaxonal damage and degeneration 
in MS has been difficult to assess, in part, due to the lack of reliable, quantitative 
biomarkers. 
Fingolimod (Gilenya™, Novartis Pharma AG), a sphingosine-1-phosphate receptor 
modulator, is the first oral therapy approved for the treatment of RRMS. Preclinical 
findings  (174) and consistent effects on brain atrophy observed in MS clinical trials 
(175-177) suggest fingolimod has potential neuroprotective properties.  
In this study I assessed the reliability of CSF NfL, as a therapeutic biomarker in RRMS, 
by comparing levels in fingolimod-treated patients versus placebo, and correlating NfL 
levels with clinical and MRI outcomes. 
 
3.6. Methods 
This was a post-hoc investigation of NfL in CSF samples collected at baseline and 
Month-12 in a subgroup of RRMS patients participating in the 2-year, placebo-
controlled, phase III FREEDOMS study (ClinicalTrials.gov number, NCT00289978), 
that evaluated fingolimod at the doses of 0.5mg and 1.25mg, once-daily (176). 
Provision of CSF samples was an optional component of the FREEDOMS study 
protocol. Definitions and methodologies of clinical and MRI assessments, protocol 
approvals and registration details, have been previously described (176). The study 
was approved by the local Institutional review Boards. All patients provided written 
informed consent. 
CSF samples were available from 36 consenting patients (0.5mg, n=9; 1.25mg, n=15; 
placebo, n=12). I measured CSF NfL levels using the Uman Diagnostics NF-light® 
ELISA kit (Umeå, Sweden). The assay was conducted blinded to the clinical data and 
treatment allocation (101, 104, 171). Inter- and intra assay variability (CV) in three 
longitudinal control samples were below 15%. 
 
Statistical analysis 
Variables are described as medians (interquartile range) or numbers and percentages. 
The Mann-Whitney test was used for between group comparisons (0.5mg, 1.25mg and 
pooled fingolimod-treated [0.5mg and 1.25mg] versus placebo). The Wilcoxon matched 
pairs test was used to evaluate longitudinal comparisons. Correlations were analyzed 
using the Spearman correlation methodology on the pooled fingolimod-treated (0.5mg 
or 1.25mg) patient group. A two-sided p-value <0.05 was considered significant. All 
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analyses were conducted using SPSS (version 20, Chicago, IL) and GraphPad Prism 
5.04 (GraphPad Software, San Diego, CA). 
One patient discontinued from the fingolimod 1.25mg group due to an adverse event 
(increased liver enzymes) after 6.4 months on treatment. Although month-12 CSF 
sample was available from this patient, considering the short duration on treatment, the 
data of this patient was included only in the primary but not the correlation analyses. 
 
3.7. Results 
Baseline and on study characteristics for the 36 patients evaluated in this study, are 
presented in Table 3.1 (A-G). The median time since onset-of-the-last relapse to 
baseline was 159 days (122-277). During the study, three patients on placebo 
experienced a total of five relapses. Two patients in the fingolimod groups reported one 
confirmed relapse each, and one patient in the fingolimod 1.25mg group experienced 
two confirmed relapses. One patient in the placebo group had a relapse with onset 13 
days prior to CSF sampling at Month-12. Fingolimod-treated patients had better clinical 
and MRI outcomes versus placebo at Month-12. 
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Table 3.1. Baseline and month 12 results 
 Fingolimod 
0.5 mg 
N=9 
Fingolimod 
1.25 mg 
N=15 
Placebo 
N=12 
A] Demographics 
Age, years  
 29.0 (25.5 – 39.0) 40.0 (32.0 – 42.0) 37.5 (27.8 –50.0) 
Gender: females,  
n (%) 
7 (77.8%) 8 (53.3%) 6 (50.0%) 
B] Relapses# 
Previous 2 years   2.0 (1.0 –2.5) 2.0 (1.0 – 2.0) 2.0 (1.0 –3.0) 
BL to M12 (n)* 1 3 5** 
C] T2 volume (mm3) 
BL 
1966  
(582 – 3754) 
1957  
(1170 – 5153) 
1858  
(479 – 6438) 
M12 
2040 
 (635 – 3554) 
1828 
 (1127 – 5159) 
2352  
(830 – 6885) 
Change 
-52  
(-210 – 53) 
6  
(-89 – 60) 
318  
(-30 – 1213) 
D] new enlarging T2 lesion count 
M12 0 (0 – 3) 0 (0 – 1.0) 4.5 (0.3 – 11.0) 
E] Gd+ T1 lesion count 
BL 0 (0 – 1.0) 0 (0 – 1.0) 0 (0 – 1.8) 
M12 0 (0 – 0) 0 (0 - 0) 0 (0 – 1) 
Change 0 (-1 – 0) 0 (-1.0 – 0) 0  (-0.8 -0.8) 
F] Brain volume 
BL normalized  
brain volume (mm3) 
1596 (1507 – 1634) 1538 (1481 – 1585) 1522 (1481 – 1569) 
PBVC (%): BL-M12 -0.6 (-0.8 – 0.5) 0.04 (-1.1 – 0.2) -0.4 (-0.7 – -0.1) 
PBVC (%): BL-M24  
 
-0.3 (-1.1 – -0.2) -0.2 (-1.3 – -0.1) -0.8 (-1.6 – -0.0) 
Values are median (interquartile range, IQR) unless indicated otherwise. BL: Baseline;; 
Gd+:gadolinium enhancing; M12: month 12; PBVC: Percentage brain volume change; * 
Confirmed relapses; ** Two patients experienced two relapses and one patient one 
relapse.# Acute relapses were defined as those starting within 30 days before CSF 
sampling 
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3.7.1. Effect of fingolimod treatment on NfL levels (Figure 3.2.) 
NfL levels at baseline were comparable across the treatment groups (0.5mg: 644pg/ml; 
1.25mg: 659pg/ml; pooled fingolimod 0.5/1.25mg: 652pg/ml; placebo: 886pg/ml, p-
value [fingolimod vs. placebo] =0.619, 0.495 and 0.481 respectively). By Month-12, 
median NfL levels had decreased significantly, as compared to baseline in the 
fingolimod treated groups (0.5mg: 401pg/ml [37.7% reduction], p=0.028; 1.25mg: 
321pg/ml [51.3% reduction], p=0.017; pooled fingolimod 0.5/1.25mg: 335pg/ml [48.6% 
reduction], p=0.001), while the reduction in the placebo group between baseline and 
month 12 was not significant (738pg/ml [16.7% reduction], p=0.433). At month-12, NfL 
levels were lower in the pooled fingolimod group than placebo (p=0.022). 
 
 
 
Figure 3.2. NfL levels at baseline and after 12-months, cross-sectional analysis. 
NfL levels at baseline; pooled fingolimod 0.5/1.25mg: 652pg/ml; placebo: 886pg/ml, 
p=0.481. At 12 months, NfL levels pooled fingolimod group: 335pg/ml; placebo: 738 
pg/ml, p=0.022.                          
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NfL: neurofilament light chain in CSF; * Mann-Whitney test; # Wilcoxon matched pairs 
test: baseline versus month-12. Dots represent individual samples. Box and whiskers 
plotted according to the Tukey method. 
 
3.7.2. Evaluation of NfL outliers (Figure 3.3. A-C) 
Four patients, one patient each in the 
placebo and fingolimod 0.5mg groups 
and two patients in the fingolimod 
1.25mg group, showed extreme 
changes in NfL levels at Month-12 
compared with baseline. The overall 
results were not affected by inclusion 
or exclusion of these outlier patients in 
the analysis.  
Patients W (Figure 3A) and X (Figure 
3B) in the fingolimod groups showed a 
marked reduction in NfL levels at 
Month-12 versus baseline. These were 
paralleled by clinical and paraclinical 
improvements over the 12-month 
observation period. Patient Y (Figure 
3B) experienced a marked increase in 
NfL levels, paralleled by two relapses, 
an increase in Expanded Disability 
Status Scale (EDSS) score and T2 
lesion volume. This patient 
subsequently discontinued from the 
study drug after 6.4 months due to an 
adverse event. Patient Z (placebo; 
Figure 3C) experienced an increase in 
NfL levels at Month-12 compared with 
baseline and a corresponding increase 
in EDSS.  
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3.7.3. Correlation analysis (n=35 patients) 
Baseline CSF NfL levels did not correlate with age (r=-0.08, p=0.63) or gender 
although trending to higher values in males (female: 576pg/ml [426-920], male: 
1023pg/ml [634-1238], p=0.106). 
Month-12 NfL levels were higher in patients who experienced relapses during the study 
(1398pg/ml [428-1826]) versus those who did not (384pg/ml [285-698], p=0.048). In 
patients receiving placebo, Month-12 NfL correlated with Month-12 EDSS (r=0.65, 
p=0.021, n=12) as well as EDSS change from baseline to Month-12 (r=0.58, p=0.047, 
n=12). Similar correlations did not reach statistical significance in the entire cohort or in 
patients treated with fingolimod.Across all groups, baseline NfL levels positively 
correlated with T2 lesion volume at baseline (r=0.37, p=0.027). Month-12 NfL levels 
and new/enlarging T2 lesions count (r=0.54, p=0.001) were also positively correlated. 
Reductions in NfL levels were associated with reductions in gadolinium enhancing 
(Gd+) T1 lesion count (r=0.44, p=0.008) and Gd+ lesion volume (r=0.44, p=0.008). 
NfL levels inversely correlated with normalized brain volume (nBV) (r=−0.38, p=0.025) 
across all groups at baseline. Correlations of percentage brain volume change from 
baseline to months (M)-12 and -24 with baseline NfL levels in both fingolimod 
(rM12=−0.17, p=0.602; rM24=−0.32, p=0.137) and placebo (rM12=−0.17, p=0.602; 
rM24=−0.47, p=0.124) groups did not reach statistical significance.  
 
3.8. Discussion 
The results of this study supported the premise that CSF NfL levels suitably indicate 
the treatment effect due to immunomodulatory drugs on ongoing neuroaxonal damage 
in MS. My data demonstrates that CSF NfL levels decrease markedly in fingolimod-
treated patients, whereas a similar change is not seen in patients on placebo. The 
reduction in NfL levels correlated with the absence of any worsening in clinical and MRI 
measures of disease activity in treated patients, consistent with outcomes observed in 
the fingolimod trials (175, 176). Additionally, extreme changes in CSF NfL levels were 
reflected by the clinical and paraclinical disease course even in individual patients.  
These results are consistent with those of chapter 3A which showed that natalizumab 
treatment also considerably decreases CSF NfL levels in RRMS patients to levels 
observed in healthy controls. It is important to note that the methodology used by 
myself and Gunnarson et al to measure CSF NfL levels is the same (101).  
The design of the FREEDOMS trial (176) allowed me to analyze clinical and MRI data 
longitudinally and to include placebo-treated patients. A  reduction in CSF NfL levels 
was also observed in the placebo group, however this was not statistically significant 
and I believe this could potentially reflect a regression to the mean phenomenon for 
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CSF NfL. Indeed, all patients included in the study required a high level of disease 
activity to fulfill the inclusion criteria of the trial. However, changes in NfL levels were 
clearly more pronounced in both fingolimod groups than in placebo and this strongly 
suggests a valid fingolimod treatment effect, rather than spontaneous fluctuations in 
disease activity. 
The relationship between CSF NfL and MRI measures in RRMS has been rarely 
investigated. A correlation between CSF NfL levels and the number of T2 (r=0.35, 
p<0.024) and Gd+ (r=0.50, p<0.001) has been reported (100). In partial contrast, one 
study in patients with a CIS found no association between CSF NfL levels and T2 
lesion volume or nBV. However, higher CSF NfH levels correlated with brain volume 
loss over a median follow-up of one year (r=-0.518, p<0.01) (102). In my study, 
baseline CSF NfL levels and normalized brain volume showed an inverse correlation 
(r=-0.38, p=0.025). Further, in favour of NfL reflecting subclinical disease activity and 
ongoing axonal degeneration, I noted an association between M12 CSF NfL levels and 
MRI measures and confirmed relapses over the 12 months. In addition, baseline CSF 
NfL levels were associated with the PBVC over 24 months thus suggesting a potential 
of predicting future brain volume loss. 
Limitations of this study are the relatively small sample size, due to the difficulty in 
obtaining paired CSF samples and the short duration of follow-up. The main strength is 
represented by the longitudinal and placebo controlled design.   
 
To conclude, I present the first study evaluating the effect of fingolimod treatment on 
CSF NfL levels in RRMS patients. My results support CSF NfL quantification as a 
surrogate measure of subclinical disease activity related to ongoing CNS 
neurodegeneration and as a putative therapeutic biomarker in clinical trials of novel 
agents for MS therapy. In this context, it is foreseeable that CSF NfL levels could 
provide relevant information to facilitate treatment decisions in the future possibly also 
including tailored therapeutic regimens based on individual treatment response. 
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4. Increased NfL blood levels in neurodegenerative neurological  
 diseases (94) 
 
 
4.1. Introduction 
Blood Nf levels could be useful for both predicting and monitoring disease progression 
and for assessing the efficacy and/or toxicity of future neuroprotective treatment 
strategies. 
Several previous studies have demonstrated the presence of NfH and NfL in CSF, 
which has been assumed to reflect brain pathology more accurately than the peripheral 
blood compartment (92, 98, 100, 101, 149, 151-153, 178-180). However, obtaining 
longitudinal CSF samples is considered too invasive outside the clinical trial arena, 
precluding the broader clinical use of Nf. In contrast to CSF, serial blood samples can 
readily be collected, hence reliable quantification of NfL in blood would be a major 
stride towards a biomarker of the course of neurodegeneration. Several reports have 
suggested peripheral blood levels of NfH as a potential marker of neurodegeneration in 
ALS (168, 181), stroke (182, 183), subarachnoid hemorrhage (184), neurotoxicity after 
aggressive chemotherapy (169), or brain injury after cardiac arrest (185). In contrast, 
only one study has investigated serum NfL by examining its relation with neurological 
outcome following cardiac arrest (170). 
So far, only a few studies investigated NfH levels in blood samples from MS patients, 
while NfL concentrations in serum or plasma of MS patients had never been assessed. 
An initial study showed that plasma NfH concentrations were significantly higher in 
patients with an acute episode of optic neuritis (170 pg/ml, n=18) as compared to 
healthy controls (5 pg/ml, n=14). NfH levels were inversely correlated with visual acuity 
at presentation (r=0.67; p = 0.01) and were higher in patients with poor compared to 
good visual recovery (0.25ng/mL vs. 0.09 ng/mL; p=0.05) (154). A recent study found 
slightly higher serum NfH levels in SPMS compared to healthy controls (HC) (p=0.011), 
CIS (p=0.041), and RRMS (p=0.048). RRMS and SPMS patients with NfH levels above 
the cut-off had a higher median MSSS score than patients with normal NfH levels 
(p<0.05), but did not have higher serum NfH levels than HC (156). Similarly, to my 
knowledge only one study had reported correlations between serum and CSF NfH 
levels (CSF and plasma: n=20, r=0.47; CSF and serum: r=0.51) (186). 
The commercially available ELISA (UmanDiagnostics NF-light® assay) (see also 
previous chapters) uses two highly specific, non-competing monoclonal antibodies 
(47:3 and 2:1) to quantify soluble NfL in CSF samples but it cannot in its present form 
be used for analysis of blood samples (95).  
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The aim of this study was to develop and validate (both analytically and clinically) a 
sensitive ECL-based NfL assay suitable for the quantification of NfL in serum at 
concentrations relevant to clinical settings. 
 
4.2. Materials and Methods 
4.2.1. Antibodies and chemicals 
The following mouse antibodies were used: Capture monoclonal antibody (mAB) 47:3, 
and the biotinylated detector mAB 2:1 (92, 95). MSD SULFO-TAGTM labelled 
streptavidin was used as detection reagent to generate ECL (MSD, Gaithersburg, MD). 
Bovine serum albumin (BSA), NaCl, phosphate buffered saline, pH 7.5 (PBS), tris base 
and Tween 20 were of analytical grade (Sigma-Aldrich, Saint Louis, MO).  
 
4.2.2. Standards 
Bovine lyophilized NfL was obtained from UmanDiagnostics (N Norgren). Standards 
were diluted in tris buffered saline (TBS) containing 1% BSA, 0.1% Tween 20, pH 7.5 
and ranged from 0 to 10,000 pg/ml. Batch prepared standards were stored at -80°C. 
 
4.2.3. Patients and Controls 
Paired CSF and serum samples were collected during routine diagnostic investigations 
as indicated by the treating physicians. Samples were collected and processed at room 
temperature within two hours. Serum samples were spun at 2,000 g, CSF samples at 
400 g at room temperature for 10 minutes, aliquoted in polypropylene tubes and stored 
at -80°C.  
Serum samples from 67 healthy control subjects (HC) were included in the study. For 
ethical reasons CSF samples were not available from these subjects. The group of 
control patients (CP) (n=68) consisted of patients who, based on extensive diagnostic 
evaluation had no objective clinical, structural (cranial magnetic resonance imaging, 
MRI), laboratory (CSF analysis) or functional (electroencephalography, EEG) deficit. 
These patients suffered from tension type headache (n=21), lower back pain (n=7), 
psychiatric disorders (n=26) or miscellaneous non-specific symptoms for which no 
neurological explanation could be found (n=14). From two of these patients there was 
not enough CSF left for further analysis. In addition, 49 patients with probable or 
definite ALS (for three no serum and for one no CSF sample was available) (187), 
probable AD (63), or GBS (for one no serum sample was available) (n=20 each) were 
included (table 4.1.). 
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Table 4.1. Demographic characteristics of healthy controls, control patients and 
patients. 
 HC CP AD GBS ALS 
N 67 68 20 20 49 
Females 
(n [%])a 38 (56.7) 41 (60.3) 13 (65.0) 10 (50.0) 14 (28.6) 
Age [years, 
median 
(IQR)]b  
35.0 
(28.0-42.0) 
38.3 
(27.5-46.4) 
72.5 
(70.1-80.2) 
59.6 
(39.1-71.7) 
62.7 
(54.5-70.7) 
 
a There were less female ALS patients compared to HC (p=0.004), CP (p=0.001) and 
AD (p=0.007). 
b HC and  CP, were younger compared to AD, GBS and ALS (p<0.0001, respectively). 
HC: Healthy controls; CP: Control patients; AD: Alzheimer’s disease; GBS: Guillain-
Barré syndrome; ALS: Amyotrophic lateral sclerosis; IQR: Interquartile range. 
 
Samples for precision and accuracy experiments as well as for stability and parallelism 
were chosen based on their NfL levels (high, medium and low) irrespective of their 
diagnosis due to availability of limited sample volumes. 
 
4.2.4. Analytical procedure 
The 96-well plates (Multi-Array® plates, Meso Scale Discovery, Gaithersburg, MD) 
include integrated screen-printed carbon ink electrodes on the bottom of the wells. 
Coating was done overnight with 30 µl of capture antibody (mAB 47:3,1.25 µg/ml) 
diluted in PBS (pH 7.4) at 4ºC. All following incubation steps were done on a plate 
shaker (800 rpm) and were preceded by three wash steps with 200 µl of TBS, 
containing 0.1% Tween 20 (pH 7.5) per well. Non-specific binding sites were blocked 
with 100 µl of TBS, containing 3% BSA, per well for 1h. After washing, 25 µl of TBS 
containing 1% BSA and 0.1% Tween 20 was added as sample diluent to each well. 25 
µl of standard, control or serum/CSF sample was then added in duplicate and the plate 
incubated at RT for 2h. After washing, 25 µl of the secondary antibody (mAB 2:1, 0.5 
µg/ml) diluted in TBS containing 1% BSA and 0.1% Tween 20 was added to each well 
and the plate incubated for 1 h at RT. After washing, MSD SULFO-TAGTM labelled 
streptavidin (0.25 µg/ml), diluted in TBS containing 1% BSA and 0.1% Tween 20, was 
added and incubated for 1h at RT. Following a final wash, 150 µl of ECL read buffer 
(MSD) diluted 1:2 with distilled water was added and the ECL signal, detected by 
photodetectors, measured using the MSD Sector Imager 2400 plate reader. A four-
parameter weighted logistic fit curve was generated, sample concentrations 
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extrapolated and analysed using the Discovery Workbench 3.0 software (MSD). If 
required, samples were appropriately diluted to fall in the range of the standard curve. 
Non measurable NfL samples were reported as 0 pg/ml. 
 
4.2.5. Statistical analysis 
Continuous variables were described by their median and interquartile range (IQR), 
and categorical variables by numbers and percentages. Comparison of demographic 
data was performed using the Kruskal-Wallis test, and pairwise post-hoc comparisons 
using Dunn’s post-test or chi-square test as appropriate. Serum and CSF levels of NfL 
were log-transformed to achieve a normal distribution for subsequent analysis. To 
control for age as a potential confounding factor, an analysis of covariance with age as 
covariate and disease group as fixed factor, was performed (152). Group-specific 
levels of NfL were expressed as geometric means with 95%-confidence intervals. For 
log-normal variables, the geometric mean equals the median. Correlations were 
computed by determining the Spearman rank correlation coefficient (r). The cut-off 
(upper reference range of normal) providing optimal sensitivity and specificity in 
distinguishing ALS from HC by serum NfL was defined by ROC curve analysis (by 
maximizing the Youden index) (188). Proportions above and below this cut-off were 
compared with the Chi-Square test. A two-sided p-value < 0.05 was considered as 
significant. P-values of post-hoc comparisons were adjusted using a Bonferroni 
correction. All statistical analyses and graphs were performed using SPSS (Version 
15.0 SPSS, Chicago, IL) and Graph Pad Prism 5.02 for Windows (GraphPad Software, 
San Diego, CA). 
 
4.3. Results 
4.3.1. Reproducibility of the standard curve 
Figure 4.1. shows the mean raw counts of 20 consecutive standard curves in the 
range of 0-1,000 pg/ml and the resulting regression line. Individual standard curves 
showed a high degree of linearity (R2 = 0.99) (figure 4.1.). 
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Figure 4.1. Reproducibility of the standard curve. 
Reproducibility of 20 consecutive standard curves. The graph shows the mean counts 
(dots) ± SD (bars), linear regression line and 5% and 95% confidence interval curves 
(broken lines) (R2=0.99). 
 
 
4.3.2. Precision and accuracy 
Reproducibility (intra-assay variability) and repeatability (inter-assay variability) of the 
assay was evaluated with native serum samples in 10 consecutive assays on 
independent days. In four independent samples of native serum the mean coefficients 
of variation (CV) of duplicates (intra-assay precision) for NfLUmea47:3 were 4.9% (12.1 
pg/ml, sample 1), 5.5% (39.6 pg/ml, sample 2), 4.1% (83.1 pg/ml, sample 3) and 3.8% 
(103 pg/ml, sample 4, average: 4.6%). In CSF the mean intra-assay CVs were 6.0% 
(569 pg/ml, sample 1), 6.4% (3,645 pg/ml, sample 2), 2.7% (7,501 pg/ml, sample 3) 
and 6.8% (12,762 pg/ml, sample 4) averaging at 5.5%. Inter-assay CVs for serum were 
23.6% (sample 1), 16.9% (sample 2), 8.5% (sample 3), and 10.9% (sample 4, average: 
15.0%). In CSF inter-assay CVs were 10.3% (sample 1), 10.4% (sample 2), 6.7% 
(sample 3) and 11.7% (sample 4, average: 9.8%). 
Recovery rates were tested in 6 serum samples from healthy volunteers. Recovery of 
NfL (serum spiked with 50 pg/ml of HPLC purified bovine NfL) was 72% and 114%. For 
serum spiked with 100 pg/ml of NfL it was 81% and 96%, and for 1,000 pg/ml of NfL 
recovery was 82% and 116%. 
 
4.3.3. Analytical sensitivity and stability of the analyte 
Sensitivity (lowest standard above blank) was calculated as blank signal plus three SD 
from 32 assays. The mean blank signal was 138 counts (SD 20.9 counts). The mean 
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signal of the lowest standard (15.6 pg/ml) was 184.5 counts (SD 23.2): accordingly, 
analytical sensitivity was defined to be 15.6 pg/ml. We tested the stability of NfL at RT, 
4 °C and compared this to samples stored at -80 °C. Four aliquoted serum samples 
were frozen at -80 °C. The aliquots were thawed on days 0, 3 hours before 
measurement, days 1, 4 and 8 and stored at RT or 4 °C until analysis. The measured 
signals were normalised to the signal of the day 0. There was no significant change in 
signal in samples stored at RT and at 4 °C (RT: day 8: 1.06 ± 0.08 (mean ± SD), p = 
0.4063 and 4 °C: day 8: 1.01 ± 0.09, p = 0.1721). Four serum samples were analysed 
for stability during freeze-thawing cycles. The samples underwent 1, 2, 3, 4 or 5 freeze-
thawing cycles and the signal was normalised to the sample freeze-thawed once, 
without any relevant effect of freeze-thawing on the measured signals (5 freeze-
thawing cycles: 1.03 ± 0.03, p = 0.5076). 
 
3.3.4. Parallelism 
Parallelism between standards and samples was studied by reciprocal dilutions of 
three serum samples and three standard curves. The obtained signals were normalised 
to the highest value within this series (100%). The parallel relationship is demonstrated 
in figure 4.2., suggesting the absence of aggregate formation or endogenous binding 
between NfL and other blood substrates (159) (figure 4.2.). 
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Figure 4.2. Parallelism between standards and serum dilutions. 
Parallelism for NfL between standards (open line, open dots) and serum (closed line, 
black squares). The linear regression lines, mean (open dots or black squares) and 
±SD are shown. 
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4.3.5. Reference populations 
NfL was determined in serum of 67 HC (56.7% females, median age 35.0 years) and in 
serum of 68 and CSF of 66 CP (60.3% female, median age: 38.3 years) (table 4.1.). 
Serum levels between HC (3.3 pg/ml, 2.0-5.3) and CP (4.4 pg/ml, 2.4-8.1) did not differ 
(p=1.0) and did not correlate with either age or gender. Conversely, CSF levels in CP 
correlated with age (r=0.68, p<0.0001).   
 
4.3.6. Neurological disease population 
A. Serum 
AD (30.8 pg/ml, 22.6-41.9), GBS (79.4 pg/ml, 24.3-259.6) and ALS (95.4 pg/ml, 57.9-
157.0) had higher serum NfL levels compared with HC and CP (AD versus CP: 
p=0.002 all other comparisons versus HC and CP: p<0.0001). NfL levels correlated 
with age in GBS (r=0.48, p=0.038) and ALS (r=0.30, p=0.04). In the age-corrected 
group comparisons versus HC and CP, differences remained significant for all diseases 
except AD (figure 4.3.). 
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Figure 4.3. Serum NfL levels in the two reference groups (HC and CP) and 
neurological disease groups. 
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Patients with a GBS (79.4 pg/ml) or ALS (95.4 pg/ml) had higher values compared with 
HC (3.3 pg/ml; p<0.0001, respectively) and CP (4.4 pg/ml, p<0.0001 and p=0.001). 
Significances for comparisons between patients with AD and HC (p<0.0001) and AD 
and CP (p=0.002) were lost after age corrections. The horizontal dotted line represents 
the upper reference range (cut-off value) of 26.6 pg/ml. Geometric mean and 95% CI 
are displayed. Dots represent individual samples. P-values are adjusted for age and 
corrected by Bonferroni method. 
 
 
A cut-off level of 26.6 pg/ml (figure 4.3.) for serum NfL resulted in a sensitivity of 91.3 
% and a specificity of 91.0 % for differentiating ALS versus HC. A higher proportion 
(p<0.0001 for all comparisons) of patients had serum NfL values above this cut-off: 
16/20 (80.0 %) in AD, 13/19 (68.4 %) in GBS, 42/46 (91.3 %) in ALS, compared to HC 
(6/67, 9.0%). 
 
B. CSF 
NfL levels in AD (1396 pg/ml, 1139-1711), GBS (1361 pg/ml, 726-2554) and ALS (5513 
pg/ml, 4151-7323) were higher than in CP (324 pg/ml, 282-372, p<0.0001 for all), and 
CSF NfL concentrations in ALS were higher than in AD and GBS (p<0.0001, 
respectively). 
Similar to the serum results, CSF levels of NfL correlated with age in GBS (r=0.65, 
p=0.002) and ALS (r=0.30, p=0.048). After correction for age, a significant difference 
remained between GBS (p=0.001) and ALS (p<0.0001), but not AD (p=1.0) versus CP. 
Similarly, I confirmed the higher levels in ALS as compared to AD and GBS (p<0.0001, 
for both comparisons) (figure 4.4.). 
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Figure 4.4. CSF NfL levels in the reference group (control patients, CP) and 
neurological disease cohorts. 
Patients with ALS (5513 pg/ml) or a GBS (1361 pg/ml) had higher levels than CP (324 
pg/ml, p<0.0001 and p=0.001). In addition ALS had higher levels than patients with AD 
(1361 pg/ml) and GBS (p<0.0001, respectively). Geometric mean and 95% CI are 
displayed. Dots represent individual samples. P-values are adjusted for age and 
corrected by Bonferroni method. 
 
C. CSF – serum relationship 
Overall geometric mean levels in CSF (1,142 pg/ml, 906-1,439) were 96.8-fold higher 
than in serum (11.8 pg/ml, 8.5-16.5, p<0.0001; fold-increase in CSF versus serum: CP: 
73.6, AD: 45.3, GBS: 17.1, ALS: 57.8, p<0.0001, respectively). 
Serum and CSF measurements of NfL correlated in the disease groups (figure 4.5.A): 
AD (r=0.48, p=0.033), GBS (r=0.79, p<0.0001) and ALS (r=0.70, p<0.0001), conversely 
this was not seen in CP (r=0.11, p=0.3739) (figure 4.5.B).  
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Figure 4.5. Correlation of serum and CSF NfL measurements. 
Serum and CSF measurements of NfL correlated in the disease groups (A): AD 
(r=0.48, p=0.033), GBS (r=0.79, p<0.0001) and ALS (r=0.70, p<0.0001): overall: 
r=0.68, p<0.001. Conversely this was not seen in the control patients (CP) (r=0.11, 
p=0.3739) (B). 
 
 
4.4. Discussion 
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A highly sensitive method for the detection of a clinically relevant biomarker of 
neurodegeneration has been developed. Importantly, this method allows us to make 
use of readily available longitudinal patient blood samples, instead of being restricted to 
CSF samples which are difficult to obtain because of ethical reasons. One potential 
clinical application for serum NfL levels is demonstrated by the diagnostic sensitivity of 
91.3% for ALS, a rapidly progressive neurodegenerative disease (189, 190). 
Notably, this is the first ECL based solid phase immunoassay for the NfL protein in 
blood based on two non-competitive, monoclonal antibodies. These antibodies have 
been widely used and validated in a commercial ELISA for CSF measurements of NfL 
(NF-light® assay) (95, 101, 191) (see chapter 1). NfL is considered to represent the 
most abundant and also most soluble Nf subunit (192).  
 
The optimised ECL-NfL assay protocol proved to be highly accurate (intra-assay CV < 
6%, inter-assay CV < 24%), sensitive (sensitivity 15.6 pg/ml) and demonstrated 
linearity and parallelism (figures 4.1. and 4.2.) over a wide analytical range (15.6-
10,000 pg/ml). In addition I found NfLUmea47:3 to be stable in serum. This is relevant for a 
potential value to monitor drug effects by serum NfL in ALS where Nf aggregate 
formation is a key pathological finding (159). In contrast to NfHSMI34 and NfHSMI35, no 
such aggregates were found for NfLUmea47:3, essentially overcoming the limitations of 
the Nf “hook effect” (matrix effect) (159). In this context, a more than 20-fold elevation 
of serum NfLUmea47:3 levels in ALS compared to HC cannot be overestimated. 
Interestingly, the fold-differences between disease groups and CP for serum NfLUmea47:3 
was higher compared to the respective CSF levels (serum/CSF: ALS: 21.7/17.0; AD: 
7.0/4.3 and GBS: 18.0/4,2). 
CSF Nf measurements are increasingly accepted as measures of axonal injury (179, 
193). Importantly in this context we found strong correlations between CSF and serum 
NfL measurements in all disease groups (overall: r=0.68, p<0.001). The reason behind 
the lack of such correlation in controls is unclear. However, the presence of very low 
blood NfL levels and the fact that these may approach or fall below the analytical 
detection limit represent potential explanations. 
An important and unresolved question is whether or not there is a relevant correlation 
between Nf levels and age. If present, such a relationship would require age dependent 
cut-off values (152). A major limitation to all studies in this field to date (91, 100, 102, 
151, 152, 194) is that they have not been powered to investigate this potential 
correlation in the CSF, due to lack of samples from a sufficiently large healthy control 
group across all age categories. Again, the availability of the present method to 
investigate this in readily available serum samples is highly relevant. Importantly, I did 
not find a correlation between serum NfLUmea47:3 levels and age in either HC or CP. 
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Whether or not a possible relationship with age exists for ALS, GBS or AD is 
questionable, as older patients are often more severely affected and higher age is the 
most important prognostic factor in these conditions and therefore not independent of 
the neurodegeneration related release of NfLUmea47:3. 
 
The absence of the Nf hook-effect is an important analytical advantage for 
quantification of the ECL based serum NfLUmea47:3 assay compared to the serum 
NfHSMI34 and NfHSMI35 ELISA, as there is no necessity for a time-consuming pre-
incubation step with urea (159). Given the important prognostic information that NfH 
levels provide on a number of clinical conditions, I believe that NfLUmea47:3 will be 
relevant for future studies. Serum NfLUmea47:3 bears the potential for predicting disease 
progression in ALS (186, 195, 196) and MS (155), detecting particularly disabling acute 
episodes of optic neuritis or relapses in MS (154), identifying primary and secondary 
brain damage in stroke (182, 183), SAH (184), TBI (197) and in the emerging concept 
of chronic traumatic encephalopathy (CTE) (197, 198). Like serum NfHSMI35, serum 
NfLUmea47:3 may also be exploited as a safety biomarker for recognising neurotoxicity 
(169). There is already data that serum NfL levels are of comparable prognostic value 
to NfHSMI35 levels following cardiac arrest (170, 185). Of note there were no controls 
and no analytical validation data from the NfL assay that was performed in one study 
(170). 
Similar to our previous findings for NfHSMI35 in CSF, a bimodal distribution of serum NfL 
levels was seen in patients with GBS (151). There are no previous studies on Nf in 
blood from patients with GBS. Earlier studies have shown that CSF levels of NfH are 
higher in patients with evidence of axonal damage compared to those with purely 
demyelinating GBS, with CSF NfH levels predictive of outcome (180, 199). Future 
prospective studies incorporating detailed longitudinal clinical and electrophysiological 
assessments, and sampling are clearly warranted. These studies will also shed light on 
the role of proximal versus more distal axonotmesis and secondary axonal peripheral 
degeneration and the relationship of increased blood NfL levels (200).  
 
Blood levels of Nf have similarly not been investigated in patients with dementia. In this 
study the differences in serum and CSF NfL levels in AD compared to HC and CP 
(p<0.0001 and p=0.002) lost significance after age and Bonferroni correction. This is in 
line with previous investigations where CSF NfHSMI35 levels were increased, but 
diagnostic sensitivity, and hence potential for clinical use of NfH SMI35 was not superior 
to that of the benchmark biomarkers total tau, phospho tau, or amyloid beta 1-42 (120, 
201). To explore these questions further I am currently trying to obtain a larger and well 
characterised cohort of AD and control patients. 
 83 
 
Unfortunately, cross sectional or longitudinal data on disease activity or disease 
severity were not available in this study. Also, due to lack of follow-up clinical 
information I could not investigate the potential prognostic role of NfL. An important 
limitation is also the fact that age between controls and all three patient groups was not 
balanced and this needed statistical correction. In summary, I developed and validated 
a sensitive and reliable assay for measurements of NfL in human blood samples. For 
the first time, I was able to demonstrate increased blood NfL levels in patients with ALS 
and GBS. These differences were more pronounced for the ECL-NfLUmea 47:3 assay than 
those reported in ALS for NfH in previous reports (168, 196). These data support 
further studies of serum NfL in well-defined longitudinal cohorts of neurodegenerative 
diseases. These studies will show if serum NfL measurements can be used as a 
biomarker for disease progression and as an outcome measure in clinical trials. 
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5. Serum NfL is a biomarker of human spinal cord injury    
 severity and outcome (202) 
 
 
5.1. Introduction 
Acute spinal cord injuries (SCI) are one of the most devastating accidents affecting a 
young and active population. Mechanical injury of the spinal cord results in damage to 
neurons, axons, and glia at the area of impact (203). Over days to weeks several 
secondary injury cascades lead to further progressive tissue damage within and 
adjacent to the primary lesion, on top of the sequelae of exogenous trauma. Other than 
the trauma itself, secondary injury (204, 205) represents a window for therapeutic 
interventions to preserve axons and their support structures (206-208). A recent 
placebo-controlled trial suggested clinical improvement across several outcome 
measures in patients receiving the drug minocycline (161), using the American Spinal 
Injury Association (ASIA) exam (209). The ASIA exam can be used to determine the 
ASIA grade of injury severity. While this is a universally accepted classification, each 
grade represents a broad category of patients and the scale lacks sensitivity for 
longitudinal change making it insensitive as a drug response marker (210). A number 
of biomarkers have been evaluated for their capacity to be more sensitive and accurate 
tools to measure neuronal injury, but in part because these tests are restricted to 
cerebrospinal fluid (CSF) they have as yet provided limited clinical utility (211, 212). 
In this chapter I analysed levels of NfL longitudinally in serum samples derived from 
subjects enrolled in a phase II clinical trial investigating the utility of minocycline to 
attenuate neurological deficits after spinal injury (161). I investigated the correlation of 
serum NfL with acute and long-term clinical outcome. Further, I analyzed the potential 
of serum NfL as drug response marker of the therapeutic effect of minocycline in SCI. 
Among several activities, minocycline downregulates microglial activation, 
neuroinflammation and apoptosis, effects that may reduce neuronal injury reflected in 
lower serum levels of NfL in SCI (206). 
 
5.2. Methods 
The research protocol was approved by the University of Calgary Conjoint Health 
Research Ethics Board. All patients and healthy controls provided written informed 
consent. Serum samples from 67 healthy controls (HC) and 27 SCI patients (with 
sufficient amount of serum symples available (161)) were included: 13 patients with a 
motor-complete SCI (cSCI; ASIA A or B; due to lack of material no 96 and 108 hours 
(h) samples for two patients and no 84 and 120 h samples for one patient each), 10 
patients with a motor-incomplete SCI (iSCI; ASIA C or D; no 36 h sample for one 
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patient) and 4 patients with a central cord syndrome (CCS; ASIA C or D with more 
selective injury to the centrally located motor tracts and disproportionately greater 
motor impairment in the upper compared to lower extremities (mean lower extremity 
motor scores>upper extremity) (213)) (Table 5.1.) (161).  
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Table 5.1. Baseline characteristics of healthy controls (HC) and spinal cord injury (SCI) 
patients. 
 HC CCS iSCI cSCI p-value 
n 67 4 10 13  
Gender (n 
females, %) 
38 (57) 1 (25) 3 (30) 5 (38) 0.254 
Age (years) 35 (28-42) 49 (39-62) 33 (22-43) 32 (22-45) 0.117 
Level of injury 
Cervical 
Thoracic 
 
na 
na 
 
4 
0 
 
9 
1 
 
11 
2 
0.999 
Injury mech-
anism (n, %)a 
Motor vehicle 
accident 
Work accident 
Sport injury 
Fall 
na  
 
 
1 (25) 
1 (25) 
- 
2 (50) 
 
 
 
7 (70) 
1 (10) 
2 (20) 
- 
 
 
 
10 (77) 
- 
3 (23) 
- 
0.034 
ASIA Score 
(n,%)b 
A 
B 
C 
D 
na  
 
- 
- 
2 (50) 
2 (50) 
 
 
- 
- 
7 (70) 
3 (30) 
 
 
12 (92) 
1 (8) 
- 
- 
<0.0001 
Motor score na 59 (18-83) 45 (23-63) 16 (9-29) 0.053 
Pinprick scorec na 65 (22-94) 81 (51-94) 24 (19-32) 0.020 
Light-touchd na 73 (25-106) 76 (37-97) 24 (19-32) 0.028 
Delay to 
surgery (hours) 
na 15 (10-200) 12 (8-16) 18 (12-22)* 0.285 
Treatment (n,%) 
Placebo 
Low dose** 
High dose 
na  
 
1 (25) 
1 (25) 
2 (50) 
 
 
5 (50) 
3 (30) 
2 (20) 
 
 
7 (53.8) 
1 (7.7) 
5 (38.5) 
0.499 
 
CCS: central cord syndrome; iSCI: Motor incomplete spinal cord injury; cSCI: Motor 
complete spinal cord injury; ASIA: American Spinal Injury Association standardized 
neurological examination; * one patient without surgical decompression; ** Low dose: 
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200 mg twice daily; high dose: 800 mg loading dose tapered to 200 mg twice daily. Na: 
not applicable. Medians and IQR are shown, if not specified otherwise. 
a More motor vehicle accidents in cSCI versus CCS (p<0.05). 
b higher ASIA score in cSCI versus iSCI (p<0.001) and CCS (p<0.01). 
c
 lower pinprick score in cSCI versus iSCI (p<0.05). 
d
 lower light-touch score in cSCI versus CCS (p<0.05). 
 
 
Surgical decompression and stabilization was performed within 24 h of injury and 
subjects were not treated with corticosteroids. Patients were randomized (1:1) to 
receive intravenous minocycline (Wyeth Pharmaceuticals either 200 mg of minocycline 
twice-daily (low dose) or a loading dose of 800 mg tapered by 100 mg every 12 h until 
400 mg was reached (high dose), or placebo. More detailed procedures and inclusion 
and exclusion criteria have been described previously (161).  
 
5.2.1. Clinical assessment and analytical procedure  
Neurological function was assessed using the ASIA standardized neurological 
examination, including the motor (score ranging from 0-100, with higher score 
representing better motor function) and sensory (pinprick and light-touch ranging from 
0-112 each, with higher score representing better sensory function) composites (209). 
These examinations were performed at days 1 (time of enrolment), 4, 5 and 7; weeks 
3, 6 and 12; and months 6 and 12. Motor function observed in the study population 
plateaued after 3 months (161). Motor and sensory outcome was defined as the mean 
of the motor or sensory scores at time points 3, 6 and 12 months (161). 
We examined blood samples drawn within 12 h of the SCI prior to treatment 
randomization and every 12 h thereafter for 7 days (15 time points, including the 
baseline sample). Samples were spun at 2,000 g for 10 minutes, aliquoted in 
polypropylene tubes and stored at -80°C within two hours (161). 
 
The immunoassay developed in-house for NfL (NfLUmea47:3) was used for quantification 
of NfL in serum (see chapter 4, (94)). The mean intra- and inter-assay coefficients of 
variation were 4.3% and 9.7% in these measurements respectively. 
 
5.2.2. Statistics 
Baseline characteristics were compared between groups using Kruskal Wallis test for 
continuous variables, or Fisher’s exact test for categorical variables. Continuous 
variables were described by their median and interquartile range (IQR), and categorical 
variables by numbers and percentages. The NfL area under the curve (AUC) for the 7 
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days sampling period was calculated using the trapezoidal rule. NfL values were log-
transformed to achieve a Gaussian distribution. The longitudinal data of the groups 
(twice daily NfL levels) were analysed using mixed effects linear regression, which 
allows for repeated measurements and missing values. One-way ANOVA with 
Bonferroni adjustment if significance was reached was used to compare log NfL 
between groups at individual time points. In addition, mixed effects linear regression 
was used to test for the effect of minocycline on log NfL, motor score, pin prick or light 
touch (baseline values were subtracted from all values at individual time points for this 
analysis). Since the number of patients per group was small, a pooled analysis 
(placebo versus both minocycline dosing schemes) was performed. Motor outcome 
was classified as “good” or “poor” considering the median value as cut-off. All 
correlation analyses were performed with Spearman’s R. A two-sided p-value < 0.05 
was considered as significant. All statistical analyses were performed using Stata 
version 12 (StataCorp, College Station, Texas) and Graph Pad Prism 5.02 for Windows 
(GraphPad Software, San Diego, CA). 
 
5.3. Results 
5.3.1. Disease characteristics 
Table 5.1. shows baseline characteristics of the SCI subgroups and healthy controls. 
The vast majority (24/27) of patients had a cervical level of injury. Across all subgroups, 
motor vehicle accidents represented two thirds of causes of injury. cSCI, iSCI and CCS 
patients differed significantly for overall injury severity (ASIA score, p<0.0001), pinprick 
(p=0.020) and light-touch scores (p=0.028), while differences in motor scores were 
borderline significant (p=0.053), at baseline. Otherwise there were no significant 
differences with regard to gender, age, or delay to surgery.  
Fourteen patients (52%) were treated with either low dose (n=5) or high dose (n=9) 
minocycline, and 13 patients received placebo. 
 
5.3.2. Levels of NfL at baseline and during follow-up 
Baseline NfL levels were different between groups (F(3,90)=9.49, p<0.001); iSCI (21 
(15-90) pg/ml, p=0.006) and cSCI (70 (17-134) pg/ml, p<0.001) had higher levels of 
serum NfL than HC (5 (2-11) pg/ml). Similarly, serum NfL levels in iSCI and cSCI were 
higher than in CCS (6 (0.3-18) pg/ml, p=0.025 and p=0.010, respectively) (Figure 5.1.).  
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Figure 5.1. Baseline serum NfL levels in healthy controls and spinal cord injury 
patients. 
At baseline serum NfL levels were different between the groups (F(3,90)=9.49, 
p<0.0001); motor incomplete SCI (iSCI, p=0.006) and motor complete SCI (cSCI, 
p<0.001) had higher levels of serum NfL than healthy controls (HC). Similarly, serum 
NfL levels in iSCI and cSCI were higher than in patients with a central cord syndrome 
(CCS, p=0.025 and p=0.010, respectively). Median and IQR are displayed. Dots 
represent individual samples. 
 
 
There was an increase of serum NfL levels over time (p<0.001, mixed effects model). 
Levels increased in all three groups from baseline (p<0.001) and were higher in cSCI 
versus iSCI (p=0.011) and CCS (p<0.001) (p=0.045 for iSCI versus CCS). Differences 
for individual time points especially between cSCI and CCS were strong (Figure 5.2., 
Table 5.2.). Accordingly, the NfL AUC was significantly higher in cSCI (4,614 (3,486-
7,701)) versus CCS (1,260 (420-2,257), p=0.012; F(2,24)=5.9, p=0.008). 
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Figure 5.2. Serum NfL levels over time in different groups of spinal cord injury patients. 
Serum NfL levels increased over time in the overall group (p<0.001, n=27) and in all 
three groups from baseline (p<0.001). Serum NfL was higher in motor complete SCI 
(cSCI, n=13) versus motor incomplete SCI (iSCI, n=10, p=0.011) and central cord 
syndrome patients (CCS, n=4, p<0.001). ISCI had higher serum NfL levels as 
compared to CCS (p=0.045). Differences for individual time points especially between 
cSCI and CCS were strong (see table 5.2.). Mean and standard error of the mean are 
displayed. 
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Table 5.2. Serum NfL levels in spinal cord injury patients over time. 
 CCS 
(NfL, 
pg/ml) 
iSCI 
(NfL, 
pg/ml) 
cSCI 
(NfL, 
pg/ml) 
p-values 
CCS 
vs. 
iSCI  
CCS 
vs. 
cSCI 
iSCI 
vs. 
cSCI 
Baseline 6 21 70 0.019 0.009 0.999 
12 h 18 48 85 0.174 0.048 0.999 
24 h 21 47 113 0.218 0.012 0.191 
36 h 21 58 114 0.023 0.001 0.267 
48 h 24 51 129 0.065 0.001 0.053 
60 h 34 70 163 0.136 0.002 0.062 
72 h 38 100 199 0.080 <0.001 0.084 
84 h 41 127 210 0.021 <0.001 0.166 
96 h 56 155 237 0.053 0.005 0.558 
108 h 88 184 303 0.027 0.002 0.434 
120 h 114 220 338 0.046 0.002 0.341 
132 h 153 278 558 0.087 0.001 0.095 
144 h 193 333 617 0.127 0.003 0.133 
156 h 194 384 710 0.138 0.003 0.120 
162 h 230 379 796 0.153 0.003 0.130 
 
Median NfL concentrations for the individual time points in pg/ml and p-values are 
displayed. CCS: Central cord syndrome; iSCI: motor incomplete spinal cord injury; 
cSCI: motor complete spinal cord injury; vs.: versus; h: hours post baseline. 
 
 
5.3.3. Baseline NfL and motor, pinprick and light-touch scores 
NfL levels were negatively correlated with the motor score at baseline (r=-0.53, 
p=0.004; Figure 5.3.a and Table 5.3.), but not with the pinprick or light-touch scores 
(Table 5.3.). Levels also inversely correlated with several of the post baseline motor 
scores, less so with the sensory scales (Table 5.3.). 
Interestingly, serum NfL levels determined after 24h showed a stronger association 
with the baseline motor score (r=-0.69, p<0.001) and throughout all other sampling time 
points, including also the sensory scores (Figure 5.3.a and Table 5.3.). These 
correlations were of similar frequency and strength for the NfL AUC (ASIA score: 
r=0.60, p=0.001, Figure 5.3.a and Table 5.3.). 
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Figure 5.3. Correlation of NfL and NfL area under the curve (AUC) and motor score 
at baseline (A.) and motor outcome (B.). 
A. 
Left: Baseline serum NfL concentration and baseline motor score. Baseline NfL 
levels correlated with the motor score at baseline (r=-0.53, p=0.004; central cord 
syndrome patients, CCS: r=-0.40, p=0.6; motor incomplete SCI, iSCI: r=-0.46, 
p=0.184; motor complete SCI, cSCI: r=-0.63, p=0.022).  
Middle: 24H NfL concentration and baseline motor score. 24H NfL levels correlated 
with the motor score at baseline (r=-0.69, p<0.001; CCS: r=0.5, p=0.667; iSCI: r=-
0.78, p=0.008; cSCI: r=-0.64, p=0.017). 
Right: Serum NfL area under the curve and baseline motor score. 
The NfL AUC correlated with the baseline motor score (r=-0.74, p<0.0001, CCS: r=-
0.8, p=0.2; iSCI: r=-0.73, p=0.017; cSCI: r=-0.65, p=0.017). 
B. 
Left: NfL levels at baseline correlated with the motor outcome (r=-0.43, p=0.026, 
CCS: r=-0.40, p=0.600; iSCI: r=-0.44, p=0.206; cSCI: r=-0.29, p=0.334). 
Middle: 24H NfL concentration and motor outcome. 24H NfL levels correlated with 
the motor outcome (r=-0.75, p<0.0001; CCS: r=0.50, p=0.667; iSCI: r=-0.76, 
p=0.011; cSCI: r=-0.52, p=0.07). 
Right: Serum NfL area under the curve and motor outcome. 
The NfL AUC correlated with the motor outcome (r=-0.83, p<0.0001, CCS: r=-0.80, 
p=0.200; iSCI: r=-0.79, p=0.006; cSCI: r=-0.69, p=0.009). 
Filled triangles: cSCI; empty triangles: iSCI, open circles: CCS. AUC: Area under the 
curve; BL: baseline. The Spearman’s correlation coefficients of the ranks and p-
values are indicated. 
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Table 5.3. Correlations between baseline NfL concentration and NfL area under the 
curve and motor, pinprick and light touch scores at different time points. 
Day BL 4 7 21 42 90 182 365 
Motor Score 
n 27 22 23 23 23 25 24 24 
BL 
NfL 
-0.53 
0.004 
ns -0.49 
0.019 
ns -0.41 
0.049 
-0.44 
0.028 
-0.44 
0.031 
-0.42 
0.039 
24H 
NfL 
-0.69 
* 
-0.56 
0.007 
-0.64 
0.001 
-0.69 
* 
-0.68 
* 
-0.72 
* 
-0.69 
* 
-0.73 
* 
NfL 
AUC 
-0.74 
* 
-0.73 
* 
-0.68 
* 
-0.72 
* 
-0.80 
* 
-0.82 
* 
-0.79 
* 
-0.82 
* 
Pinprick 
n 27 20 23 22 22 25 24 24 
BL 
NfL 
ns ns -0.55 
0.007 
-0.43 
0.046 
ns ns ns Ns 
24H 
NfL 
-0.52 
0.001 
-0.57 
0.008 
-0.70 
* 
-0.71 
* 
-0.50 
0.022 
ns -0.47 
0.024 
Ns 
NfL 
AUC 
-0.65 
* 
-0.56 
0.011 
-0.69 
* 
-0.79 
* 
-0.60 
0.003 
-0.43 
0.033 
0.58 
0.003 
0.44 
0.032 
Light-touch 
n 27 21 22 22 22 25 24 24 
BL 
NfL 
ns ns -0.55 
0.008 
-0.55 
0.008 
ns ns ns Ns 
24H 
NfL 
-0.57 
0.002 
-0.46 
0.037 
-0.70 
* 
-0.80 
* 
-0.61 
0.003 
-0.46 
0.025 
-0.48 
0.022 
Ns 
NfL 
AUC 
-0.62 
0.001 
-0.51 
0.017 
-0.62 
0.002 
-0.85 
* 
-0.74 
* 
-0.58 
0.002 
-0.63 
0.001 
-0.49 
0.016 
 
BL: baseline examination; n: number of patients at each time point (in days post-
baseline); BL NfL: NfL measurement at baseline; 24H NfL: NfL measurement after 24 
hours; NfL AUC: NfL area under the curve over the 7 day sampling period; 
Spearman r and p values are displayed; *: p<0.001. 
 
5.3.4. Correlation of NfL with clinical outcomes 
Motor outcome plateaued at three months after SCI (median ASIA score: 60 points), 
regardless of whether the injury was motor-complete, motor-incomplete or of central 
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cord type. As expected, the motor outcome was better in CCS (89 points, p<0.05) 
and iSCI (86.0 points, p<0.01) versus cSCI (25 points), and correlated strongly with 
respective baseline motor score values (r=0.83, p<0.0001) (161). Similar correlations 
between baseline and outcome scores were seen for the pinprick and light-touch 
(r=0.63, p<0.001 and r=0.58, p=0.001). 
During the period of 24 to 168 hours after injury, NfL levels were increasingly higher 
(Figure 5.4.) in patients with a poor outcome (as defined by below median motor 
score, n=13) compared to those with a better outcome (median motor score above 
median, n=14, p=0.001).  
 
 
Figure 5.4. NfL over time depending on motor outcome. 
Patients with a better motor outcome (as defined by median, n=13) had lower NfL 
levels than patients with a poor outcome (n=14, p=0.001). For individual time points, 
patients with a poor outcome had higher serum NfL levels between serum sampling 
after 24 hours and throughout all samplings up to 168 hours. Mean, standard error of 
the mean and corresponding p-values (*: p<0.05; **: p<0.01; ***: p<0.001) for poor 
outcome versus good outcome group are displayed. 
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This was corroborated by an AUC analysis of NfL (better outcome: 1,878 (1,058-
3,464) versus worse outcome: 5,234 (3,017-8,584), p=0.002). In line with the 
correlation of clinical scores at baseline with those of outcome, NfL levels at baseline 
correlated with motor outcome (r=-0.43, p=0.026, Figure 5.3.b). Again, this 
correlation became stronger over time for NfL measurements after 24h (12 h: r=-
0.56, p=0.003; 24 h: r=-0.72 (Figure 5.3.b); 48 h: r=-0.82; 72 h: r=-0.81; 120 h: r=-
0.79; 144 h: r=-0.83; 168 h: r=-0.82, p<0.0001 for all) and for the AUC analysis 
(Figure 5.3.b). Similar correlations were noted for the outcome of pinprick and light-
touch (data not shown). 
 
5.3.5 Correlation of NfL with Minocycline treatment 
Treatment was not evenly allocated across CCS, iSCI and cSCI (Table 5.1.); the 
median motor score at baseline was 30 for patients receiving placebo (n=13, 54% 
cSCI patients), 46 for those receiving low dose (n=5, 20% cSCI patients), and 26 for 
those receiving high dose minocycline (n=9, 56% cSCI patients) (p=0.9050). 
Compared to placebo, treatment with low or high dose of minocycline (median 
baseline motor score: 27 points) versus placebo did not have a significant effect on 
the longitudinal profile of serum NfL levels in this group of patients (p=0.67, mixed 
effects model, Figure 5.5.a). Likewise, minocycline treatment had no effect on the 
longitudinal profile of motor (p=0.495), pinprick (p=0.324) or light-touch scores 
(p=0.264) in an all patients analysis. A more comprehensive analysis of the effect of 
minocycline treatment on neurological outcome including these patients was 
previously published (161). 
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A. 
 
B. 
 
C. 
 
 
Figure 5.5. Comparison of longitudinal serum NfL between minocycline and placebo 
treated patients. 
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A. In all patients (n=27) treatment with minocycline (n=14) versus placebo (n=13) did 
not have an effect on the longitudinal profile of serum NfL levels (p=0.671). 
B. In patients with a motor complete SCI (cSCI, n=13) patients on minocycline (n=6, 
5 high dose, 1 low dose) had lower longitudinal NfL levels than placebo (n=7) treated 
patients (p=0.048). 
C. In patients with a baseline motor score below the median of the baseline motor 
score of all patients (28 points, n=13) minocycline treated patients (n=7) showed a 
trend for lower NfL levels over time in comparison to the placebo treated group (n=6, 
p=0.85).  
Mean and standard error of the mean are displayed. 
 
 
In contrast, in cSCI (6 patients receiving minocycline, and 7 patients receiving 
placebo) minocycline treated patients showed lower longitudinal NfL levels than 
placebo (p=0.048) (Figure 5.5.b). The effect of minocycline was more pronounced 
after removing the one patient on the low dose regimen (p=0.006), or the two 
patients with a thoracic level of the injury (p=0.030).  
This difference of NfL levels was not paralleled by clinical findings, as scores 
between treatment groups were not different (motor: p=0.234; after removing one 
patient on low dose minocycline: p=0.132, or the two patients with the thoracic injury 
level: p=0.686; pinprick: p=0.681, and p=0.827, p=0.417 or light-touch: p=0.185, and 
p=0.186, p=0.312) and failed to indicate a treatment effect of minocycline. 
Similarly, in the 13 patients who had a motor score below the median motor score 
(28) at baseline (1 patient with CCS, 3 with iSCI and 9 cSCI), minocycline treated 
patients (n=7) showed a trend for lower NfL levels over time in comparison to the 
placebo treated group (n=6, p=0.085, Figure 5.5.c, after removing 2 patients on low 
dose minocycline: p<0.001). Again, clinical scores were not different (motor: 
p=0.567, and p=0.972; pinprick: p=0.551, and p=0.656; light-touch: p=0.636, and 
p=0.320) between minocycline and placebo treated patients. 
 
5.4. Discussion 
This is the first study exploring the utility of NfL in serum as a marker of injury 
severity and outcome in patients with SCI, using a high-sensitivity ECL-immunoassay 
(94). NfL is the most abundant and also most soluble Nf subunit, factors that likely 
contribute to the superior sensitivity of NfL over neurofilament heavy chain (NfH) 
assays (192). The assay system is validated for CSF and serum, the latter allowing 
the acquisition of longitudinal measures in routine clinical settings. 
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In the course of acute and chronic neuronal damage, disruption to the axonal cell 
membrane releases Nf into the interstitial fluid, that eventually reaches the CSF and 
blood compartments (214, 215). In SCI, trauma causes direct acute neuronal 
necrosis, followed by secondary injury mechanisms that increase neuronal loss by 
apoptosis or necrosis, a process that may last from days to weeks (216, 217). 
At baseline, NfL levels in iSCI and cSCI were increased 4.2-fold and 14-fold 
compared to healthy controls, and 3.5-fold and 11.7-fold compared to CCS, 
respectively. Over the 7 day follow-up NfL levels steadily increased in all three 
disease groups, with maximum levels (CCS: 230 pg/ml, iSCI: 384 pg/ml, cSCI: 796 
pg/ml) being markedly higher than in more chronic diseases like Alzheimer’s disease 
(37 pg/ml), Guillain-Barré syndrome (102 pg/ml) or amyotrophic lateral sclerosis (120 
pg/ml) (94). Only limited human data is available beyond this time point: three of four 
ASIA A and one of two ASIA C patients reached their highest NfH plasma levels after 
10 days in a recent pilot study (218), leaving the question of peak and duration of 
release open. 
Only a few studies have investigated Nf in CSF or blood in SCI so far. First evidence 
for the usefulness of NfL as a marker of neuronal damage in SCI arose from a study 
investigating CSF in acute spinal cord disease: all 6 patients with SCI and 3 of the 17 
with whiplash injury showed increased concentrations of NfL (219). In a rat model of 
SCI, NfH levels in blood (195) were correlated with the extent of damage and were 
reduced by treatment with minocycline: this difference did not reach significance 
however (220). The same group of investigators performed the first study in humans 
with acute cervical SCI: NfH was detectable in plasma of 11 of the 14 included 
patients and ASIA A showed higher levels than ASIA C patients; however, correlation 
with clinical subscores, or outcome was not presented (218). 
The prognostic value of the ASIA grading system is limited by its lack of dynamic 
change over time on individual grounds, and its susceptibility to interference due to 
other injuries such as head or multi-system traumas, and drug effects (210). The 
consequence of these constraints for clinical studies are large patient numbers to 
achieve adequate statistical power, to observe differences in treatment regimens 
(221). The inclusion of motor and sensory subscores may increase the accuracy of 
the clinical grading (218). Our results show a high correlation between NfL and motor 
scores, both at baseline, during follow-up, and for long-term outcome, indicating that 
serum NfL may be a reliable quantitative biomarker of the degree of SCI. This may 
be of specific value in the context of clinical trials where inter-rater variability of 
clinical assessment may increase the threshold to detect treatment effects. 
Furthermore, serum NfL may also allow for better evaluation of injury severity than 
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the ASIA grade. In particular, it may allow further stratification and prognostication of 
the large population of ASIA A injuries. 
So far, no drug has been shown to ameliorate the course of SCI, despite several 
candidate compounds showing promising results in animal models (222-224). Apart 
from the larger heterogeneity of human disease when compared to experimental SCI 
(225), this failure may also be attributed in part to the lack of sensitive biomarkers 
with a broad dynamic measuring range.  
Minocycline is a tetracycline antibiotic that has shown neuroprotective properties in a 
variety of models of degenerative and acute neurological diseases, including SCI 
(226-230), by pathways unrelated to its antimicrobial activity (206). In the minocycline 
trial an intravenous loading and maintenance dose to achieve serum levels similar to 
those efficacious in animal models of SCI was used (161, 231). In the subgroups of 
cSCI, despite the small sample size, treated patients showed lower NfL levels at 
every time point beyond 24 hours post injury, whereas the clinical scales were 
insensitive to detect a difference between the treatment groups. This reduction of NfL 
levels was more pronounced after excluding the patients with a thoracic SCI or those 
on low dose minocycline. These findings are in line with the clinical scores of the 
core study (161) in which thoracic SCI patients did not benefit from minocycline 
treatment, and the comparison of the low- and high-dose minocycline groups 
suggested a greater effect with higher doses. 
The study is limited by the retrospective design and the fact that only a subfraction of 
participants in the original trial was available for serial serum NfL measurements 
(161). This may also have caused large heterogeneity in injury severity and 
mechanisms between minocycline treated and non-treated patients and, at least in 
part, precluded a potential minocycline treatment effect in the overall SCI cohort. 
In summary, this data provides new evidence that serum NfL may represent a useful 
indicator of acute severity and long-term outcome of neuronal injury, especially in 
cases where accurate clinical assessment is not possible. Further studies are 
warranted to increase the evidence for NfL as drug response marker in SCI.  
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6. Predicting multiple sclerosis: a large international   
 multicentre study (232, 233) 
 
 
6.1. Introduction 
The cause of MS is unknown, but the disease appears to develop in genetically 
susceptible populations as a result of environmental exposures. Leading candidates 
for environmental factors associated with MS risk are vitamin D deficiency, Epstein-
Barr virus (EBV) infection and smoking (234). 
In approximately 85% of MS patients the disease starts as a single demyelinating 
episode known as CIS (42, 57). Prospective studies have shown that approximately 
60%-70% of CIS patients develop a second clinically evident demyelinating event 
separated in time and space within 20 years and will, therefore, be diagnosed with 
clinically definite MS (CDMS) (57, 235). The identification of factors influencing the 
risk of conversion to CDMS is relevant for prognosis, early intervention strategies 
and for the understanding of the biological mechanisms driving MS. Several studies 
have investigated which clinical and experimental variables can predict the onset of 
CDMS. The presence and number of MRI lesions in the CNS as well as that of 
oligoclonal bands (OCB) in the CSF of CIS patients have been independently 
associated with an increased risk of conversion (57, 235, 236). Other studies have 
focused on candidate environmental factors in MS and demonstrated that CIS 
patients with low vitamin D levels and high anti-EBV antibody titers are more 
susceptible to conversion to CDMS (237, 238). 
 
CSF Nf levels are abnormally high in CIS and MS patients and correlate with disease 
activity (100, 104, 239, 240). Unfortunately, obtaining CSF is a relatively invasive 
procedure and this has limited the potential use of Nf as biomarkers in MS, especially 
in longitudinal study designs with repetitive samplings. As pointed out in chapter 4, I 
recently developed a sensitive ECL based immunoassay for quantification of NfL in 
serum (94). 
Given the potential interdependence between risk factors, it is vital to assess all of 
them collectively and test their association with risk of conversion using a large 
population of CIS cases. To our knowledge, only one study has comprehensively 
analyzed a number of suggested factors in a cohort of patients experiencing a first 
demyelinating event. However, the cohort was relatively small (n=302) and only 
cases with pediatric onset were included (241). In this multicentre study we aimed to 
assess which clinical and environmental variables predict the risk of conversion from 
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adult CIS to CDMS using the largest cohort of adult CIS cases ever studied to date 
(n=1,047). 
For the serum NfL analysis I decided to follow a two staged process: In the initial 
step I selected 100 CIS with the shortest time to conversion to CDMS (fast 
converters (FC)) and 100 CIS with the longest follow-up time in the absence of 
conversion (non-converters (NC)) and serum samples from 92 HC. It was decided 
that only if I saw a difference in serum NfL levels between FC and NC serum NfL 
would be measured in the entire cohort of patients. 
 
6.2. Methods 
6.2.1. Participants and inclusion criteria 
This was an international collaborative study across 33 centres located in 17 different 
countries (table 6.1.).  
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Table 6.1. Participating centres and number of provided cases. 
Centre  Country 
Number of 
samples 
Amsterdam Netherlands 48 
Barcelona* Spain 26 
Barcelona** Spain 45 
Bari Italy 55 
Basel Switzerland 20 
Belgrade Serbia 11 
Bergen Norway 9 
Buenos Aires Argentina 4 
Copenhagen Denmark 15 
Düsseldorf Germany 25 
Genoa Italy 6 
Gothenburg Sweden 14 
Graz Austria 21 
Innsbruck Austria 46 
Istanbul Turkey 23 
Lublin Poland 14 
Lyon France 17 
Madrid Spain 32 
Marseille France 20 
Milan# Italy 8 
Milan## Italy 144 
Montpellier France 54 
Novara Italy 34 
Pavia Italy 22 
Prague Czech Republic 31 
Rome Italy 7 
Rotterdam Netherlands 81 
St Petersburg Russia 81 
Stockholm Sweden 44 
Szeged Hungary 25 
Toulouse France 20 
Ulm Germany 24 
Valencia Spain 21 
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Total 17 1047 
* Hospital Clinic of Barcelona; ** Vall d'Hebron Research Institute; # Ospedale 
Policlinico; ## San Raffaele Hospital. 
 
 
Each centre was asked to provide baseline clinical data and stored serum samples 
from CIS patients, on whom a minimum of 2 years of follow-up data were available. 
Inclusion criteria were: 1) the presence of a monophasic clinical episode suggestive 
of MS (CIS), not attributable to other diseases (for example infectious, neoplastic, 
congenital, metabolic or vascular disease) (242); 2) clinical follow-up of at least 2 
years; 3) available serum sample collected at time of CIS; 4) available basic 
demographic and clinical data (age at serum sampling or month and year of birth, 
gender, dates of CIS onset, serum sampling, CSF examination, MRI, conversion to 
CDMS (if present) and last follow-up visit); 5) information on presence or absence of 
OCB in CSF at time of CIS; 6) available data on T2 hyperintense lesions on cranial 
MRI at time of CIS.  
Patients with neuromyelitis optica (NMO), opticospinal MS in Asian populations or a 
history of a progressive course from onset were excluded. CDMS was diagnosed 
according to Poser criteria when new symptoms occurred after an interval of at least 
one month, and only when other diagnoses had been excluded (243). The study was 
approved by the corresponding local ethics committees and participants gave written 
informed consent. 
 
6.2.2. Data collection 
MRI, CSF and clinical assessments were performed in each participating centre as 
part of the diagnostic workup. The number of T2 hyperintense lesions on cranial MRI 
at time of CIS was used to group patients into three separate categories (0-1 lesions, 
2-9 lesions and >9 lesions). Grouping of lesion load was performed in order to control 
for variations in imaging protocol and individual analysis between centres. The 
presence of IgG OCB was determined by isoelectric focusing combined with 
immunoblotting of matched serum and CSF sample pairs in all patients (244). 
Additional clinical and CSF data were provided for a more limited number of patients 
(topography of CIS, CSF IgG index and CSF cell count) (245).   
Serum samples were aliquoted and stored at -80° C according international 
consensus guidelines (246). Liquid chromatography-tandem mass spectrometry 
(LCMS/MS) was used to measure 25-hydroxy-vitamin D3 levels (25-OH-D) (Royal 
London Hospital, Barts Health NHS Trust, London, UK). Daily internal quality 
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samples are measured by LCMS/MS and the institution follows an external quality 
assurance scheme (The International Vitamin D Quality Assessment Scheme, 
DEQAS). IgG titres against the EBV nuclear antigen 1 (EBNA1) and cytomegalovirus 
(CMV) were evaluated using commercially available ELISA (ETI-EBNA-G and ETI-
CYTOK-G PLUS Diasorin, Saluggia, Italy) following the manufacturers’ 
recommendations. Internal run validation criteria specified by the manufacturer and 
based on the calibrators were met for all ELISA plates measured. According to the 
manufacturer's instruction the cut-off for positivity was 20 arbitrary units (AU) for 
EBNA1 IgG and 0.4 international units (IU) for CMV IgG. Results were calculated by 
dividing the optical density (OD) of each sample by the OD of the 20 AU/0.4 IU 
calibrator on each ELISA plate. Serum cotinine levels were assessed using a 
commercially available ELISA (Calbiotech Inc., Spring Valley, USA) according to the 
manufacturer’s instructions and were used as a marker for smoking behaviour with 
levels > 14 ng/ml indicating a positive smoking status (247). Intra- and inter-assay 
variability for all ELISA and the NfL immunoassay measurements (see chapter 4, 
(94)) was below 15%. All the ELISA assays were performed a single center (Blizard 
Institute London, UK), with the analyst blinded to clinical data. 
 
6.2.3. Statistical analysis 
A. NfL analysis 
We selected 100 FC patients and 100 NC (two patients with insufficient sample 
volume). EDSS, number of T2 hyperintense and Gd+ lesions on cranial MRI and 
presence of OCB in the CSF at the time of CIS were assessed in each participating 
center as part of their diagnostic workup. EDSS and Gd+ lesion data were available 
on 170 and 146 CIS patients respectively. Patients were grouped in categories 
based on EDSS scores (0.0-1.0 vs 1.5-2.0 vs >2.0), number of T2 lesions (0-1 vs 2-9 
vs >9) and presence or absence of Gd+ lesions and OCB.  
Variables were described by median with IQR and counts with percentages. 
Normalized (log10) NfL levels were treated as a continuous variable and used for all 
analyses. Logistic regression models were used to assess the ability of NfL levels to 
predict disease status (FC vs HC, NC vs HC and FC vs NC). Similarly, we tested the 
association between NfL levels and markers of disease activity using logistic 
regression (NfL predicting OCB and Gd+ status) and ordinal regression models (NfL 
predicting increase in T2 and EDSS categories). In all models, results were corrected 
for both age and sex. All analyses were performed using R (http://www.r-
project.org/). 
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B. All other examined risk factors 
Variables were described by their median and IQR or by counts and percentages. 
Serum 25-OH-D varies according to season. In order to correct for this, raw 25-OH-D 
values were converted into deseasonalized 25-OH-D levels using the methods 
described by Mowry et al. (248).  Briefly, sine and cosine terms were generated to 
model the influence of the date of blood draw on vitamin D status; these were then 
included in a linear regression model providing the adjusted 25-OH-D levels (248). 
The impact of each variable on the cumulative risk of conversion to CDMS was 
assessed in both univariate (Kaplan-Meier survival curves and univariate Cox 
regression) and multivariate analyses (multivariate Cox regression with backward 
stepwise selection of variables). The assumption of proportional hazards was tested 
by including time-dependent covariates (interactions) in the model. Centre 
information was included in all Cox regression models by using a generalized 
estimating equation sandwich estimate of variance approach. Differences between 
groups of CIS patients according to their OCB and MRI status were also assessed 
using logistic and ordinal regression models. All statistical analyses were performed 
using STATA (http://www.stata.com/) and R (http://www.r-project.org/). 
 
6.3. Results 
6.3.1. Overall characteristics of CIS patients 
A total of 1,047 CIS patients were included in the study. These patients had 
presented to neurology services between November 1986 and December 2011; 
1,010 (96.5%) after 2000 and 794 (75.8%) after 2005. The median time between 
onset of neurological symptoms and serum sampling, CSF and MRI examination was 
33 (12-81), 28 (10-67) and 19 (4-59) days respectively. In 729 patients (69.6%) all 
evaluations were performed within three months since onset of symptoms. Patients 
were longitudinally followed up for a median time of 1,574 days (4.31 years). During 
this time 623 patients (59.5%) converted to CDMS (median survival time before 
conversion=1,096 days, 95% CI=973-1,267). 
The demographic and clinical features of CIS patients are shown in table 6.2.. CSF 
IgG index was available in 696 patients (66.5%) and CSF cell count in 513 patients 
(49.0%).13 CIS patients were more likely to be female than male (female/male 
ratio=2.1). The majority of patients had OCB in their CSF (74.3%) and had more than 
one CNS T2 lesion on MRI (2-9 T2 lesions=41.8%; >9 T2 lesions=43.7%).  
Clinical CIS information was available on 911 patients (87%). Of these patients, 288 
(31.6%) presented with optic neuritis (ON), 188 (20.6%) with a brainstem attack (BS), 
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257 (28.2%) with a spinal cord syndrome and the remaining 178 (19.5%) with other 
symptoms. 
 
 
 
 
 
 
 
  
 
Table 6.2. Demographic and clinical characteristics of the total CIS cohort, patients who converted and not converted to CDMS during follow-up 
  
All CIS patients 
(n=1,047) 
Missing 
values 
Converted to CDMS  
(n=623, 59.5%) 
Missing 
values 
Not converted to 
CDMS (n=424, 40.5%) 
Missing 
values 
Age (years) 32.0 (26.0 - 39.0) 0 (0) 31.0 (25.2 - 38.1) 0 (0) 33.2 (27.1 - 39.7) 0 (0) 
Females 714 (68.2) 0 (0) 440 (70.6) 0 (0) 274 (64.7) 0 (0) 
Follow-up (days) 1,574 (1,042 - 2,330) 0 (0) 1,768 (1,110 - 2,558) 0 (0) 1,332 (965 - 1,971) 0 (0) 
Type of 
presentation 
ON=288 (31.6) 
BS=188 (20.6) 
Spinal=257 (28.2)  
Other=178 (19.5) 
136 (13) 
ON=160 (30.7) 
BS=103 (19.8) 
Spinal=151 (29.0)  
Other=107 (20.5) 
102 (16.4) 
ON=128 (32.8) 
BS=85 (21.8) 
Spinal=106 (27.2) 
Other=71 (18.2) 
34 (8.0) 
Days to 
conversion 
to CDMS 
NA NA 421 (212 - 853) 0 (0) NA NA 
Cotinine (> 14 
ng/ml) 350 (33.7) 10 (1.0) 205 (33.2) 5 (0.8) 145 (34.6) 5 (1.2) 
OCB positive 778 (74.3) 0 (0) 525 (84.3) 0 (0) 253 (59.7) 0 (0) 
MRI T2 lesions 
0-1=151 (14.4) 
2-9=438 (41.8) 
>9=458 (43.7) 
0 (0) 
0-1=48 (7.7) 
2-9=249 (40.0) 
>9=326 (52.3) 
0 (0) 
0-1=103 (24.3) 
2-9=189 (44.6) 
>9=132 (31.1) 
0 (0) 
25-OH-D (nmol/l) 49.3 (32.2 - 72.5) 6 (0.6) 47.9 (31.3 - 71.9) 4 (0.6) 50.5 (34.7 - 73.5) 2 (0.5) 
EBNA1 IgG 11.3 (6.7 - 14.7) 3 (0.3) 11.6 (6.7 - 15.0) 1 (0.2) 10.9 (6.7 - 14.2) 2 (0.5) 
CMV IgG 1.7 (0.2 - 3.3) 12 (1.1) 1.9 (0.2 - 3.3) 8 (1.3) 1.2 (0.2 - 3.4) 4 (0.9) 
CSF IgG index 0.7 (0.5 - 1.1) 351 (34) 0.8 (0.6 - 1.1) 231 (37.1) 0.6 (0.5 - 0.9) 120 (28.3) 
CSF cell count 
(n/µl) 5.0 (2.8 - 12.0) 534 (51) 5.8 (2.0 - 12.0) 315 (50.6) 5.0 (3.0 - 11.0) 219 (51.7) 
Median and interquartile range (IQR) or n (%). 
ON: optic neuritis; BS: brainstem syndrome; Spinal: spinal cord syndrome; NA: not applicable.
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6.3.2. Serum NfL analysis in FC versus NC and HC (n=290) 
The median time to conversion to CDMS in FC was 110 days (79-139), while the 
median follow-up time in NC was 6.5 years (5.3-7.9). The general characteristics of 
FC, NC and HC are provided in table 6.3..  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Table 6.3. General characteristics of CIS patients and healthy individuals included in the study. 
Variable Category FC (n=100) NC (n=98) HC (n=92) 
Age (years) - 30.6 (25.1-37.9) 31.6 (27.4-37.8) 35.0 (29.0-45.0) 
Sex F  67 (67%) 61 (62.2%) 58 (63.0%) 
OCB Positive 87 (87%) 60 (61.2%) - 
T2 lesion count 0 to 1 5 (5%) 21 (21.4%) - 
  2 to 9 38 (38%) 52 (53.1%) - 
  > 9 57 (57%) 25 (25.5%) - 
Gd+ lesions Positive 46 (58.2%) 25 (37.3%) - 
EDSS - 2.0 (1.5-3.0) 1.5 (1.0-2.0) - 
NfL (pg/ml) - 24.1 (13.5-51.8) 19.3 (13.6-35.2) 7.9 (5.6-17.2) 
FC: fast converters to CDMS; NC: non-converters to CDMS; HC: healthy controls; OCB: oligoclonal bands in CSF; T2: T2 hyperintense MRI 
lesions; Gd+: gadolinium enhancing MRI lesions; EDSS: Expanded Disability Status Scale; NfL: neurofilament light chain in serum. 
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The number of patients with OCB, Gd+ and >9 T2 lesions was higher in FC than NC 
(87% vs 61.2%, 58.2% vs 37.3% and 57% vs 25.5% respectively). EDSS scores 
were also overall higher in FC than NC (median EDSS=2.0 (1.5-3.0) vs 1.5 (1.0-2.0) 
respectively). 
There was no correlation between age and NfL in either CIS (Pearson’s r=-0.11, 
p=0.11) or HC (Pearson’s r=-0.02, p=0.83). 
NfL levels were higher in FC (24.1 pg/ml (13.5-51.8) and NC (19.3 pg/ml (13.6-35.2) 
than in HC (7.9 pg/ml (5.6-17.2)) (figure 6.1.). Increasing NfL levels were 
significantly associated with an increased risk of being either FC (OR=5.85, 
95%CI=2.63-13.02, p=1.5x10-5) or NC (OR=7.03, 95%CI=2.85-17.34, p=2.3x10-5) 
compared to HC. When comparing FC vs NC, NfL levels were not associated with 
fast conversion. 
 
Figure 6.1. Serum NfL concentrations across the three investigated groups (FC=fast 
converters to clinically definite MS (CDMS); NC=non-converters to CDMS; 
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HC=healthy controls). Each dot represents NfL concentration in a single individual. 
Boxplots indicate median and IQR with whiskers extending 1.5 times the IQR. 
 
 
However, presence of OCB, increasing number of T2 lesions, presence of Gd+ 
lesions and higher EDSS scores were all positively associated with FC status (table 
6.4. upper panel).  
 
  
 
Table 6.4. Upper panel: results of logistic regression models investigating serum NfL, OCB, T2, Gd+ and EDSS as predictors of disease status 
(adjusted by age and sex). 
Lower panel: results of logistic and ordinal regression models investigating NfL concentration as predictor of OCB, EDSS, T2 and Gd+ lesions 
(adjusted by age and sex). 
Comparison Predictor OR 95%CI p 
NC vs HC NfL 7.03 2.85 - 17.34 2.3 x 10-5 
FC vs HC NfL 5.85 2.63 - 13.02 1.5 x 10-5 
FC vs NC NfL 1.36 0.69 - 2.69 0.376 
FC vs NC OCB 4.13 2.02-8.45 9.9 x 10-5 
FC vs NC T2 (2-9 lesions) 3.11 1.07-9.06 0.037 
 T2 (>9 lesions) 9.63 3.25-28.58 4.4 x 10-5 
FC vs NC Gd+ 2.45 1.23-4.86 0.011 
FC vs NC EDSS (1.5-2.0) 1.40 0.67-2.94 0.374 
 EDSS (>2.0) 5.29 2.18-12.84 0.0002 
          
Predicted variable Predictor OR 95%CO p 
OCB NfL 1.66 0.75-3.70 0.214 
T2 NfL 2.36 1.21-4.59 0.011 
Gd+ NfL 2.69 1.13-6.41 0.026 
EDSS NfL 2.54 1.21-5.31 0.013 
OR: odds ratio; 95%CI: 95% confidence interval; SE: standard error; NC: non-converters to CDMS; HC: healthy controls; FC: fast converters to 
CDMS; NfL: neurofilament light chain in serum; OCB: oligoclonal bands in CSF; T2: T2 hyperintense lesions; Gd+: gadolinium enhancing 
lesions. 
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Finally, NfL concentration was positively associated with presence of Gd+ lesions 
(OR=2.69; 95%CI=1.13-6.41; p=0.026), increasing T2 lesion load (OR=2.36; 
95%CI=1.21-4.59; p=0.011), increasing EDSS category (OR=2.54; 95%CI=1.21-
5.31; p=0.013), but not OCB status (OR=1.66; 95%CI=0.75-3.70; p=0.214) (table 
6.4. lower panel, figure 6.2.). 
 
 
Figure 6.2. a) serum NfL levels across T2 lesion categories; b) serum NfL levels in 
patients with and without gadolinium enhancing MRI lesions (Gd+); c) serum NfL 
levels across EDSS categories; d) serum NfL levels in patients with and without 
oligoclonal bands (OCB). Each dot represents NfL concentration in a single 
individual. Boxplots indicate median and IQR with whiskers extending 1.5 times the 
IQR. 
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Since there was no significant difference in serum NfL concentrations between FC 
and NC, the a priori decision criterion to not measure serum NfL in the entire study 
cohort was fulfilled. 
 
 
6.3.3. Predictors of conversion to CDMS in the entire CIS cohort (n=1,047) 
Each variable was tested as a predictor of conversion from CIS to CDMS using a 
univariate Cox regression model (table 6.5.). OCB positive CIS patients were more 
than twice as likely to convert to CDMS as OCB negative individuals (hazard ratio 
(HR)=2.49, 95%CI=1.91-3.23, p<0.001; figure 6.3.a). Similarly, a higher IgG index 
was associated with conversion to CDMS (HR=1.22, 95%CI=1.10-1.36, p<0.001), 
whilst CSF cell count was not. A gradient of risk of conversion was observed with 
increasing numbers of T2 lesions (2-9 vs 0/1 lesions: HR=2.28, 95%CI=1.70-3.06, 
p<0.001; >9 vs 0/1 lesions: HR=3.26, 95%CI=2.28-4.65, p<0.001; >9 vs 2-9 lesions: 
HR=1.43, 95%CI=1.21-1.68, p<0.001; figure 6.3.b). Females were at slightly higher 
risk of CDMS but this did not reach statistical significance (HR=1.17, 95%CI=0.94-
1.46, p=0.160; figure 6.4.a). Age at CIS onset was inversely associated with risk of 
conversion (HR per year increase=0.98, 95%CI=0.976-0.99, p<0.001; figure 6.4.b).  
 
  
 
 
Table 6.5. Univariate and multivariate stepwise Cox regression results for all variables investigated as predictors of conversion to CDMS. 
  Univariate  
 
Multivariate  
 
Variable Category HR 95%CI p HR 95%CI p 
Age - 0.98 0.976 - 0.99 <0.001 0.98 0.98 - 0.99 <0.001 
Sex F vs M 1.17 0.94 - 1.46 0.160 - - - 
OCB Positive vs Negative 2.49 1.91 - 3.23 <0.001 2.18 1.71 - 2.77 <0.001 
CSF IgG index - 1.22 1.10 - 1.36 <0.001 - - - 
MRI T2 lesions 2-9 vs 0/1 2.28 1.70 - 3.06 <0.001 1.97 1.52 - 2.55 <0.001 
 > 9 vs 0/1 3.26 2.28 - 4.65 <0.001 2.74 2.04 - 3.68 <0.001 
25-OH-D (quartiles) 2nd vs 1st 0.76 0.60 - 0.95 0.016 0.82 0.70 - 0.97 0.019 
 3rd vs 1st 0.69 0.58 - 0.83 <0.001 0.76 0.63 - 0.91 0.003 
 4th vs 1st 0.76 0.62 - 0.94 0.010 0.85 0.68 - 1.07 0.167 
EBNA1 IgG 
(quartiles) 2
nd
 vs 1st 0.85 0.69 - 1.05 0.127 0.75 0.60 - 0.94 0.014 
 3rd vs 1st 0.92 0.70 - 1.23 0.586 0.81 0.59 - 1.13 0.220 
 4th vs 1st 1.11 0.83 - 1.49 0.464 1.00 0.75 - 1.34 0.986 
CMV IgG (quartiles) 2nd vs 1st 1.13 0.92 - 1.38 0.238 1.22 0.98 - 1.52 0.075 
 3rd vs 1st 1.24 0.94 - 1.62 0.126 1.36 1.10 - 1.67 0.004 
 4th vs 1st 1.12 0.89 - 1.41 0.346 1.25 0.97 - 1.60 0.07 
Cotinine >14 vs <14 ng/ml 0.95 0.79 - 1.14 0.549 - - - 
CSF cell count - 1.00 0.99 - 1.01 0.988 - - - 
Type of CIS BS vs ON 1.04 0.74 - 1.46 0.831 - - - 
 Spinal vs ON 1.12 0.89 - 1.41 0.318 - - - 
 Other vs ON 1.22 0.93 - 1.59 0.155 - - - 
HR: hazard ratio; CI: confidence interval; F: female; M: male; vs: versus; CSF: cerebrospinal fluid; OCB: oligoclonal bands in CSF; 25-OH-D: 
25-hydroxyvitamin D3; EBNA1: Epstein-Barr nuclear antigen 1; CMV: cytomegalovirus; CIS: clinically isolated syndrome; BS: brainstem 
syndrome; ON: optic neuritis; Spinal: spinal cord syndrome.
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Figure 6.3. Survival curves of conversion to CDMS and numbers of individuals at risk 
of conversion (below the x axis) stratified according to: a) OCB status; b) number of T2 
lesions on MRI; c) quartiles of 25-OH-D levels. 
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Figure 6.4. Survival curves of conversion to CDMS and numbers of individuals at risk 
of conversion (below the x axis) stratified according to: a) gender; b) age. 
 
 
We attempted to make these statistical measures of risk more clinically relevant by 
estimating the risk of conversion to CDMS in different categories of CIS patients at 2 
and 5 years of follow-up. The risk of conversion varied widely across different exposure 
categories (table 6.6.) and was high among individuals with evidence of OCB and 
more than 9 T2 lesions on MRI (57.0% and 85.5% at 2 and 5 years of follow-up 
respectively). Including 25-OH-D information did not considerably change these 
estimates. Notably, the risk of conversion among OCB negative CIS cases with either 0 
or 1 T2 lesions and higher vitamin D status was  low (6.8% and 21.4% at 2 and 5 years 
respectively). These estimates should however be interpreted with caution given the 
small number of patients lacking all risk factors for conversion and the correspondingly 
wide confidence intervals. 
  
 
 
 
Table 6.6. Risk of conversion to CDMS in different categories of CIS patients after 2 and 5 years of follow-up.  
 At 2 years of follow-up At 5 years of follow-up 
Category n % risk of conversion (95%CI) n % risk of conversion (95%CI) 
OCB positive 778 47.9 (44.4 - 51.5) 607 81.1 (77.6 - 84.0) 
OCB negative 269 22.7 (17.9 - 28.2) 154 58.4 (50.2 - 66.2) 
MRI > 9 T2 lesions 458 51.7 (47.1 - 56.4) 372 82.5 (78.2 - 86.2) 
MRI 2-9 T2 lesions 438 39.9 (35.4 - 44.7) 314 74.5 (69.3 - 79.2) 
MRI 0-1 T2 lesions 151 14.6 (9.5 - 21.4) 75 54.7 (42.8 - 66.0) 
25-OH-D 1st quartile 260 47.3 (41.1 - 53.6) 205 82.4 (76.4 - 87.2) 
25-OH-D 2nd quartile 260 41.5 (35.5 - 47.8) 182 76.4 (69.4 - 82.2) 
25-OH-D 3rd quartile 260 40.0 (34.0 - 46.3) 179 71.5 (64.2 - 77.9) 
25-OH-D 4th quartile 261 36.8 (31.0 - 43.0) 191 74.3 (67.4 - 80.2) 
OCB positive / > 9 T2 377 57.0 (51.8 - 62.1) 310 85.5 (80.9 - 89.1) 
OCB negative / > 9 T2 81 27.2 (18.1 - 38.4) 62 67.7 (54.5 - 78.7) 
OCB positive / 2-9 T2 328 43.9 (38.5 - 49.5) 251 77.7 (71.9 - 82.6) 
OCB negative / 2-9 T2 110 28.2 (20.2 - 37.7) 63 61.9 (48.8 - 73.6) 
OCB positive / 0-1 T2 73 19.2 (11.2 - 30.4) 46 69.6 (54.1 - 81.8) 
OCB negative / 0-1 T2 78 10.3 (4.8 - 19.7) 29 31.0 (16.0 - 51.0) 
OCB positive / >9 T2 / 25-OH-D < median 192 56.2 (48.9 - 63.3) 154 87.0 (80.4 - 91.7) 
OCB negative / 0-1 T2 / 25-OH-D > median 44 6.8 (1.8 - 19.7) 14 21.4 (5.7 - 51.2) 
CI: confidence interval; OCB: oligoclonal bands in CSF; 25-OH-D: 25-hydroxyvitamin D3. 
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6.3.4. Predictors of OCB and MRI lesions 
The clinical and biological parameters associated with the presence of OCB and T2 
hyperintense lesions at disease onset were assessed. The median age, sex ratio, 
vitamin D status, EBNA1 IgG and CMV IgG levels of OCB positive and OCB negative 
CIS patients are described in table 6.7.. OCB positive individuals were younger, more 
likely to be female, had more T2 lesions and lower 25-OH-D levels than those who 
were OCB negative. OCB positive patients also had higher EBNA1 but not CMV IgG 
levels compared to OCB negative patients. In a multivariate logistic regression model 
predicting OCB status, the number of T2 lesions (>9 vs 0/1 lesions: odds ratio 
(OR)=5.03, 95%CI=3.35-7.58, p<0.001), lower age at CIS onset (OR per year 
increase=0.98, 95%CI=0.97-0.997, p=0.019) and higher EBNA1 IgG levels (OR=1.08, 
95%CI=1.04-1.11, p<0.001) were significantly associated with OCB (table 6.7.). 
  
 
 
Table 6.7. Association between demographic and clinical features of CIS patients with presence or absence of OCB.  
     
Univariate 
  
Multivariate 
 
Variable OCB positive OCB negative OR 95%CI p OR 95%CI p 
Age Median (IQR) 31.3 (25.4 - 39.0) 33.6 (27.7 - 38.8) 0.98 0.97 - 0.998 0.025 0.98 0.97 - 0.997 0.019 
T2 MRI 2 – 9 328 (42.2%) 110 (40.9%) 3.19 2.17 - 4.68 <0.001 3.16 2.13 - 4.70 <0.001 
 > 9 377 (48.5%) 81 (30.1%) 4.97 3.34 - 7.41 <0.001 5.03 3.35 - 7.58 <0.001 
EBNA1 IgG Median (IQR) 11.8 (7.6 - 14.9) 9.3 (4.2 - 14.1) 1.08 1.05 - 1.11 <0.001 1.08 1.04 - 1.11 <0.001 
25-OH-D Median (IQR) 49.0 (31.2 - 71.3) 50.1 (36.1 - 76.8) 0.995 0.99 - 0.999 0.035 - - - 
Sex Females 544 (69.9%) 170 (63.2%) 1.35 1.01 - 1.81 0.042 - - - 
CMV IgG Median (IQR) 1.5 (0.2 to 3.4) 2.2 (0.2 to 3.3) 1.03 0.98 - 1.09 0.225 - - - 
OCB: oligoclonal bands in CSF; OR: odds ratio; CI: confidence interval; IQR: interquartile range; EBNA1: Epstein-Barr nuclear antigen 1; 25-OH-D: 
25-hydroxyvitamin D3; CMV: cytomegalovirus. 
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The general features of CIS patients in the three different categories based on number 
of T2 lesions are shown in table 6.8.. We used a multivariate ordinal regression model 
to investigate which variables were independently associated with an increased 
number of T2 lesions. Only presence of OCB was significantly associated with an 
increased lesion load (OR=2.73, 95%CI=2.08-3.58, p<0.001) (table 6.8.). 
  
 
 
Table 6.8. Demographic and clinical features of CIS patients associated with MRI status. 
      
Univariate 
  
Multivariate 
 
Variable 0-1 T2 2-9 T2 > 9 T2 OR 95%CI p OR 95%CI p 
OCB Positive 73 (48.3%) 328 (74.9%) 377 (82.3%) 2.73 2.08 - 3.58 <0.001 2.73 2.08 - 3.58 <0.001 
Age Median 31.2 (25.5-36.9) 32.3 (26.6 -39.1) 32.2 (26.0 - 39.3) 1.00 0.99 - 1.02 0.458 - - - 
Sex Females 104 (68.9%) 301 (68.7%) 309 (67.5%) 0.95 0.74 - 1.21 0.667 - - - 
EBNA1 
IgG Median 10.1 (5.3 -13.7) 11.8 (7.0 – 15.0) 11.3 (6.9 - 14.7) 1.02 0.99 - 1.04 0.206 - - - 
CMV IgG Median (IQR) 2.1 (0.2 - 3.5) 1.7 (0.2 - 3.6) 1.7 (0.2 - 3.2) 0.97 0.94 - 1.01 0.119 - - - 
25-OH-D Median (IQR) 50.2 (35 - 77) 50.0 (33 - 73) 48.0 (30 - 70) 1.00 0.99 - 1.00 0.132 - - - 
OR: odds ratio; CI: confidence interval; OCB: oligoclonal bands in CSF; IQR: interquartile range; EBNA1: Epstein-Barr nuclear antigen 1; CMV: 
cytomegalovirus; 25-OH-D: 25-hydroxyvitamin D3. 
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6.4. Discussion 
I report the largest study ever performed on CIS patients and aimed to elucidate the 
factors driving the onset of CDMS. This is also the first study investigating serum NfL in 
CIS patients. These were significantly higher in both FC and NC than in HC. This 
supports the presence of accumulating axonal injury starting in the very early phases of 
the disease and ongoing Wallerian degeneration from focal lesion(s) presenting as 
CIS. We noted some HC had higher NfL levels than CIS patients. To what extent these 
high NfL levels in HC represent minor neurological insults occuring in day-to-day life 
(e.g. minor head injuries or compression of peripheral nerves) rather than normal 
synaptic and neuronal turnover is unclear and needs further study. 
Interestingly, the difference in serum NfL between FC and NC was not statistically 
significant (and hence the decision to restrict this analyses to extreme outcome groups 
in this study). Therefore, while increased NfL levels appear a good indicator of axonal 
damage, this does not appear to be specific to CIS with a relatively rapid conversion to 
CDMS. Increased serum NfL and NfH levels have been found in neurological 
conditions other than MS such as ALS and GBS, and have been used as a marker of 
neurotoxicity after chemotherapy (94, 168, 169). Results from previous studies in CIS 
have been controversial with one study showing slightly higher CSF NfL levels in CIS 
patients converting to CDMS than in non-converters (100), while others have not (102, 
178). It should be noted that, even in this cohort, NfL levels were to some extent higher 
in FC than NC and it is plausible that by increasing the sample size the difference may 
become statistically significant. As compared to CSF, serum samples are more easily 
accessible but also more distant from the pathological process taking place in the CNS. 
This may affect the sensitivity of serum NfL to predict conversion to CDMS. 
Importantly, higher serum NfL concentration was associated with the presence of both 
T2 and Gd+ lesions; the former a burden of disease marker and the latter a marker of 
acute focal inflammation. Furthermore, NfL levels increased with increasing EDSS 
scores at the time of CIS. These results are in agreement with previous studies 
showing that Nf levels in the CSF are correlated with both MRI and clinical activity of 
MS (98, 100, 152, 240). It will be important to determine if raised serum NfL levels at 
presentation predict long-term disability outcomes similarly to CSF NfL levels (99). 
 
I confirmed a strong association between an increasing number of T2 hyperintense 
lesions on baseline MRI and risk of conversion in keeping with several previous studies 
(57, 235, 249). Similarly, CSF markers of B cell activity (OCB and a higher IgG index) 
were strongly and independently associated with conversion to CDMS (250-252). 
Notably, the risk of conversion appeared particularly high in those patients carrying 
both OCB and a high number of T2 lesions (57% and 86% risk of conversion after 2 
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and 5 years of follow-up respectively). As previously suggested, age at disease onset 
was also inversely associated with risk of conversion (253). 
Two recent studies have demonstrated a significant inverse relation between vitamin D 
status and risk of conversion (237, 254). Our study appears to confirm this finding, and 
indeed extends this in a heterogeneous sample of CIS patients from a variety of 
latitudes. It is noteworthy that our study included both a considerably larger number of 
patients (237) and also incorporated information on OCB (254). In the univariate model 
predicting conversion to CDMS the 2nd, 3rd and 4th quartiles versus the 1st (lowest) 
quartile of vitamin D levels were all significantly associated with a lower risk of 
converting to CDMS. Nevertheless, already in this analysis and more so in the 
multivariate approach no apparent dose-response relationship was visible. In addition, 
significance was lost in the multivariate model for comparing the 4th with the 1st quartile. 
Even if the effect of 25-OH-D levels on risk of conversion appears partially attenuated 
in the multivariate analysis, our overall results confirm that CIS patients with lower 25-
OH-D levels tend to convert to CDMS more rapidly. Studies outside the field of MS 
have reported that vitamin D levels may fall in the presence of systemic inflammation 
and this may happen to a greater extent in those CIS patients, who go on to convert to 
CDMS (255). Although reverse causation cannot be excluded, the increasing evidence 
for regulatory effects of vitamin D on the immune system support a potential causal link 
between vitamin D deficiency and conversion to CDMS (256, 257).  
Previous studies have suggested that individuals with higher antibody levels against 
EBV are at increased risk of conversion (238, 241). However, we did not see any 
association between IgG production against EBNA1 and CMV and conversion to 
CDMS in univariate analyses. Some quartiles appeared significantly associated in the 
multivariate model, but this was not consistent across quartiles. Given the lack of 
significance in univariate analyses and the known risk of false positive associations in 
stepwise models, we believe these data should be interpreted with caution. The 
difference in the methods used by previous studies could at least partly contribute to 
the discrepancy in these results. We only tested a single EBV antigen using an ELISA 
based kit, which is less accurate than immunofluorescence based methods (258). 
 
We were particularly interested in the relation between OCB and IgG against EBNA1, 
as previous studies have suggested a potential link between these markers of B cell 
activation in MS. A similarly large proportion of patients with MS have OCB in their CSF 
and antibodies against EBV in their serum (244, 259). In addition, both the presence of 
OCB and high antibody titres against EBV proteins are positively associated with the 
HLA-DRB1*1501 allele, the main genetic risk factor in MS (260-263). Our finding that 
EBNA1 but not CMV IgG levels are significantly associated with the presence of OCB 
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further strengthens the link between EBV and intrathecal B cell activation. This 
highlights a potential connection between exposure to this virus and the most 
consistent immunological finding in MS patients. 
OCB status was also positively associated with MRI T2 lesion load and lower age at 
onset. Notably, these variables were also associated with risk of conversion and this 
confirms the importance of OCB and B cell activation within the CNS in the pathology 
of this disease. 
Our multicentre approach enabled the retrospective collection of more than 1,000 CIS 
patients who have been followed up for several years, but this real-life clinical setting 
also inevitably leads to some limitations. Potential bias can arise from centre specific 
effects, despite adjusting for them in the regression models. This includes the potential 
consequences of various different clinical care protocols employed across the 
participating sites, and possible recall bias depending on the frequency of follow-up 
visits. Furthermore, we should remember that patients who participate in studies are 
those who fulfill the inclusion criteria, and differences may be present between these 
and the overall patient population. We did not include additional variables that could 
potentially act as confounders or independently influence the risk of conversion to 
CDMS such as the potential effect of disease modifying treatment, genetic factors, 
history of infectious mononucleosis, latitude, time spent outdoors, vitamin D intake and 
previous history of smoking in our analysis. Vitamin D levels were only measured at a 
single time-point, which may not appropriately reflect vitamin D status over the long 
term. Finally, MRI protocols and T2 lesion counting methods could not be pre-specified 
and hence not uniform across the different centres. We therefore chose not to use MRI 
as evidence of dissemination in time and space (as in the current diagnostic criteria 
(264)). We instead applied Poser criteria to define CDMS, which allow a more reliable 
evaluation of disease activity in multicentre studies such as this one. Nonetheless, the 
occurrence of new neurological symptoms represents an important and unequivocal 
clinical endpoint which is relevant for both patients and neurologists. Similarly, in order 
to reduce inter-rater variability in T2 lesion counts, we grouped patients in categories 
(0-1, 2-9 and >9 lesions) and used these rather than the original lesion counts for all 
analyses. 
In conclusion, despite not discriminating between fast and slow converting CIS 
patients, serum NfL levels are abnormally high in the earliest stages of MS, correlate 
with MRI activity and disability scores and represent a promising and easily accessible 
biomarker in this debilitating disease. These results strongly support future studies with 
longitudinal sampling and well conducted clinical and imaging follow-up to investigate 
serum NfL’s potential prognostic potential in CIS and also later disease stages. 
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Conversely, OCB status, number of T2 lesions and lower age at CIS onset are 
associated with an increased risk of conversion from CIS to CDMS. A role for lower 
vitamin D levels is also suggested. We confirm that patients with both OCB and several 
T2 lesions are highly likely to convert, with their risk of developing CDMS in 5 years at 
almost 90%. Given that MRI activity and OCB status are inextricably linked with 
immune activation, these data support targeting the immune system early in the 
disease in order to slow or prevent MS disease activity.  
The effect of vitamin D is intriguing and supports the need for large-scale clinical trials 
of vitamin D supplementation in order to conclusively answer the question as to 
whether this environmental factor is causal or consequential for disease activity. The 
future integration of additional parameters including genetic variants associated with 
the risk of MS will allow a more accurate assessment of risk of conversion and more 
targeted intervention strategies. 
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7. Summary and Conclusions 
 
The incidence of neurodegenerative diseases increases with age. At present about 
16% of the European population is older than 65 years with an estimated 30% by 2060. 
In contrast, neurodegeneration in children and young adults is more related to 
accidents such as traumatic brain or spinal cord injury. In addition, there are 
neurodegenerative diseases which affect adults at the prime of their active working life. 
Notably, neurodegeneration is now recognised as the key pathological feature driving 
disease progression in MS and other demyelinating syndromes, stroke and ALS. There 
is a lack of analytically and clinically validated in vitro diagnostic tests for assessment 
of neurodegeneration in this context. Until now, MRI findings have attracted most 
interest as measures and surrogates of axonal loss (265). While classical MRI 
measures (focal T2 hyperintense lesions, Gadolinium enhancement) have been 
disappointing in this regard, more elaborated quantitative outcomes including whole 
brain or regional brain atrophy were found to better depict the destructive process 
(266). Unfortunately, brain volume is a “mixed baggage” resulting from many different 
factors, pathological and physiological, not directly related to axonal loss such as fluid 
shifts, ageing, remyelination and astrogliosis, all of them affecting measures of brain 
atrophy in sometimes opposite directions (e.g. inflammation may increase water 
content and volume and its suppression – although beneficial in the long run – may 
result in volume reduction via reduction of edema (a phenomenon apostrophized as 
“treatment-induced pseudo-atrophy” (267))). Hence whole brain atrophy is a rather 
unspecific surrogate of neurodegeneration. Another significant problem of measuring 
brain atrophy relates to the delayed responsiveness of this outcome measure (268). To 
date, the best validated universal body fluid biomarkers for axonal damage are the Nf 
proteins. 
My findings support this view: NfL proved to be a stable analyte with respect to 
repeated freeze thawing cycles and prolonged exposure to room temperature. This 
does not support previous concerns about its susceptibility to proteases, especially in 
the protease-rich CSF or blood (160). It is important to conclude that there is no basis 
to prefer NfH over NfL as biomarker of axonal damage due to concerns of sample 
stability. 
My results demonstrated that CSF Nf levels are increased in the earliest stages of MS 
and correlate with signs of inflammation in CSF and relapses. Differences in CIS and 
MS were stronger for NfL than for NfHSMI35. The higher abundance of NfL and/or better 
performance of the UmanDiagnostics NF-light® assay may outweigh the known high 
sensitivity and higher dynamic range of the ECL technology used in our previously 
developed NfHSMI35 assay (95). 
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This is also supported by more pronounced reductions of CSF NfL levels as compared 
to NfHSMI35 after 12 months of natalizumab treatment in MS patients. However, it would 
be premature to generalize this to the assumption that NfL measurements would be 
universally superior to NfH. Rather these findings could reflect specific assay 
characteristics, and although both proteins originate from the same source, it is 
foreseeable that increased levels of one or the other bear differential information.  
I performed the first double-blind, placebo controlled evaluation of the effects of an 
approved MS therapy on CSF NfL levels. The data demonstrated that CSF NfL levels 
decrease substantially in fingolimod-treated patients, whereas a similar magnitude of 
change is not observed in patients on placebo. Importantly, the treatment effect on NfL 
levels was associated with improved clinical and MRI outcomes of disease activity. At 
the individual patient level, extreme changes in CSF NfL levels, irrespective of 
treatment, were reflected in the clinical and paraclinical findings. Consistent with these 
results, a recent uncontrolled study in RRMS patients with high disease activity also 
suggested an association of natalizumab treatment with a decrease in CSF NfL levels 
and corresponding improvements in clinical, MRI and other laboratory measures (101).  
 
A notable limitation of cross-sectional studies on biomarkers of neurodegeneration is 
that data are obtained almost exclusively from CSF samples. This invasive, potentially 
harmful procedure has to be performed under sterile conditions and is not well 
tolerated by all patients which explains the lack of large multi-centre longitudinal 
studies. Longitudinal data is essential for monitoring of progression of 
neurodegeneration and efficacy of neuroprotective treatment strategies. However, 
obtaining longitudinal CSF samples is considered too invasive outside the clinical trial 
arena, precluding the broader clinical use of Nf. 
Several reports have suggested peripheral blood levels of NfH as a potential marker of 
neurodegeneration (154, 155, 168, 182, 184, 185, 198, 269). In contrast to studies on 
NfH, there is only one recent report investigating NfL in serum; this work examined the 
relationship between serum NfL and neurological outcome following cardiac arrest 
(170). 
A commercially available ELISA (UmanDiagnostics NF-light® assay) uses two highly 
specific, non-competing monoclonal antibodies (47:3 and 2:1) to quantify soluble NfL in 
CSF samples. However,  this cannot be used in its present form for analysis of blood 
samples (95). In a collaborative effort with UmanDiagnostics I developed a highly 
sensitive ECL-based NfL assay (NfLUmea47:3) suitable for the quantification of NfL in 
serum at concentrations relevant to clinical settings (94). We applied this immunoassay 
to cohorts of patients with AD, GBS, ALS. All patient groups had higher serum NfL 
values than a CP and HC. Further strengthening these results, CSF and serum levels 
  
130 
 
correlated significantly in all disease groups and sensitivity and specificity of serum NfL 
for separating ALS from healthy controls was over 90%.  
 
To further my initial findings, I had access to a unique collection of longitudinally 
collected serum samples from well characterized patients with SCI. In SCI, the severity 
of disease is quantified exclusively by clinical measures that have limited sensitivity 
and reliability, and no blood-based biomarker has been established to further stratify 
the degree of injury. I investigated the role of serum NfL determined by NfLUmea47:3 as 
predictor of the clinical outcome in 27 SCI patients. I found that baseline NfL levels (in 
samples collected within 12 hours after the trauma) were significantly higher in iSCI 
and cSCI than in HC and patients with CCS, and levels increased over time. NfL levels 
correlated with ASIA motor score at baseline and after 24 hours and the long term 
motor outcome. Minocycline treatment showed decreased NfL levels in the subgroup of 
cSCI patients. 
These findings are important since they show for the first time that serum NfL 
concentrations in SCI patients are closely correlated with injury severity and functional 
outcome and provide evidence that serum NfL is of prognostic value in SCI patients. 
Further, blood NfL levels may qualify as drug response markers in SCI. 
Finally, I collected and studied the largest cohort of CIS patients to date in order to 
investigate serum NfL levels in CIS patients and which factors predict conversion from 
CIS to CDMS, defined by the occurrence of a second clinical relapse. 
NfL levels were higher in FC (24.1 pg/ml) and NC (19.3 pg/ml) than in HC (7.9 pg/ml, 
p=1.5x10-5 and p=2.3x10-5 respectively). In addition, increased serum NfL 
concentration was associated with increasing numbers of T2 hyperintense MRI lesions 
(p=0.011), Gd+ lesions (p=0.026) and higher EDSS scores (p=0.013) at CIS diagnosis. 
However, NfL levels were not associated with fast conversion to CDMS (p=0.37). 
Based on this I decided not to investigate serum NfL further in the entire cohort of CIS 
patients (n=1047). Predictors of conversion in multivariate analyses were OCB 
(p<0.001), number of T2 lesions (p<0.001) and age at CIS (p<0.001). Lower 25-OH-D 
levels were associated with CDMS in univariate analysis, but this was attenuated in the 
multivariate model. Strikingly, OCB positivity was associated with higher EBNA-1 IgG 
titres. In conclusion, I validated MRI lesion load, OCB and age at CIS as the strongest 
independent predictors of conversion to CDMS in this multicentre setting. A role for 
vitamin D is also suggested but requires further investigation.  
 
Neurodegeneration is now recognised as the key pathological feature driving disease 
progression in MS and other demyelinating syndromes, but also stroke and ALS. There 
is a significant unmet need for analytically and clinically validated in vitro diagnostic 
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tests for assessing of axonal injury; and in this context, assessing the efficacy of 
neuroprotective agents in the setting of delayed axonal loss is proving extremely 
problematic. Taken together, the results of my thesis confirm and expand on previous 
findings of Nf as quantitative markers of neurodegeneration in CSF. In particular, I 
showed that NfL is a stable molecule, can be measured in both CSF and serum, is 
increased in a wide range of neurodegenerative conditions, correlates with clinical 
features of disease activity and progression and is potentially responsive to disease 
treatment. Nf is a universal measure of axonal injury, therefore specificity is limited. 
According to the definitions set up by the biomarker expert working group (137), the 
greatest potential for Nf can be anticipated in their use as a tool for quantifying disease 
severity, prognosis and monitoring therapy response. Future studies will also have to 
show if NfL may qualify as surrogate endpoint in clinical trials. It will be important to 
have independent research groups being able to technically reproduce serum NfL 
measurements. The near past has shown several examples of relevant scientific 
findings that could not be independently validated  (270-272). Longitudinal samples are 
essential for monitoring of the progression of neurodegeneration. Medium-term 
longitudinal studies investigating serum NfL in MS will have to include large patient 
numbers with well conducted clinical and paraclinical follow-up examinations. Clinical 
follow-up will have to be long enough (ie 5-10 years) to draw conclusions on the 
relationship between NfL measurements and disease severity and prognosis. This 
should also include conventional and more advanced imaging measures. I propose 
samples that have already been collected in the framework of observational cohort 
studies or randomized-controlled trials could be well suited to fulfill these requirements. 
Depending on outcome, these retrospective projects will have to be followed by 
prospective trials investigating the potential of serum NfL measurements as a surrogate 
endpoint and to measure disease severity, treatment response and prognosis in 
individual patients further.  
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